- Smilow Cancer Hospital at Yale New Haven35 Park StreetNew Haven, CT 06511
Raghav Sundar, MD, PhD
Medical Oncology
Patient type treated
Adult
Accepting new patients
Yes
Referral required
Not Applicable
Biography
Raghav Sundar, MD, PhD, is a medical oncologist specializing in gastrointestinal cancers, with particular expertise in gastroesophageal cancers and tumors that spread to the peritoneum (the lining of the abdominal cavity). At Yale Cancer Center and Smilow Cancer Hospital, he leads the Gastroesophageal Cancer Program, specifically focused on complex, multidisciplinary care and innovative treatment approaches and clinical trials.
"Building meaningful relationships with my patients and their families is the heart of what I do," Dr. Sundar says. "Cancer brings uncertainty, and I believe in taking this journey together, one step at a time. My team and I are here to support you with both advanced medical care and the emotional guidance needed during treatment."
Dr. Sundar takes a collaborative approach to patient care, working closely with surgeons, radiation oncologists, and other specialists to provide comprehensive treatment plans tailored to each patient. "Every patient's cancer is unique," he explains. "By bringing together experts from different fields, we can offer the most advanced and personalized care possible."
As an associate professor at Yale School of Medicine, Dr. Sundar is internationally recognized for his research in gastroesophageal cancers. He pioneers innovative clinical trials and treatment approaches, particularly for patients with challenging conditions like peritoneal metastases. His work has led to significant discoveries that help predict how cancers might respond to treatment, potentially opening new paths for more effective therapies.
Dr. Sundar completed his medical training and doctoral degree at the National University of Singapore and received specialized fellowship training at the prestigious Royal Marsden Hospital in the United Kingdom in experimental therapeutics and early phase clinical trials. Before joining Yale, he served as a senior consultant medical oncologist and research director in Singapore, where he led numerous clinical trials and research initiatives. His work has been published in top medical journals, advancing the field of cancer treatment globally.
"I will be with you every step of the way," Dr. Sundar assures his patients. "We'll work together to understand your diagnosis, explore all treatment options, and ensure you feel informed and empowered throughout your care journey."
Titles
- Associate Professor of Internal Medicine (Medical Oncology & Hematology)
- Leader, Gastroesophageal Cancer Program, Medical Oncology
Education & Training
- PhDNational University of Singapore
- FellowshipNational University Hospital, Singapore
- ResidencyNational University Hospital, Singapore
- MDNational University of Singapore
Additional Information
Publications
- Sundar R, Chia D, Zhao J, Lee A, Kim G, Tan H, Pang A, Shabbir A, Willaert W, Ma H, Huang K, Hagihara T, Tan A, Ong C, Wong J, Seo C, Walsh R, Chan G, Cheo S, Soh C, Callebout E, Geboes K, Ng M, Lum J, Leow W, Selvarajan S, Hoorens A, Ang W, Pang H, Tan P, Yong W, Chia C, Ceelen W, So J. Phase I PIANO trial—PIPAC-oxaliplatin and systemic nivolumab combination for gastric cancer peritoneal metastases: clinical and translational outcomes. ESMO Open 2024, 9: 103681. PMID: 39288528, PMCID: PMC11421236, DOI: 10.1016/j.esmoop.2024.103681.
- Zhao J, Ong C, Srivastava S, Chia D, Ma H, Huang K, Sheng T, Ramnarayanan K, Ong X, Tay S, Hagihara T, Tan A, Teo M, Tan Q, Ng G, Tan J, Ng M, Gwee Y, Walsh R, Law J, Shabbir A, Kim G, Tay Y, Her Z, Leoncini G, Teh B, Hong J, Tay R, Teo C, Dings M, Bijlsma M, Lum J, Mathur S, Pietrantonio F, Blum S, van Laarhoven H, Klempner S, Yong W, So J, Chen Q, Tan P, Sundar R. Spatially Resolved Niche and Tumor Microenvironmental Alterations in Gastric Cancer Peritoneal Metastases. Gastroenterology 2024, 167: 1384-1398.e4. PMID: 39147169, DOI: 10.1053/j.gastro.2024.08.007.
- Yap D, Leone A, Wong N, Zhao J, Tey J, Sundar R, Pietrantonio F. Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma. JAMA Oncology 2023, 9: 215-224. PMID: 36480211, PMCID: PMC9857522, DOI: 10.1001/jamaoncol.2022.5816.
- Yeong J, Lum H, Teo C, Tan B, Chan Y, Tay R, Choo J, Jeyasekharan A, Miow Q, Loo L, Yong W, Sundar R. Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy. Gastric Cancer 2022, 25: 741-750. PMID: 35661944, PMCID: PMC9226082, DOI: 10.1007/s10120-022-01301-0.
- Gwee Y, Chia D, So J, Ceelen W, Yong W, Tan P, Ong C, Sundar R. Integration of Genomic Biology Into Therapeutic Strategies of Gastric Cancer Peritoneal Metastasis. Journal Of Clinical Oncology 2022, 40: 2830. PMID: 35649219, PMCID: PMC9390822, DOI: 10.1200/jco.21.02745.
- Lee A, Wong S, Chai L, Lee S, Lee M, Muthiah M, Tay S, Teo C, Tan B, Chan Y, Sundar R, Soon Y. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. The BMJ 2022, 376: e068632. PMID: 35236664, PMCID: PMC8889026, DOI: 10.1136/bmj-2021-068632.
- Kumar V, Ramnarayanan K, Sundar R, Padmanabhan N, Srivastava S, Koiwa M, Yasuda T, Koh V, Huang K, Tay S, Ho S, Tan A, Ishimoto T, Kim G, Shabbir A, Chen Q, Zhang B, Xu S, Lam K, Lum H, Teh M, Yong W, So J, Tan P. Single-Cell Atlas of Lineage States, Tumor Microenvironment, and Subtype-Specific Expression Programs in Gastric CancerSingle-Cell Atlas of Gastric Cancer Subtypes. Cancer Discovery 2022, 12: 670-691. PMID: 34642171, PMCID: PMC9394383, DOI: 10.1158/2159-8290.cd-21-0683.
- Zhao J, Yap D, Chan Y, Tan B, Teo C, Syn N, Smyth E, Soon Y, Sundar R. Low Programmed Death-Ligand 1–Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma. Journal Of Clinical Oncology 2021, 40: 392-402. PMID: 34860570, DOI: 10.1200/jco.21.01862.
- Sundar R, Huang K, Kumar V, Ramnarayanan K, Demircioglu D, Her Z, Ong X, Bin Adam Isa Z, Xing M, Tan A, Tai D, Choo S, Zhai W, Lim J, Thakur M, Molinero L, Cha E, Fasso M, Niger M, Pietrantonio F, Lee J, Jeyasekharan A, Qamra A, Patnala R, Fabritius A, De Simone M, Yeong J, Ng C, Rha S, Narita Y, Muro K, Guo Y, Skanderup A, So J, Yong W, Chen Q, Göke J, Tan P. Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition. Gut 2021, 71: 1277-1288. PMID: 34433583, PMCID: PMC9185816, DOI: 10.1136/gutjnl-2021-324420.
- Sundar R, Kumarakulasinghe N, Chan Y, Yoshida K, Yoshikawa T, Miyagi Y, Rino Y, Masuda M, Guan J, Sakamoto J, Tanaka S, Tan A, Hoppe M, Jeyasekharan A, Ng C, De Simone M, Grabsch H, Lee J, Oshima T, Tsuburaya A, Tan P. Machine-learning model derived gene signature predictive of paclitaxel survival benefit in gastric cancer: results from the randomised phase III SAMIT trial. Gut 2021, 71: 676-685. PMID: 33980610, PMCID: PMC8921574, DOI: 10.1136/gutjnl-2021-324060.
- Sundar R, Liu D, Hutchins G, Slaney H, Silva A, Oosting J, Hayden J, Hewitt L, Ng C, Mangalvedhekar A, Ng S, Tan I, Tan P, Grabsch H. Spatial profiling of gastric cancer patient-matched primary and locoregional metastases reveals principles of tumour dissemination. Gut 2020, 70: 1823-1832. PMID: 33229445, PMCID: PMC8458060, DOI: 10.1136/gutjnl-2020-320805.
- Molassiotis A, Cheng H, Lopez V, Au J, Chan A, Bandla A, Leung K, Li Y, Wong K, Suen L, Chan C, Yorke J, Farrell C, Sundar R. Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy. BMC Cancer 2019, 19: 132. PMID: 30736741, PMCID: PMC6368751, DOI: 10.1186/s12885-019-5302-4.
- Sachdeva M, Zhao J, Zhu K, Yap D, Wong N, Kumarakulasinghe N, Tey J, Sundar R. PD-L1 expression as a negative predictive biomarker in advanced esophageal squamous-cell cancer treated with chemotherapy alone. ESMO Gastrointestinal Oncology 2025, 7: 100109. DOI: 10.1016/j.esmogo.2024.100109.
- Bandla A, Wong R, Santhanakrishnan P, Magarajah G, Yee Y, Ng W, Ow S, Chan G, Choo J, Lim S, Wong A, Vijayan J, Paxman R, Lee Y, Hui F, Hairom Z, Ang E, Loprinzi C, Thakor N, Lee S, Kumarakulasinghe N, Lim J, Sundar R. Safety and feasibility of concomitant scalp cooling and limb cryocompression to prevent paclitaxel-induced alopecia and neuropathy. Supportive Care In Cancer 2025, 33: 180. PMID: 39937296, PMCID: PMC11821790, DOI: 10.1007/s00520-024-08982-6.
- Zhao J, Ong J, Liu Y, Srivastava S, Teo M, Lee J, Walsh R, Loo L, Tan Q, Ng G, Tan J, Ma H, Ong X, Tay S, Sheng T, Lum J, Yong W, Pietrantonio F, Tan P, Sundar R. Diverse stromal phenotypes at spatial resolution in colorectal cancer peritoneal metastasis. Journal Of Clinical Oncology 2025, 43: 218-218. DOI: 10.1200/jco.2025.43.4_suppl.218.
- Zhao J, Ong J, Chia D, Ng M, Walsh R, Tan Q, Tan J, Ma H, Ong X, Tay S, Yong W, So J, Tan P, Sundar R. 160P Peritoneal niche evolution and micro-environmental remodeling in gastric cancer peritoneal metastasis. Annals Of Oncology 2024, 35: s1467-s1468. DOI: 10.1016/j.annonc.2024.10.184.
- Lee V, Loh J, Hui F, Sundar R, Tan B, Lee M, Lin H, Ong L, Visvanadan N, Ow S, Wong A, Chan G, Lim S, Lim Y, Tan D, Ang Y, Choo J, Lee M, Ngoi N, Lee S, Paxman R, Parker A, Lee Y, Lim J. Scalp cooling therapy for chemotherapy-induced hair loss in patients with breast or gynecological cancers—an Asian tertiary institution experience. Supportive Care In Cancer 2024, 32: 762. PMID: 39482416, DOI: 10.1007/s00520-024-08940-2.
- Leone A, Mai A, Fong K, Yap D, Kato K, Smyth E, Moehler M, Seong J, Sundar R, Zhao J, Pietrantonio F. Immune checkpoint inhibitors in advanced gastroesophageal adenocarcinoma: a series of patient-level meta-analyses in different programmed death-ligand 1 subgroups. ESMO Open 2024, 9: 103962. PMID: 39426081, PMCID: PMC11533044, DOI: 10.1016/j.esmoop.2024.103962.
- Srikumar T, Sundar R. Multimodality Treatment for Locally Advanced Gastric Adenocarcinoma. Surgical Clinics Of North America 2024, 105: 75-94. PMID: 39523078, DOI: 10.1016/j.suc.2024.06.007.
- Sachdeva M, Tay R, KIM Y, Kim H, Cheong J, Grabsch H, Sundar R. 1418P Tumor microenvironment B-cell abundance and survival in resectable gastric cancer: A translational analysis from the CLASSIC trial. Annals Of Oncology 2024, 35: s885. DOI: 10.1016/j.annonc.2024.08.1484.
- Walsh R, Jayagopal A, Tan T, Pitt J, Sundar R, Lee S, Goh B, Rajan V, Tan D, Jeyasekharan A. 229TiP A phase II trial of a neural network-based treatment decision support tool in patients (pts) with refractory solid organ malignancies. Annals Of Oncology 2024, 35: s307-s308. DOI: 10.1016/j.annonc.2024.08.2233.
- Petrillo A, Oudijk L, Sundar R, Daumer C, Casas J, D’Haese D, Mauer M, van Grieken N, Smyth E, Moehler M. EORTC stomach cancer PD-L1 biomarker European initiative: the ASPIRE study protocol. ESMO Gastrointestinal Oncology 2024, 5: 100071. DOI: 10.1016/j.esmogo.2024.100071.
- Blasiak A, Tan L, Chong L, Tadeo X, Truong A, Senthil Kumar K, Sapanel Y, Poon M, Sundar R, de Mel S, Ho D. Personalized dose selection for the first Waldenström macroglobulinemia patient on the PRECISE CURATE.AI trial. Npj Digital Medicine 2024, 7: 223. PMID: 39191913, PMCID: PMC11350179, DOI: 10.1038/s41746-024-01195-5.
- Lee C, Yoo C, Hong J, Park J, Kim J, Tai D, Kim H, Korphaisarn K, Tanasanvimon S, Chen S, Kim J, Kim I, Kim M, Choo J, Oh S, Chen C, Bae W, Kim H, Huh S, Yen C, Park S, Lee D, Chan L, Kang B, Kang M, Sundar R, Choi H, Chan S, Chon H, Lee M. Real-World Study of Systemic Treatment after First-Line Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma in Asia-Pacific Countries. Liver Cancer 2024, 1-15. DOI: 10.1159/000540969.
- Hirano H, Naito Y, Sundar R, Komatsu Y, Kurokawa Y, Li J, Ozaka M, Iwatsuki M, Chen J, Yen C, Zalcberg J, Roy A, Chen L, Nishida T, Doi T. CHAPTER-GIST-101: A phase I study of pimitespib combined with imatinib in patients with imatinib-refractory gastrointestinal stromal tumor. Journal Of Clinical Oncology 2024, 42: tps97-tps97. DOI: 10.1200/jco.2024.42.23_suppl.tps97.
- Lim J, Aau M, Yeong J, Goh B, Yong W, Soo R, Wong A, Tan D, Chee C, Sundar R, Jeyasekharan A, Wong C, Chen P, Liu H, Yu Q, Tam W, Lee S. A phase Ib/II study of pacritinib, an interleukin 1 receptor associated kinase 1 (IRAK1) inhibitor, in patients (pts) with solid tumors harboring the 1q21.3 copy number amplification (CNA). Journal Of Clinical Oncology 2024, 42: 43-43. DOI: 10.1200/jco.2024.42.23_suppl.43.
- Thanh T, Tu N, Nguyet L, Thuy C, Thuan N, Ny N, Nhu L, Thanh L, Hong N, Anh N, Truong N, Van Vinh Chau N, Yen L, Van E P, Thuong N, Van Truc N, Trung P, Yap W, Pandey R, Yee S, Weng R, Mongkolsapaya J, Dejnirattisai W, Hamers R, Chantratita N, Screaton G, Dunachie S, Jones E, Stuart D, Dung N, Thwaites G, Wang L, Tan C, Van Tan L, Wang L, Cruz K, Yee S, Lu H, Ruifen W, Pandey R, Young B, Sundar R, Soebandrio A, Sawitri A, Sutarsa I, Chan Y, Jantarabenjakul W, Chan N, Tan C, Van Tan L, Anh N, Hong N, Truc T, Ny N, Han D, Thanh L, Nguyet L, Thuy C, Nhu L, Thanh T, Yen L, Hang V, Kieu P, Hoang V, Thao N, Chambers M, Thanh V, Hoang T, van Doorn H, Tung T, Thwaites C, Thwaites G, Wang L, Lim B, Hamers R, Shankar A, Suwarti S, Tayipto Y, Simarmata E, Dien R, Mongkolsapaya J, Dejnirattisai W, Chantima W, Chantratita N, Poolchanuan P, Tiacharoen V, Dulsuk A, Iamsirithaworn S, Day N, Cheah P, Poomchaichote T, Boonthaworn K, Screaton G, Dijokaite-Guraliuc A, Das R, Liu C, Supasa P, Selvaraj M, Dunachie S, Klenerman P, Jones E, Stuart D, Kronsteiner-Dobramysl B, Zewdie M, Abraham P, Hill J, Ngoc N, Grifoni A, Sette A, Yap W, Tan C, Van Tan L. Immunogenicity of Abdala COVID-19 vaccine in Vietnamese people after primary and booster vaccinations: a prospective observational study in Vietnam. International Journal Of Infectious Diseases 2024, 147: 107173. PMID: 39094762, DOI: 10.1016/j.ijid.2024.107173.
- Cecchini M, Sundar R. Proofreading the way: immune checkpoint inhibitors in polymerase ε/polymerase δ (POLE/POLD1)-altered colorectal cancer. Annals Of Oncology 2024, 35: 582-584. PMID: 38910015, DOI: 10.1016/j.annonc.2024.04.006.
- Balmaceda N, Petrillo A, Krishnan M, Zhao J, Kim S, Klute K, Sundar R. State-of-the-Art Advancements in Gastroesophageal Cancer Treatment: Harnessing Biomarkers for Precision Care. American Society Of Clinical Oncology Educational Book 2024, 44: e431060. PMID: 38771996, DOI: 10.1200/edbk_431060.
- Lee M, Ow S, Wong A, Lim S, Lim J, Soo R, Cheng Ean C, Tan D, Yong W, Chan G, Ho J, Sooi K, Low Q, Ang C, Cheo S, Sundar R, Goh B, Lee S. A phase Ib/II study of an anti-CD137 agonist antibody ADG106 in combination with weekly paclitaxel and dose-dense doxorubicin/cyclophosphamide. Journal Of Clinical Oncology 2024, 42: e14507-e14507. DOI: 10.1200/jco.2024.42.16_suppl.e14507.
- Walsh R, Ong R, Cheo S, Low P, Jayagopal A, Lee M, Ngoi N, Ow S, Wong A, Lim S, Lim Y, Heong V, Sundar R, Soo R, Chee C, Yong W, Goh B, Lee S, Tan D, Lim J. Molecular profiling of metastatic breast cancer and target-based therapeutic matching in an Asian tertiary phase I oncology unit. Frontiers In Oncology 2024, 14: 1342346. PMID: 38812774, PMCID: PMC11133600, DOI: 10.3389/fonc.2024.1342346.
- Lee Y, Chen L, Chew V, Chow E, Deng L, Hunziker W, Lee A, Leong G, Ngeow J, Pervaiz S, Sabapathy K, Skanderup A, Sundar R, Tay Y, Virshup D, Wong S, Tergaonkar V, Tam W. Pushing the Frontiers of Cancer Research: Highlights from the Frontiers in Cancer Science Conference 2023. Cancer Research 2024, 84: 1195-1198. PMID: 38616656, DOI: 10.1158/0008-5472.can-24-0721.
- Hagihara T, Huang K, Sundar R, Uchihara T, Ng C, Tay S, Tan A, So J, Tan P. Abstract P37: Establishment of Gastric Organoids Biobank and Its Usage. Cancer Research 2024, 84: p37-p37. DOI: 10.1158/1538-7445.fcs2023-p37.
- Xu C, Huang K, Law J, Chua J, Sheng T, Flores N, Pizzi M, Okabe A, Tan A, Zhu F, Kumar V, Lu X, Benitez A, Lian B, Ma H, Ho S, Ramnarayanan K, Anene-Nzelu C, Razavi-Mohseni M, Ghani S, Tay S, Ong X, Lee M, Guo Y, Ashktorab H, Smoot D, Li S, Skanderup A, Beer M, Foo R, Wong J, Sanghvi K, Yong W, Sundar R, Kaneda A, Prabhakar S, Mazur P, Ajani J, Yeoh K, So J, Tan P. Abstract P28: Comprehensive Molecular Phenotyping of ARID1A -deficient Gastric Cancer Reveals Pervasive Epigenomic Reprogramming and Therapeutic Opportunities. Cancer Research 2024, 84: p28-p28. DOI: 10.1158/1538-7445.fcs2023-p28.
- Choo J, Tan W, Luk L, Zeng J, Soh T, Soon S, Lieow J, Wong C, Pang M, Bari S, Poon M, Koh L, Chng W, Jeyasekharan A, Tan L, Chan E, Sundar R. Abstract CT160: A phase I trial to evaluate allogeneic NKG2DL-targeting chimeric antigen receptor-grafted γδ T cells in subjects with advanced solid tumors or hematological malignancies (the ANGELICA Trial). Cancer Research 2024, 84: ct160-ct160. DOI: 10.1158/1538-7445.am2024-ct160.
- Zhao J, Ong J, Chia D, Teo M, Tan Q, Ng G, Tan J, Ma H, Ong X, Tay S, Tan P, Sundar R. Abstract 2759: Transcriptional intra-tumoral heterogeneity of putative therapeutic targets in colorectal cancer peritoneal metastases. Cancer Research 2024, 84: 2759-2759. DOI: 10.1158/1538-7445.am2024-2759.
- Zhao J, Chia D, Her Z, Ma H, Ong X, Tay S, So J, Chen Q, Tan P, Sundar R. Abstract 1497: Humanized mouse model unveils niche conditioning in gastric cancer peritoneal metastasis. Cancer Research 2024, 84: 1497-1497. DOI: 10.1158/1538-7445.am2024-1497.
- Fu J, Pukhari M, Dela Cruz K, Soebandrio A, Tan L, Jantarabenjakul W, Sawitri A, Chantasrisawad N, Yee S, Weng R, Sundar R, Tan C, Wang L, Sam I, Young B, Sutarsa I, Chan Y, Putcharoen O, Wacharapluesadee S, Syed Omar S, Rajasuriar R, Kukreja A, Basri S, Kamarulzaman A, Tan C, Said A, Su’ut L, Tu N, Thuy C, Nguyet L, Thanh L, Ny N, Hong N, Nhu L, Thanh T, Truong N, Ho Y, Pandey R, Diong S, Libau E, Ongko J, Lim J, Abdullah R, Yeo H, Chin Y, Jin J, Lim B, Zhu F, Chee Y, Lumandas M, Dizon T, Demetria C, Biocarles M, Inobaya M, Sornillo J, Morin J, Digman A, Roxas C, Jiz M, Pinatih K, Yuliyatni P, Manuaba I, Wisnawa I, Kusmawati A, Rissa Cempaka P. Charting the path forward in Southeast Asia: Learning from the COVID-19 vaccination challenges in six ASEAN countries. Journal Of Global Health 2024, 14: 03016. PMCID: PMC10940960, DOI: 10.7189/jogh.14.03016.
- Sundar R, Smyth E. Inconsistencies in the predictive value of PD-L1 in metastatic gastroesophageal cancer. The Lancet Gastroenterology & Hepatology 2024, 9: 495-497. PMID: 38492581, DOI: 10.1016/s2468-1253(24)00043-8.
- Ling R, Ueno R, Alamgeer M, Sundararajan K, Sundar R, Bailey M, Pilcher D, Subramaniam A. FRailty in Australian patients admitted to Intensive care unit after eLective CANCER-related SURGery: a retrospective multicentre cohort study (FRAIL-CANCER-SURG study). British Journal Of Anaesthesia 2024, 132: 695-706. PMID: 38378383, DOI: 10.1016/j.bja.2024.01.020.
- Shitara K, Falcone A, Fakih M, George B, Sundar R, Ranjan S, Van Cutsem E. Efficacy and Safety of Trifluridine/Tipiracil-Containing Combinations in Colorectal Cancer and Other Advanced Solid Tumors: A Systematic Review. The Oncologist 2024, 29: e601-e615. PMID: 38366864, PMCID: PMC11067808, DOI: 10.1093/oncolo/oyae007.
- Zhao J, Huang K, Chia D, Law J, Tan A, So J, Tan P, Sundar R. Oncogenic aberrations in primary gastric cancer tumors to predict metachronous peritoneal metastasis. Journal Of Clinical Oncology 2024, 42: 392-392. DOI: 10.1200/jco.2024.42.3_suppl.392.
- Wang M, Gwee Y, Lin Z, Yong W, Sundar R, Tan H, Choo J, Tan K, Lieske B, Cheong W, Tan T, Tey J, Chee C, Chan G. Total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC): Real-world experience from a tertiary Asian cancer center. Journal Of Clinical Oncology 2024, 42: 39-39. DOI: 10.1200/jco.2024.42.3_suppl.39.
- Provenzano L, Gwee Y, Conca V, Lonardi S, Bozzarelli S, Tamburini E, Passardi A, Zaniboni A, Tosi F, Aprile G, Nasca V, Boccaccino A, Ambrosini M, Vetere G, Carullo M, Guaglio M, Battaglia L, Zhao J, Chia D, Yong W, Tan P, So J, Kim G, Shabbir A, Ong C, Casella F, Cremolini C, Bencivenga M, Sundar R, Pietrantonio F. Unveiling the prognostic significance of malignant ascites in advanced gastrointestinal cancers: a marker of peritoneal carcinomatosis burden. Therapeutic Advances In Medical Oncology 2024, 16: 17588359241289517. PMID: 39502404, PMCID: PMC11536604, DOI: 10.1177/17588359241289517.
- A proteomic-based approach for tumour neoantigen discovery on pre-clinical model of pancreas cancer.Chew C, Lee Y, Yang H, Sundar R, Chee C, Bonney G. A proteomic-based approach for tumour neoantigen discovery on pre-clinical model of pancreas cancer. Hepato Pancreato Biliary 2024, 26: s809. DOI: 10.1016/j.hpb.2024.07.276.
- Alamgeer M, Ling R, Ueno R, Sundararajan K, Sundar R, Pilcher D, Subramaniam A. Frailty and long-term survival among patients in Australian intensive care units with metastatic cancer (FRAIL-CANCER study): a retrospective registry-based cohort study. The Lancet Healthy Longevity 2023, 4: e675-e684. PMID: 38042160, DOI: 10.1016/s2666-7568(23)00209-x.
- Choo J, Jeraj S, Chan G, Sundar R, Yong W, Lee M, Ngoi N, Wong A, Soo R, Chee C, Lim J, Goh B, Lee S, Tan D. 82P NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies. Annals Of Oncology 2023, 34: s1498. DOI: 10.1016/j.annonc.2023.10.217.
- Low Q, Zhao J, Wong R, Ho C, Lin Z, Tan L, Choo J, Chan G, Ho J, Asokumaran Y, Sundar R, Chee C, Yong W. MO34-4 Advanced hepatocellular carcinoma viral status and immunotherapy efficacy: A propensity-score matched analysis. Annals Of Oncology 2023, 34: s1417-s1418. DOI: 10.1016/j.annonc.2023.09.240.
- Huang K, Ma H, Chong R, Uchihara T, Lian B, Zhu F, Sheng T, Srivastava S, Tay S, Sundar R, Tan A, Ong X, Lee M, Ho S, Lesluyes T, Ashktorab H, Smoot D, Van Loo P, Chua J, Ramnarayanan K, Lau L, Gotoda T, Kim H, Ang T, Khor C, Lee J, Tsao S, Yang W, Teh M, Chung H, So J, Yeoh K, Tan P, Consortium S. Spatiotemporal genomic profiling of intestinal metaplasia reveals clonal dynamics of gastric cancer progression. Cancer Cell 2023, 41: 2019-2037.e8. PMID: 37890493, PMCID: PMC10729843, DOI: 10.1016/j.ccell.2023.10.004.
- Wong N, Yap D, Ong R, Zhao J, Chan Y, Tey J, Sundar R, Lim J, Dawood S. Efficacy of Oral SERDs in the treatment of ER+, HER2 - metastatic breast cancer, a stratified analysis of the ESR1 wild type and mutant subgroups. Annals Of Oncology 2023 PMID: 37871699, DOI: 10.1016/j.annonc.2023.10.122.
- Smyth E, Sundar R. Combining chemotherapy, trastuzumab, and immune-checkpoint inhibitors in HER2-positive gastro-oesophageal cancer. The Lancet 2023, 402: 2168-2170. PMID: 37871605, DOI: 10.1016/s0140-6736(23)02296-1.
- Low Q, Looi W, Sukumar S, Ang Y, Wong A, Soo R, Sundar R, Lum J, Chee C, Bonney G, Tan H, Yong W. 2282P Tissue glycan profiling in predicting immunotherapy response in renal cell carcinoma and hepatocelllular carcinoma. Annals Of Oncology 2023, 34: s1170. DOI: 10.1016/j.annonc.2023.09.1310.
- Moschetta M, Doi T, Kuboki Y, Sundar R, Möbitz H, Jaco I, Cros M, Ferretti S, Jankovic D, Thérier M, Clementi G, Li Y, De Kanter R, Quadt C. 719TiP A phase I/Ib study of the Werner (WRN) helicase inhibitor HRO761 as single agent and in combination with irinotecan or tislelizumab in patients with microsatellite instability-high (MSIhi) or mismatch repair deficient (dMMR) advanced solid tumors. Annals Of Oncology 2023, 34: s496. DOI: 10.1016/j.annonc.2023.09.1905.
- Sachdeva M, Zhao J, Zhu K, Yap D, Wong N, Barr N, Sundar R. 1559P PD-L1 expression as a negative predictive biomarker in advanced esophageal squamous cell cancer treated with chemotherapy alone: A KMSubtraction derived analysis. Annals Of Oncology 2023, 34: s873. DOI: 10.1016/j.annonc.2023.09.1471.
- Sundar R, Chia D, Ceelen W, Chia C, Kim G, Shabbir A, Willaert W, Ong J, Wong J, Seo C, Tan H, Callebout E, Geboes K, Ng M, Lum J, Leow W, Selvarajan S, Hoorens A, Yong W, So J. 1550P Evaluating the novel combination of pressurized intraperitoneal aerosol chemotherapy-oxaliplatin (PIPAC-OX) as an immunomodulator in combination with systemic nivolumab for gastric cancer peritoneal metastases. Annals Of Oncology 2023, 34: s869. DOI: 10.1016/j.annonc.2023.09.1462.
- Loh J, Choo J, Sooi K, Low P, Ang C, Sundar R, Walsh R, Wijaya S, Low J, Hsing S, Jain S, Chee C. 593P Role of circulating tumor DNA (ctDNA) in assessing primary anti–epidermal growth factor receptor (EGFR) resistance in untreated RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC) patients (pts). Annals Of Oncology 2023, 34: s429. DOI: 10.1016/j.annonc.2023.09.1784.
- Keogh G, Ann D, Cunningham D, Langley R, Allum W, Nankivell M, Tan P, Sundar R, Grabsch H. 1565P ERCC1 gene polymorphism influences overall survival in early oesophageal cancer: Results from the phase III MRC OEO2 randomised controlled trial. Annals Of Oncology 2023, 34: s875. DOI: 10.1016/j.annonc.2023.09.1477.
- Zhao J, Fong K, Chan Y, Tey J, Dawood S, Lee S, Finn R, Sundar R, Lim J. Indirect Treatment Comparison of First-Line CDK4/6-Inhibitors in Post-Menopausal Patients with HR+/HER2− Metastatic Breast Cancer. Cancers 2023, 15: 4558. PMID: 37760527, PMCID: PMC10527344, DOI: 10.3390/cancers15184558.
- Tan W, Tan J, Lim J, Tan R, Bin Lee A, Leong F, Lee S, Chai L, Tan T, Bin Abdul Malek M, Ong B, Lye D, Chiew C, Chng W, Lim S, Bharwani L, Tan I, Sundar R, Tan K. COVID-19 Severity and Waning Immunity After up to 4 mRNA Vaccine Doses in 73 608 Patients With Cancer and 621 475 Matched Controls in Singapore. JAMA Oncology 2023, 9: 1221-1229. PMID: 37440245, PMCID: PMC10346511, DOI: 10.1001/jamaoncol.2023.2271.
- Lim J, Ow S, Wong A, Lee M, Chan G, Low J, Sundar R, Choo J, Chong W, Ang Y, Tai B, Lee S. Phase II study of trifluridine/tipiracil in metastatic breast cancers with or without prior exposure to fluoropyrimidines. European Journal Of Cancer 2023, 193: 113311. PMID: 37717281, DOI: 10.1016/j.ejca.2023.113311.
- Zhao J, Pietrantonio F, Sundar R. Evidence on Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma—Reply. JAMA Oncology 2023, 9: 1005-1006. PMID: 37166787, DOI: 10.1001/jamaoncol.2023.0975.
- Wong Zhun Hong N, Zhao J, Zhu K, Yap D, Kumarakulasinghe N, Huang Y, Sundar R. PD-L1 expression as a unique negative predictive biomarker in advanced squamous NSCLC when treated with first-line chemotherapy. Journal Of Clinical Oncology 2023, 41: e21140-e21140. DOI: 10.1200/jco.2023.41.16_suppl.e21140.
- Chan G, Ho C, Lin Z, Wu J, Chieng J, Lieske B, Yong W, Sundar R, Tan H, Ho J, Choo J, Walsh R, Cheong W, Tan K, Chee C, Liu X, Lim F, Goh S, Chee C. Value-driven colorectal cancer survivorship through partnership with primary care. Journal Of Clinical Oncology 2023, 41: 6649-6649. DOI: 10.1200/jco.2023.41.16_suppl.6649.
- Zhao J, Fong K, Chan Y, Tey J, Dawood S, Lee S, Finn R, Sundar R, Lim J. Indirect treatment comparison of first-line CDK4/6-inhibitors in post-menopausal patients with HR+/HER2- metastatic breast cancer. Journal Of Clinical Oncology 2023, 41: 1071-1071. DOI: 10.1200/jco.2023.41.16_suppl.1071.
- Lim J, Ow S, Wong A, Lee M, Chan G, Low J, Sundar R, Choo J, Tai B, Lee S. Phase II study of trifluridine/tipiracil (FTD/TPI) in HER2-negative metastatic breast cancers with or without prior exposure to fluoropyrimidines. Journal Of Clinical Oncology 2023, 41: 1099-1099. DOI: 10.1200/jco.2023.41.16_suppl.1099.
- Zhao J, Wong Zhun Hong N, Yap D, Ong R, Sundar R, Lim J, Dawood S. Efficacy of oral selective estrogen receptor degraders (SERD)s in the treatment of estrogen receptor positive (ER+), HER2-negative metastatic breast cancer (MBC): A stratified analysis of the ESR1 wild type (wt) and mutant (mt) subgroups. Journal Of Clinical Oncology 2023, 41: 1096-1096. DOI: 10.1200/jco.2023.41.16_suppl.1096.
- Shitara K, George B, Taieb J, Sundar R, Fakih M, Makris L, Benhadji K, Ghidini M. Effects of prior therapies on outcomes with trifluridine/tipiracil in patients with metastatic gastric/gastroesophageal junction cancer in a randomized phase III trial (TAGS). Journal Of Cancer Research And Clinical Oncology 2023, 149: 9361-9374. PMID: 37213030, PMCID: PMC10374776, DOI: 10.1007/s00432-023-04813-z.
- Senthil Kumar K, Miskovic V, Blasiak A, Sundar R, Pedrocchi A, Pearson A, Prelaj A, Ho D. Artificial Intelligence in Clinical Oncology: From Data to Digital Pathology and Treatment. American Society Of Clinical Oncology Educational Book 2023, 43: e390084. PMID: 37235822, DOI: 10.1200/edbk_390084.
- Chee C, Ooi M, Lee S, Sundar R, Heong V, Yong W, Ng C, Wong A, Lim J, Tan D, Soo R, Tan J, Yang S, Thura M, Al-Aidaroos A, Chng W, Zeng Q, Goh B. A Phase I, First-in-Human Study of PRL3-zumab in Advanced, Refractory Solid Tumors and Hematological Malignancies. Targeted Oncology 2023, 18: 391-402. PMID: 37060431, PMCID: PMC10192144, DOI: 10.1007/s11523-023-00962-w.
- Petrillo A, Maron S, Sundar R. Controversies in upper GI oncology: first-line checkpoint inhibitor use in metastatic GEA: guided by PD-L1 CPS or not? ESMO Open 2023, 8: 101211. PMID: 37054477, PMCID: PMC10123152, DOI: 10.1016/j.esmoop.2023.101211.
- Xu C, Huang K, Law J, Chua J, Sheng T, Flores N, Pizzi M, Okabe A, Tan A, Zhu F, Kumar V, Lu X, Benitez A, Lian B, Ma H, Ho S, Ramnarayanan K, Anene-Nzelu C, Razavi-Mohseni M, Ghani S, Tay S, Ong X, Lee M, Guo Y, Ashktorab H, Smoot D, Li S, Skanderup A, Beer M, Foo R, Wong J, Sanghvi K, Yong W, Sundar R, Kaneda A, Prabhakar S, Mazur P, Ajani J, Yeoh K, So J, Tan P. Comprehensive molecular phenotyping of ARID1A-deficient gastric cancer reveals pervasive epigenomic reprogramming and therapeutic opportunities. Gut 2023, 72: 1651-1663. PMID: 36918265, DOI: 10.1136/gutjnl-2022-328332.
- Li J, Lee M, Peng S, Bin Lee A, Tay R, Chee C, Ho C, Walsh J, Chan Y, Tan K, Lee S, Chai L, Sundar R. Clinical efficacy and Long-term Immunogenicity of early triple dose COVID-19 mRNA vaccine in cancer patients. European Journal Of Surgical Oncology 2023, 49: e60-e61. PMCID: PMC9941290, DOI: 10.1016/j.ejso.2022.11.202.
- Loh J, Wu J, Chieng J, Chan A, Yong W, Sundar R, Lee S, Wong A, Lim J, Tan D, Soo R, Goh B, Tai B, Chee C. Clinical outcome and prognostic factors for Asian patients in Phase I clinical trials. British Journal Of Cancer 2023, 128: 1514-1520. PMID: 36797357, PMCID: PMC10070409, DOI: 10.1038/s41416-023-02193-2.
- Choo J, Kua L, Soe M, Asuncion B, Tan B, Teo C, Tay R, So J, Shabbir A, Guowei K, Tan H, Chan G, Ma H, Ramachandran G, Lum J, Chee C, Sridharan S, Tan P, Sundar R, Yong W. Clinical relevance of PD-1 positive CD8 T-cells in gastric cancer. Gastric Cancer 2023, 26: 393-404. PMID: 36781556, PMCID: PMC10115710, DOI: 10.1007/s10120-023-01364-7.
- Walsh R, Sundar R, Lim J. Immune checkpoint inhibitor combinations—current and emerging strategies. British Journal Of Cancer 2023, 128: 1415-1417. PMID: 36747017, PMCID: PMC10070427, DOI: 10.1038/s41416-023-02181-6.
- Lee M, Peng S, Lee A, Wong S, Tay R, Li J, Tariq A, Goh C, Tan Y, Tan B, Teo C, Chan E, Ooi M, Chng W, Chee C, Ho C, Walsh R, Wong M, Su Y, Alexander L, Sethi S, Tan S, Chan Y, Tan K, Lee S, Chai L, Sundar R. Clinical efficacy and long-term immunogenicity of an early triple dose regimen of SARS-CoV-2 mRNA vaccination in cancer patients. Annals, Academy Of Medicine, Singapore 2023, 52: 8-16. PMID: 36730801, DOI: 10.47102/annals-acadmedsg.2022302.
- Lee M, Peng S, Bin Lee A, Tay R, Li J, Wong S, Tariq A, Goh C, Tan Y, Tan B, Teo C, Chan E, Ooi M, Chng W, Chee C, Ho C, Walsh R, Sethi S, Tan S, Chan Y, Tan K, Lee S, Chai L, Sundar R. Neutralising antibody titers and COVID outcomes in cancer patients. Pathology 2023, 55: s33. PMCID: PMC9906789, DOI: 10.1016/j.pathol.2022.12.108.
- Gwee Y, Chia D, Provenzano L, Lonardi S, Conca V, Cremolini C, Yong W, Tan P, So J, Kim G, Shabbir A, Ong J, Pietrantonio F, Sundar R. Malignant ascites as a marker of peritoneal carcinomatosis burden in patients with colorectal and gastroesophageal cancer. Journal Of Clinical Oncology 2023, 41: 455-455. DOI: 10.1200/jco.2023.41.4_suppl.455.
- Chia D, Sundar R, Kim G, Ang J, Shabbir A, So J, Yong W. Outcomes of a Phase II Study of Intraperitoneal Paclitaxel Plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases. Annals Of Surgical Oncology 2022, 30: 1889-1890. PMID: 36564654, DOI: 10.1245/s10434-022-12877-3.
- Teo Y, Tan B, Tan N, Yap D, Chai Y, Teo Y, Sia C, Sundar R, Tan E, See A, Toh S. Obstructive sleep apnea and the incidence and mortality of gastrointestinal cancers: a systematic review and meta-analysis of 5,120,837 participants. Journal Of Gastrointestinal Oncology 2022, 0: 0-0. PMID: 36636076, PMCID: PMC9830329, DOI: 10.21037/jgo-22-153.
- Chia D, Sundar R, Kim G, Ang J, Lum J, Nga M, Goh G, Seet J, Chee C, Tan H, Ho J, Ngoi N, Lee M, Muthu V, Chan G, Pang A, Ang Y, Choo J, Lim J, Teh J, Lwin A, Soon Y, Shabbir A, So J, Yong W. ASO Visual Abstract: Outcomes of a Phase II Study of Intraperitoneal Paclitaxel Plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases. Annals Of Surgical Oncology 2022, 29: 8608-8609. DOI: 10.1245/s10434-022-12043-9.
- Chia D, Ang J, Sundar R, Kim G, Shabbir A, So J, Yong W. ASO Author Reflections: Combination Intra-Peritoneal and Systemic Chemotherapy for Gastric Cancer with Peritoneal Metastases. Annals Of Surgical Oncology 2022, 29: 8606-8607. PMID: 36192514, DOI: 10.1245/s10434-022-12102-1.
- Yeong J, Teo C, Tay R, Tan B, Chan Y, Smyth E, Sundar R. Reply to: Letter to editor on the article “Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy”. Gastric Cancer 2022, 25: 1133-1135. PMID: 36152122, DOI: 10.1007/s10120-022-01343-4.
- Chia D, Sundar R, Kim G, Ang J, Lum J, Nga M, Goh G, Seet J, Chee C, Tan H, Ho J, Ngoi N, Lee M, Muthu V, Chan G, Pang A, Ang Y, Choo J, Lim J, Teh J, Lwin A, Soon Y, Shabbir A, So J, Yong W. Outcomes of a Phase II Study of Intraperitoneal Paclitaxel plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases. Annals Of Surgical Oncology 2022, 29: 8597-8605. PMID: 36070113, DOI: 10.1245/s10434-022-11998-z.
- Wang M, Bandla A, Sundar R, Molassiotis A. The phenotype and value of nerve conduction studies in measuring chemotherapy-induced peripheral neuropathy: A secondary analysis of pooled data. European Journal Of Oncology Nursing 2022, 60: 102196. PMID: 36067640, DOI: 10.1016/j.ejon.2022.102196.
- Fong K, Zhao J, Sultana R, Lee J, Lee S, Chan S, Yau T, Tai D, Sundar R, Too C. First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Systematic Review and Patient-Level Network Meta-Analysis. Liver Cancer 2022, 12: 7-18. PMID: 36872922, PMCID: PMC9982345, DOI: 10.1159/000526639.
- Ho S, Sheng T, Xing M, Ooi W, Xu C, Sundar R, Huang K, Li Z, Kumar V, Ramnarayanan K, Zhu F, Srivastava S, Bin Adam Isa Z, Anene-Nzelu C, Razavi-Mohseni M, Shigaki D, Ma H, Tan A, Ong X, Lee M, Tay S, Guo Y, Huang W, Li S, Beer M, Foo R, Teh M, Skanderup A, Teh B, Tan P. Regulatory enhancer profiling of mesenchymal-type gastric cancer reveals subtype-specific epigenomic landscapes and targetable vulnerabilities. Gut 2022, 72: 226-241. PMID: 35817555, DOI: 10.1136/gutjnl-2021-326483.
- Loh J, Ang Y, Jain A, Yeong J, Sundar R. Targeting Anaplastic Lymphoma Kinase in GI Primary Malignancies. JCO Precision Oncology 2022, 6: e2200208. PMID: 35939772, PMCID: PMC9384951, DOI: 10.1200/po.22.00208.
- Chia D, Gwee Y, Sundar R. Resistance to systemic immune checkpoint inhibition in the peritoneal niche. Journal For ImmunoTherapy Of Cancer 2022, 10: e004749. PMID: 35728873, PMCID: PMC9214396, DOI: 10.1136/jitc-2022-004749.
- Chan S, Chotipanich C, Choo S, Kwang S, Mo F, Worakitsitisatorn A, Tai D, Sundar R, Ng D, Loke K, Li L, Ng K, Peng Y, Yu S. Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres Followed by Gemcitabine plus Cisplatin for Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Single-Arm Multicenter Clinical Trial. Liver Cancer 2022, 11: 451-459. PMID: 36158588, PMCID: PMC9485918, DOI: 10.1159/000525489.
- Mai A, Lee A, Tay R, Shapiro L, Thakkar A, Halmos B, Grinshpun A, Herishanu Y, Benjamini O, Tadmor T, Shroff R, LaFleur B, Bhattacharya D, Peng S, Tey J, Lee S, Chai L, Soon Y, Sundar R, Lee M. Booster doses of COVID-19 vaccines for patients with haematological and solid cancer: a systematic review and individual patient data meta-analysis. European Journal Of Cancer 2022, 172: 65-75. PMID: 35753213, PMCID: PMC9163022, DOI: 10.1016/j.ejca.2022.05.029.
- Tay R, Yeong J, Lum J, Teo C, Tan B, Chan Y, Choo J, Jeyasekhran A, Miow Q, Loo L, Yong W, Sundar R. Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy. Journal Of Clinical Oncology 2022, 40: 4026-4026. DOI: 10.1200/jco.2022.40.16_suppl.4026.
- Ang C, Low Q, Ho C, Walsh R, Asokumaran Y, Choo J, Chan G, Ho J, Ang Y, Tan L, Yong W, Sundar R, Chee C. Real-world experience on the efficacy and tolerability of biweekly trifluridine/tipiracil with or without bevacizumab in metastatic colorectal cancer. Journal Of Clinical Oncology 2022, 40: 3584-3584. DOI: 10.1200/jco.2022.40.16_suppl.3584.
- Blasiak A, Truong A, Jeit L, Kumar K, Tan S, Teo C, Tan B, Tadeo X, Tan L, Chee C, Yong W, Ho D, Sundar R. PRECISE CURATE.AI: A prospective feasibility trial to dynamically modulate personalized chemotherapy dose with artificial intelligence. Journal Of Clinical Oncology 2022, 40: 1574-1574. DOI: 10.1200/jco.2022.40.16_suppl.1574.
- Sooi K, Low J, Miow Q, Kumarakulasinghe N, Sundar R, Huang Y. Pan-immune-inflammation value as a predictive biomarker for survival in advanced non-small cell lung cancer patients treated with immunotherapy. Journal Of Clinical Oncology 2022, 40: e21095-e21095. DOI: 10.1200/jco.2022.40.16_suppl.e21095.
- Chan J, Zhang B, Chew X, Salhi A, Kwok Z, Lim C, Desi N, Subramaniam N, Siemens A, Kinanti T, Ong S, Sanchez-Mejias A, Ly P, An O, Sundar R, Fan X, Wang S, Siew B, Lee K, Chong C, Lieske B, Cheong W, Goh Y, Fam W, Ooi M, Koh B, Iyer S, Ling W, Chen J, Yoong B, Chanwat R, Bonney G, Goh B, Zhai W, Fullwood M, Wang W, Tan K, Chng W, Dan Y, Pitt J, Roca X, Guccione E, Vardy L, Chen L, Gao X, Chow P, Yang H, Tay Y. Pan-cancer pervasive upregulation of 3′ UTR splicing drives tumourigenesis. Nature Cell Biology 2022, 24: 928-939. PMID: 35618746, PMCID: PMC9203280, DOI: 10.1038/s41556-022-00913-z.
- Nargund A, Xu C, Mandoli A, Okabe A, Chen G, Huang K, Sheng T, Yao X, Teo J, Sundar R, Kok Y, See Y, Xing M, Li Z, Yong C, Anand A, Bin Adam Isa Z, Poon L, Ng M, Koh J, Ooi W, Tay S, Ong X, Tan A, Smoot D, Ashktorab H, Grabsch H, Fullwood M, Teh B, Bi X, Kaneda A, Li S, Tan P. Chromatin Rewiring by Mismatch Repair Protein MSH2 Alters Cell Adhesion Pathways and Sensitivity to BET Inhibition in Gastric Cancer. Cancer Research 2022, 82: 2538-2551. PMID: 35583999, DOI: 10.1158/0008-5472.can-21-2072.
- Tan B, Teo Y, Tan N, Yap D, Sundar R, Lee C, See A, Toh S. Association of obstructive sleep apnea and nocturnal hypoxemia with all-cancer incidence and mortality: a systematic review and meta-analysis. Journal Of Clinical Sleep Medicine 2022, 18: 1427-1440. PMID: 34755597, PMCID: PMC9059590, DOI: 10.5664/jcsm.9772.
- Zhao J, Syn N, Tan B, Yap D, Teo C, Chan Y, Sundar R. KMSubtraction: reconstruction of unreported subgroup survival data utilizing published Kaplan-Meier survival curves. BMC Medical Research Methodology 2022, 22: 93. PMID: 35369867, PMCID: PMC8978435, DOI: 10.1186/s12874-022-01567-z.
- Lim J, Wong A, Ow S, Ngoi N, Chan G, Ang Y, Chong W, Lim S, Lim Y, Lee M, Choo J, Tan H, Yong W, Soo R, Tan D, Chee C, Sundar R, Yadav K, Jain S, Wang L, Tai B, Goh B, Lee S. Phase Ib/II Dose Expansion Study of Lenvatinib Combined with Letrozole in Postmenopausal Women with Hormone Receptor-Positive Breast Cancer. Clinical Cancer Research 2022, 28: 2248-2256. PMID: 35363275, DOI: 10.1158/1078-0432.ccr-21-4179.
- Lee M, Wong A, Ow S, Sundar R, Tan D, Soo R, Chee C, Lim J, Yong W, Lim S, Goh B, Wang L, Lee S. Phase Ib Dose-Finding Study of Varlitinib Combined with Weekly Paclitaxel With or Without Carboplatin ± Trastuzumab in Advanced Solid Tumors. Targeted Oncology 2022, 17: 141-151. PMID: 35195837, PMCID: PMC8995271, DOI: 10.1007/s11523-022-00867-0.
- Tan D, Lim W, Yong J, Ng C, Muthiah M, Tan E, Xiao J, Lim S, Pin Tang A, Pan X, Kabir T, Bonney G, Sundar R, Syn N, Kim B, Dan Y, Noureddin M, Loomba R, Huang D. UNOS Down-Staging Criteria for Liver Transplantation of Hepatocellular Carcinoma: Systematic Review and Meta-Analysis of 25 Studies. Clinical Gastroenterology And Hepatology 2022, 21: 1475-1484. PMID: 35181565, DOI: 10.1016/j.cgh.2022.02.018.
- Peng S, Ying A, Chan N, Sundar R, Soon Y, Bandla A. Prevention of Oxaliplatin-Induced Peripheral Neuropathy: A Systematic Review and Meta-Analysis. Frontiers In Oncology 2022, 12: 731223. PMID: 35186722, PMCID: PMC8853097, DOI: 10.3389/fonc.2022.731223.
- Cheo S, Lee J, Walsh R, Sundar R, Choo J, Chan G, Yong W, Meah W, Khor C, Chee C. Ciprofloxacin plus gemcitabine-based chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma: A pilot study of microbiome manipulation. Journal Of Clinical Oncology 2022, 40: 570-570. DOI: 10.1200/jco.2022.40.4_suppl.570.
- Tayeb Z, Dragomir A, Lee J, Abbasi N, Dean E, Bandla A, Bose R, Sundar R, Bezerianos A, Thakor N, Cheng G. Distinct spatio-temporal and spectral brain patterns for different thermal stimuli perception. Scientific Reports 2022, 12: 919. PMID: 35042875, PMCID: PMC8766611, DOI: 10.1038/s41598-022-04831-w.
- Leen A, Yap D, Teo C, Tan B, Molassiotis A, Ishiguro H, Fan S, Sundar R, Soon Y, Bandla A. A Systematic Review and Meta-Analysis of the Effectiveness of Neuroprotectants for Paclitaxel-Induced Peripheral Neuropathy. Frontiers In Oncology 2022, 11: 763229. PMID: 35070969, PMCID: PMC8766304, DOI: 10.3389/fonc.2021.763229.
- Ho J, Heong V, Yong W, Soo R, Chee C, Wong A, Sundar R, Thian Y, Gopinathan A, Pang M, Koe P, Jeraj S, Soe P, Soe M, Tang T, Ng M, Tai D, Tan T, Xu H, Chang H, Landesman Y, Shah J, Shacham S, Lee S, Tan D, Goh B, Tan D. A phase 1 study of the safety, pharmacokinetics and pharmacodynamics of escalating doses followed by dose expansion of the selective inhibitor of nuclear export (SINE) selinexor in Asian patients with advanced or metastatic malignancies. Therapeutic Advances In Medical Oncology 2022, 14: 17588359221087555. PMID: 35432603, PMCID: PMC9008867, DOI: 10.1177/17588359221087555.
- Jia J, Guo Y, Sundar R, Bandla A, Hao Z. Cryotherapy for Prevention of Taxane-Induced Peripheral Neuropathy: A Meta-Analysis. Frontiers In Oncology 2021, 11: 781812. PMID: 34912720, PMCID: PMC8667340, DOI: 10.3389/fonc.2021.781812.
- Chin Y, Jain S, Lee M, Ng C, Lin S, Mai A, Muthiah M, Foo F, Sundar R, Ong D, Leow W, Leong R, Chan W. Small bowel adenocarcinoma in Crohn’s disease: a systematic review and meta-analysis of the prevalence, manifestation, histopathology, and outcomes. International Journal Of Colorectal Disease 2021, 37: 239-250. PMID: 34704127, DOI: 10.1007/s00384-021-04050-1.
- Sheng T, Ho S, Ooi W, Xu C, Xing M, Padmanabhan N, Huang K, Ma L, Ray M, Guo Y, Sim N, Anene-Nzelu C, Chang M, Razavi-Mohseni M, Beer M, Foo R, Sundar R, Chan Y, Tan A, Ong X, Skanderup A, White K, Jha S, Tan P. Integrative epigenomic and high-throughput functional enhancer profiling reveals determinants of enhancer heterogeneity in gastric cancer. Genome Medicine 2021, 13: 158. PMID: 34635154, PMCID: PMC8504099, DOI: 10.1186/s13073-021-00970-3.
- Loh J, Wu J, Chieng J, Chan A, Yong W, Sundar R, Lee S, Wong A, Lim J, Tan D, Soo R, Chng W, Goh B, Tai B, Chee C. 1835P Clinical outcome and prognostic factors for Asian patients in phase I clinical trials. Annals Of Oncology 2021, 32: s1241. DOI: 10.1016/j.annonc.2021.08.723.
- Lim J, Sundar R, Wong A, Yong W, Soo R, Chee C, Lee S, Goh B, Dent R, Jeraj S, Kwok L, Schiavon G, Kaliaperumal N, Foxley A, Connolly J, Tan D. 515MO A phase I trial of durvalumab (Durv) in combination with olaparib (Ola) and capivasertib (Cap) in patients (pts) with advanced or metastatic cancers (Ca) (MEDIPAC). Annals Of Oncology 2021, 32: s585-s586. DOI: 10.1016/j.annonc.2021.08.1037.
- Teo C, Tan B, Tadeo X, Peng S, Soh H, Du S, Luo V, Bandla A, Sundar R, Ho D, Kee T, Blasiak A. Abstract CT211: Personalized, rational, efficacy-driven chemotherapy dosing via an artificial intelligence system (PRECISE): A protocol for the PRECISE CURATE.AI pilot clinical trial. Cancer Research 2021, 81: ct211-ct211. DOI: 10.1158/1538-7445.am2021-ct211.
- Chan S, Chotipanich C, Choo S, Kwang S, Worakitsitisatorn A, Tai D, Yong W, Sundar R, Li L, Yu S, Sungkasubun P. P-19 A multicentred phase II clinical trial on yttrium 90-resin microspheres followed by gemcitabine-cisplatin for treatment of locally advanced intra-hepatic cholangiocarcinoma. Annals Of Oncology 2021, 32: s102. DOI: 10.1016/j.annonc.2021.05.074.
- Ong S, Sundar R, Bandla A, Kim N. Wearable Physiological Stress Monitoring System—A Proof-of-Concept Study. 2021, 623-633. DOI: 10.1007/978-981-15-9472-4_54.
- Tan B, Teo C, Tadeo X, Peng S, Soh H, Du S, Luo V, Bandla A, Sundar R, Ho D, Kee T, Blasiak A. Personalised, Rational, Efficacy-Driven Cancer Drug Dosing via an Artificial Intelligence SystEm (PRECISE): A Protocol for the PRECISE CURATE.AI Pilot Clinical Trial. Frontiers In Digital Health 2021, 3: 635524. PMID: 34713106, PMCID: PMC8521832, DOI: 10.3389/fdgth.2021.635524.
- Collins D, Sundar R, Constantinidou A, Dolling D, Yap T, Popat S, O’Brien M, Banerji U, de Bono J, Lopez J, Tunariu N, Minchom A. Correction to: Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease. BMC Cancer 2021, 21: 245. PMID: 33685408, PMCID: PMC7938531, DOI: 10.1186/s12885-021-07999-y.
- Low J, Huang Y, Sooi K, Ang Y, Chan Z, Spencer K, Jeyasekharan A, Sundar R, Goh B, Soo R, Yong W. Low‐dose pembrolizumab in the treatment of advanced non‐small cell lung cancer. International Journal Of Cancer 2021, 149: 169-176. PMID: 33634869, PMCID: PMC9545741, DOI: 10.1002/ijc.33534.
- Ho J, Heong V, Yong W, Soo R, Chee C, Wong A, Thian Y, Sundar R, Gopinathan A, Lee S, Goh B, Xu H, Tan D. 40P Phase I study of the safety, pharmacokinetics and pharmacodynamics of escalating doses followed by dose expansion of selinexor in Asian patients with advanced solid tumour malignancies. Annals Of Oncology 2021, 32: s17. DOI: 10.1016/j.annonc.2021.01.055.
- An O, Song Y, Ke X, So J, Sundar R, Yang H, Rha S, Lee M, Tay S, Ong X, Tan A, Ng M, Tantoso E, Chen L, Tan P, Yong W, Consortium S. “3G” Trial: An RNA Editing Signature to Guide Gastric Cancer ChemotherapyRNA Editing Signature in Gastric Cancer. Cancer Research 2021, 81: 2788-2798. PMID: 33558338, DOI: 10.1158/0008-5472.can-20-2872.
- Shitara K, George B, Taieb J, Sundar R, Fakih M, Makris L, Benhadji K, Ghidini M. The impact of prior therapies on outcomes with trifluridine/tipiracil (FTD/TPI) in the phase III TAGS trial. Journal Of Clinical Oncology 2021, 39: 247-247. DOI: 10.1200/jco.2021.39.3_suppl.247.
- Chia D, Sundar R, Kim G, Ang J, Lum J, Nga M, Cheng Ean C, Tan H, Ho J, Ngoi N, Lee M, Muthu V, Chan G, Pang A, Ang Y, Choo J, Lim J, Shabbir A, Yong W, So J. Outcomes of a phase II study of intraperitoneal paclitaxel plus systemic capecitabine and oxaliplatin (XELOX) for gastric cancer with peritoneal metastases. Journal Of Clinical Oncology 2021, 39: 165-165. DOI: 10.1200/jco.2021.39.3_suppl.165.
- Binder J, Unver E, Clayton J, Burke P, Paxman R, Sundar R, Bandla A. A Limb Hypothermia Wearable for Chemotherapy-Induced Peripheral Neuropathy: A Mixed-Methods Approach in Medical Product Development. Frontiers In Digital Health 2020, 2: 573234. PMID: 34713046, PMCID: PMC8521967, DOI: 10.3389/fdgth.2020.573234.
- Collins D, Sundar R, Constantinidou A, Dolling D, Yap T, Popat S, O’Brien M, Banerji U, de Bono J, Lopez J, Tunariu N, Minchom A. Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease. BMC Cancer 2020, 20: 1210. PMID: 33298007, PMCID: PMC7724793, DOI: 10.1186/s12885-020-07662-y.
- Ang Y, Ho G, Soo R, Sundar R, Tan S, Yong W, Ow S, Lim J, Chong W, Soe P, Tai B, Wang L, Goh B, Lee S. A randomized phase II trial evaluating the addition of low dose, short course sunitinib to docetaxel in advanced solid tumours. BMC Cancer 2020, 20: 1118. PMID: 33203399, PMCID: PMC7672922, DOI: 10.1186/s12885-020-07616-4.
- Kim G, Tan L, Sundar R, Lieske B, Chee C, Ho J, Shabbir A, Babak M, Ang W, Goh B, Yong W, Wang L, So J. PIPAC-OX: A Phase I Study of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy in Patients with Peritoneal Metastases. Clinical Cancer Research 2020, 27: 1875-1881. PMID: 33148667, DOI: 10.1158/1078-0432.ccr-20-2152.
- Chong W, Lim C, Sinha A, Tan C, Chan G, Huang Y, Kumarakulasinghe N, Sundar R, Jeyasekharan A, Loh W, Tay J, Yadav K, Wang L, Wong A, Kong L, Soo R, Lau J, Soon Y, Goh R, Ho F, Chong S, Lee S, Loh K, Tai B, Lim Y, Goh B. Integration of Antiangiogenic Therapy with Cisplatin and Gemcitabine Chemotherapy in Patients with Nasopharyngeal Carcinoma. Clinical Cancer Research 2020, 26: 5320-5328. PMID: 32816944, DOI: 10.1158/1078-0432.ccr-20-1727.
- Cheong C, Nistala K, Ng C, Syn N, Chang H, Sundar R, Yang S, Chong C. Neoadjuvant therapy in locally advanced colon cancer: a meta-analysis and systematic review. Journal Of Gastrointestinal Oncology 2020, 11: 847-857. PMID: 33209481, PMCID: PMC7657836, DOI: 10.21037/jgo-20-220.
- Lee S, Shimasaki N, Lim J, Wong A, Yadav K, Yong W, Tan L, Koh L, Poon M, Tan S, Ow S, Bharwani L, Yap Y, Foo M, Coustan-Smith E, Sundar R, Tan L, Chong W, Kumarakulasinghe N, Lieow J, Koe P, Goh B, Campana D. Phase I Trial of Expanded, Activated Autologous NK-cell Infusions with Trastuzumab in Patients with HER2-positive Cancers. Clinical Cancer Research 2020, 26: 4494-4502. PMID: 32522887, DOI: 10.1158/1078-0432.ccr-20-0768.
- Toh J, Hoppe M, Thakur T, Yang H, Tan K, Pang B, Ho S, Roy R, Ho K, Yeoh K, Tan P, Sundar R, Jeyasekharan A. Profiling of gastric cancer cell-surface markers to achieve tumour–normal discrimination. BMJ Open Gastroenterology 2020, 7: e000452. PMID: 32816956, PMCID: PMC7437876, DOI: 10.1136/bmjgast-2020-000452.
- Cheng H, Lopez V, Lam S, Leung A, Li Y, Wong K, Au J, Sundar R, Chan A, De Ng T, Suen L, Chan C, Yorke J, Molassiotis A. Psychometric testing of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group—Neurotoxicity (FACT/GOG-Ntx) subscale in a longitudinal study of cancer patients treated with chemotherapy. Health And Quality Of Life Outcomes 2020, 18: 246. PMID: 32703223, PMCID: PMC7376939, DOI: 10.1186/s12955-020-01493-y.
- Tan H, Kim G, Charles C, Li R, Jang C, Shabbir A, Chue K, Tai C, Sundar R, Goh B, Bonney G, Looi W, Cheow E, So J, Wang L, Yong W. Safety, pharmacokinetics and tissue penetration of PIPAC paclitaxel in a swine model. European Journal Of Surgical Oncology 2020, 47: 1124-1131. PMID: 32800400, DOI: 10.1016/j.ejso.2020.06.031.
- Bandla A, Santhanakrishnan P, Magarajah G, Vaidya G, Subramanian A, Wei H, Wilder-Smith E, Chin L, Thakor N, Sundar R. Limb Hypothermia for the Prevention of Chemotherapy-Induced Peripheral Neuropathy – Modality for Optimal Cooling. Annual International Conference Of The IEEE Engineering In Medicine And Biology Society (EMBC) 2020, 00: 5061-5064. PMID: 33019124, DOI: 10.1109/embc44109.2020.9175432.
- Kim G, Tan H, Sundar R, Wang L, Shabbir A, Yong W, So J. P-159 First-in-human phase 1 dose-escalating study protocol of pressurized intraperitoneal aerosol chemotherapy with paclitaxel in peritoneal carcinomatosis (PIPAC2 study). Annals Of Oncology 2020, 31: s141. DOI: 10.1016/j.annonc.2020.04.241.
- Ng C, Jiang A, Toh E, Ng C, Ong Z, Peng S, Tham H, Sundar R, Chong C, Khoo C. Metformin and colorectal cancer: a systematic review, meta-analysis and meta-regression. International Journal Of Colorectal Disease 2020, 35: 1501-1512. PMID: 32592092, DOI: 10.1007/s00384-020-03676-x.
- Walsh R, Ngoi N, Ong R, Ow S, Wong A, Eng L, Lim Y, Heong V, Sundar R, Soo R, Yong W, Chee C, Goh B, Lee S, Tan D, Lim J. Molecular profiling of metastatic breast cancer (MBC) and target-based therapeutic matching in an Asian tertiary phase I oncology unit. Journal Of Clinical Oncology 2020, 38: 3561-3561. DOI: 10.1200/jco.2020.38.15_suppl.3561.
- Wong R, Wu J, Leen A, Tey G, Asokumaran Y, Chan G, Siddappan C, Jeyasekharan A, Chee C, Yong W, Ngiam K, Sundar R. The role of targeted therapy (TKI) in the treatment of advanced hepatocellular carcinoma (aHCC) in the era of immunotherapy: Real-world data using AI analytics from an academic medical center. Journal Of Clinical Oncology 2020, 38: e16623-e16623. DOI: 10.1200/jco.2020.38.15_suppl.e16623.
- Lim J, Wong A, Ow S, Ngoi N, Ang Y, Chan G, Eng L, Chong W, Choo J, Lee M, Tan H, Jan Y, Tan K, Sundar R, Tan D, Soo R, Chee C, Yong W, Goh B, Lee S. Clinical efficacy and molecular effects of lenvatinib (Len) and letrozole (Let) in hormone receptor-positive (HR+) metastatic breast cancer (MBC). Journal Of Clinical Oncology 2020, 38: 1019-1019. DOI: 10.1200/jco.2020.38.15_suppl.1019.
- Sundar R, Magarajah G, Ow S, Chan G, Choo J, Eng L, Wong A, Vijayan J, Hairom Z, Ang E, Paxman R, Wilder-Smith E, Thakor N, Lee S, Bandla A. Concomitant limb cryocompression and scalp cooling to reduce paclitaxel-induced neuropathy and alopecia. Journal Of Clinical Oncology 2020, 38: e24157-e24157. DOI: 10.1200/jco.2020.38.15_suppl.e24157.
- Lee M, Chong W, Tan H, Chan G, Ho J, Sundar R, Chee C, Nasrallah F, Koo E, Yong W. The chemo-brain effect in colorectal cancer patients. Journal Of Clinical Oncology 2020, 38: e24095-e24095. DOI: 10.1200/jco.2020.38.15_suppl.e24095.
- Low J, Sooi K, Huang Y, Chan G, Ang Y, Chong W, Tan H, Ngoi N, Choo J, Lee M, Muthu V, Asokumaran Y, Walsh R, Wong R, Chan Z, Soo R, Sundar R, Yong W. Cost and efficacy of low-dose pembrolizumab in the treatment of non-small cell lung cancer patients in Asia. Journal Of Clinical Oncology 2020, 38: e19385-e19385. DOI: 10.1200/jco.2020.38.15_suppl.e19385.
- Sundar R, Smyth E, Peng S, Yeong J, Tan P. Predictive Biomarkers of Immune Checkpoint Inhibition in Gastroesophageal Cancers. Frontiers In Oncology 2020, 10: 763. PMID: 32500029, PMCID: PMC7243739, DOI: 10.3389/fonc.2020.00763.
- Sundar R, Kim G, Tan H, Wang L, Chue K, Tai C, Teo S, Jang C, Chee C, Lieske B, Chee C, Shabbir A, So J, Yong W. Safety and tolerability of oxaliplatin based pressurized intraperitoneal aerosol chemotherapy (PIPAC) for patients with peritoneal carcinomatosis: A phase I dose-finding study in Asian patients. Journal Of Clinical Oncology 2020, 38: 360-360. DOI: 10.1200/jco.2020.38.4_suppl.360.
- Wang W, Xiang P, Chew W, Torta F, Bandla A, Lopez V, Seow W, Lam B, Chang J, Wong P, Chayaburakul K, Ong W, Wenk M, Sundar R, Herr D. Activation of sphingosine 1-phosphate receptor 2 attenuates chemotherapy-induced neuropathy. Journal Of Biological Chemistry 2020, 295: 1143-1152. DOI: 10.1016/s0021-9258(17)49922-4.
- Wang W, Xiang P, Chew W, Torta F, Bandla A, Lopez V, Seow W, Lam B, Chang J, Wong P, Chayaburakul K, Ong W, Wenk M, Sundar R, Herr D. Activation of sphingosine 1-phosphate receptor 2 attenuates chemotherapy-induced neuropathy. Journal Of Biological Chemistry 2019, 295: 1143-1152. PMID: 31882542, PMCID: PMC6983853, DOI: 10.1074/jbc.ra119.011699.
- Bandla A, Tan S, Kumarakulasinghe N, Huang Y, Ang S, Magarajah G, Hairom Z, Lim J, Wong A, Chan G, Ngoi N, Ang E, Lee Y, Chan A, Lee S, Thakor N, Wilder-Smith E, Sundar R. Safety and tolerability of cryocompression as a method of enhanced limb hypothermia to reduce taxane-induced peripheral neuropathy. Supportive Care In Cancer 2019, 28: 3691-3699. PMID: 31811482, PMCID: PMC7316694, DOI: 10.1007/s00520-019-05177-2.
- Wang M, Cheng H, Lopez V, Sundar R, Yorke J, Molassiotis A. Redefining chemotherapy-induced peripheral neuropathy through symptom cluster analysis and patient-reported outcome data over time. BMC Cancer 2019, 19: 1151. PMID: 31775665, PMCID: PMC6882224, DOI: 10.1186/s12885-019-6352-3.
- Sundar R, Ng A, Zouridis H, Padmanabhan N, Sheng T, Zhang S, Lee M, Ooi W, Qamra A, Inam I, Hewitt L, So J, Koh V, Nankivell M, Langley R, Allum W, Cunningham D, Rozen S, Yong W, Grabsch H, Tan P. DNA epigenetic signature predictive of benefit from neoadjuvant chemotherapy in oesophageal adenocarcinoma: results from the MRC OE02 trial. European Journal Of Cancer 2019, 123: 48-57. PMID: 31655359, DOI: 10.1016/j.ejca.2019.09.016.
- Eu J, Yadav K, Lim Y, Hirpara J, Kong L, Ng Z, Lee V, Lee S, Tan D, Soo R, Chee C, Yong W, Sundar R, Lim J, Wang L, Ohi N, Tsunoda T, Pervaiz S, Goh B, Wong A. 463P Evaluation of pharmacodynamic (PD) biomarkers in advanced cancer patients treated with oxidative phosphorylation (OXPHOS) inhibitor, OPC-317 (OPC). Annals Of Oncology 2019, 30: v174. DOI: 10.1093/annonc/mdz244.025.
- Sundar R, Tan I, Chee C. Negative Predictive Biomarkers in Colorectal Cancer: PRESSING Ahead. Journal Of Clinical Oncology 2019, 37: 3066-3068. PMID: 31550189, DOI: 10.1200/jco.19.01977.
- Scaranti M, Sundar R, Daly R, Collins D, Dolling D, Gennatas S, Rao Baikady B, Kaye S, Banerji U, Lopez J, De Bono J, Minchom A. Evaluation of Electronic Activity Monitors (EAMs) during phase I clinical trials. Journal Of Clinical Oncology 2019, 37: e18175-e18175. DOI: 10.1200/jco.2019.37.15_suppl.e18175.
- Sundar R, Qamra A, Tan A, Zhang S, Ng C, Teh B, Lee J, Kim K, Tan P. Epigenetic alternate promoter utilization and association with PD-L1 expression in Epstein–Barr virus positive gastric cancer. Journal Of Clinical Oncology 2019, 37: e15509-e15509. DOI: 10.1200/jco.2019.37.15_suppl.e15509.
- Lim J, Wong A, Ow S, Eng L, Sundar R, Chan G, Yadav K, Heong V, Tan D, Soo R, Chee C, Yong W, Goh B, Lee S. A phase Ib/II trial of lenvatinib (len) and letrozole (let) incorporating pharmacodynamics studies in postmenopausal women with hormone receptor positive (HR+) locally advanced/metastatic breast cancer (LABC/MBC). Journal Of Clinical Oncology 2019, 37: 1045-1045. DOI: 10.1200/jco.2019.37.15_suppl.1045.
- Molassiotis A, Cheng H, Leung K, Li Y, Wong K, Au J, Sundar R, Chan A, De Ng T, Suen L, Chan C, Yorke J, Lopez V. Risk factors for chemotherapy‐induced peripheral neuropathy in patients receiving taxane‐ and platinum‐based chemotherapy. Brain And Behavior 2019, 9: e01312. PMID: 31063261, PMCID: PMC6576180, DOI: 10.1002/brb3.1312.
- Yeo F, Ng C, Loh K, Molassiotis A, Cheng H, Au J, Leung K, Li Y, Wong K, Suen L, Chan C, Yorke J, Farrell C, Bandla A, Ang E, Lopez V, Sundar R, Chan A. Minimal clinically important difference of the EORTC QLQ-CIPN20 for worsening peripheral neuropathy in patients receiving neurotoxic chemotherapy. Supportive Care In Cancer 2019, 27: 4753-4762. PMID: 30972646, DOI: 10.1007/s00520-019-04771-8.
- Shimomura A, Yamamoto N, Kondo S, Fujiwara Y, Suzuki S, Yanagitani N, Horiike A, Kitazono S, Ohyanagi F, Doi T, Kuboki Y, Kawazoe A, Shitara K, Ohno I, Banerji U, Sundar R, Ohkubo S, Calleja E, Nishio M. First-in-human phase I study of an oral HSP90 inhibitor, TAS-116, in patients with advanced solid tumors. Molecular Cancer Therapeutics 2019, 18: molcanther.0831.2018. PMID: 30679388, DOI: 10.1158/1535-7163.mct-18-0831.
- Sundar R, Ng A, Zouridis H, Sheng T, Zhang S, Lee M, Padmanabhan N, Ooi W, Qamra A, Nankivell M, Langley R, Allum W, Cunningham D, Grabsch H, Tan P. DNA methylation signature predictive of benefit from neoadjuvant chemotherapy in esophageal adenocarcinoma: Results from the MRC OEO2 phase III trial. Journal Of Clinical Oncology 2019, 37: 43-43. DOI: 10.1200/jco.2019.37.4_suppl.43.
- Sundar R, Huang K, Qamra A, Kim K, Kim S, Kang W, Tan A, Lee J, Tan P. Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer. Annals Of Oncology 2019, 30: 424-430. PMID: 30624548, PMCID: PMC6442650, DOI: 10.1093/annonc/mdy550.
- Brown P, Tan A, El-Esawi M, Liehr T, Blanck O, Gladue D, Almeida G, Cernava T, Sorzano C, Yeung A, Engel M, Chandrasekaran A, Muth T, Staege M, Daulatabad S, Widera D, Zhang J, Meule A, Honjo K, Pourret O, Yin C, Zhang Z, Cascella M, Flegel W, Goodyear C, van Raaij M, Bukowy-Bieryllo Z, Campana L, Kurniawan N, Lalaouna D, Hüttner F, Ammerman B, Ehret F, Cobine P, Tan E, Han H, Xia W, McCrum C, Dings R, Marinello F, Nilsson H, Nixon B, Voskarides K, Yang L, Costa V, Bengtsson-Palme J, Bradshaw W, Grimm D, Kumar N, Martis E, Prieto D, Sabnis S, Amer S, Liew A, Perco P, Rahimi F, Riva G, Zhang C, Devkota H, Ogami K, Basharat Z, Fierz W, Siebers R, Tan K, Boehme K, Brenneisen P, Brown J, Dalrymple B, Harvey D, Ng G, Werten S, Bleackley M, Dai Z, Dhariwal R, Gelfer Y, Hartmann M, Miotla P, Tamaian R, Govender P, Gurney-Champion O, Kauppila J, Zhang X, Echeverría N, Subhash S, Sallmon H, Tofani M, Bae T, Bosch O, Cuív P, Danchin A, Diouf B, Eerola T, Evangelou E, Filipp F, Klump H, Kurgan L, Smith S, Terrier O, Tuttle N, Ascher D, Janga S, Schulte L, Becker D, Browngardt C, Bush S, Gaullier G, Ide K, Meseko C, Werner G, Zaucha J, Al-Farha A, Greenwald N, Popoola S, Rahman S, Xu J, Yang S, Hiroi N, Alper O, Baker C, Bitzer M, Chacko G, Debrabant B, Dixon R, Forano E, Gilliham M, Kelly S, Klempnauer K, Lidbury B, Lin M, Lynch I, Ma W, Maibach E, Mather D, Nandakumar K, Ohgami R, Parchi P, Tressoldi P, Xue Y, Armitage C, Barraud P, Chatzitheochari S, Coelho L, Diao J, Doxey A, Gobet A, Hu P, Kaiser S, Mitchell K, Salama M, Shabalin I, Song H, Stevanovic D, Yadollahpour A, Zeng E, Zinke K, Alimba C, Beyene T, Cao Z, Chan S, Gatchell M, Kleppe A, Piotrowski M, Torga G, Woldesemayat A, Cosacak M, Haston S, Ross S, Williams R, Wong A, Abramowitz M, Effiong A, Lee S, Abid M, Agarabi C, Alaux C, Albrecht D, Atkins G, Beck C, Bonvin A, Bourke E, Brand T, Braun R, Bull J, Cardoso P, Carter D, Delahay R, Ducommun B, Duijf P, Epp T, Eskelinen E, Fallah M, Farber D, Fernandez-Triana J, Feyerabend F, Florio T, Friebe M, Furuta S, Gabrielsen M, Gruber J, Grybos M, Han Q, Heinrich M, Helanterä H, Huber M, Jeltsch A, Jiang F, Josse C, Jurman G, Kamiya H, de Keersmaecker K, Kristiansson E, de Leeuw F, Li J, Liang S, Lopez-Escamez J, Lopez-Ruiz F, Marchbank K, Marschalek R, Martín C, Miele A, Montagutelli X, Morcillo E, Nicoletti R, Niehof M, O’Toole R, Ohtomo T, Oster H, Palma J, Paterson R, Peifer M, Portilla M, Portillo M, Pritchard A, Pusch S, Raghava G, Roberts N, Ross K, Schuele B, Sergeant K, Shen J, Stella A, Sukocheva O, Uversky V, Vanneste S, Villet M, Viveiros M, Vorholt J, Weinstock C, Yamato M, Zabetakis I, Zhao X, Ziegler A, Aizat W, Atlas L, Bridges K, Chakraborty S, Deschodt M, Domingues H, Esfahlani S, Falk S, Guisado J, Kane N, Kueberuwa G, Lau C, Liang D, Liu E, Luu A, Ma C, Ma L, Moyer R, Norris A, Panthee S, Parsons J, Peng Y, Pinto I, Reschke C, Sillanpää E, Stewart C, Uhle F, Yang H, Zhou K, Zhu S, Ashry M, Bergsland N, Berthold M, Chen C, Colella V, Cuypers M, Eskew E, Fan X, Gajda M, Gonzálezlez-Prendes R, Goodin A, Graham E, Groen E, Gutiérrez-Sacristán A, Habes M, Heffler E, Higginbottom D, Janzen T, Jayaraman J, Jibb L, Jongen S, Kinyanjui T, Koleva-Kolarova R, Li Z, Liu Y, Lund B, Lussier A, Ma L, Mier P, Moore M, Nagler K, Orme M, Pearson J, Prajapati A, Saito Y, Tröder S, Uchendu F, Verloh N, Voutchkova D, Abu-Zaid A, Bakkach J, Baumert P, Dono M, Hanson J, Herbelet S, Hobbs E, Kulkarni A, Kumar N, Liu S, Loft N, Reddan T, Senghore T, Vindin H, Xu H, Bannon R, Chen B, Cheung J, Cooper J, Esnakula A, Feghali K, Ghelardi E, Gnasso A, Horbar J, Lai H, Li J, Ma L, Ma R, Pan Z, Peres M, Pranata R, Seow E, Sydes M, Testoni I, Westermair A, Yang Y, Afnan M, Albiol J, Albuquerque L, Amiya E, Amorim R, An Q, Andersen S, Aplin J, Argyropoulos C, Asmann Y, Assaeed A, Atanasov A, Atchison D, Avery S, Avillach P, Baade P, Backman L, Badie C, Baldi A, Ball E, Bardot O, Barnett A, Basner M, Batra J, Bazanova O, Beale A, Beddoe T, Bell M, Berezikov E, Berners-Price S, Bernhardt P, Berry E, Bessa T, Billington C, Birch J, Blakely R, Blaskovich M, Blum R, Boelaert M, Bogdanos D, Bosch C, Bourgoin T, Bouvard D, Boykin L, Bradley G, Braun D, Brownlie J, Brühl A, Burt A, Butler L, Byrareddy S, Byrne H, Cabantous S, Calatayud S, Candal E, Carlson K, Casillas S, Castelvetro V, Caswell P, Cavalli G, Cerovsky V, Chagoyen M, Chen C, Chen D, Chen H, Chen H, Chen J, Chen Y, Cheng C, Cheng J, Chinapaw M, Chinopoulos C, Cho W, Chong L, Chowdhury D, Chwalibog A, Ciresi A, Cockcroft S, Conesa A, Cook P, Cooper D, Coqueret O, Corea E, Costa E, Coupland C, Crawford S, Cruz A, Cui H, Cui Q, Culver D, D’Angiulli A, Dahms T, Daigle F, Dalgleish R, Danielsen H, Darras S, Davidson S, Day D, Degirmenci V, Demaison L, Devriendt K, Ding J, Dogan Y, Dong X, Donner C, Dressick W, Drevon C, Duan H, Ducho C, Dumaz N, Dwarakanath B, Ebell M, Eisenhardt S, Elkum N, Engel N, Erickson T, Fairhead M, Faville M, Fejzo M, Festa F, Feteira A, Flood-Page P, Forsayeth J, Fox S, Franks S, Frentiu F, Frilander M, Fu X, Fujita S, Galea I, Galluzzi L, Gani F, Ganpule A, García-Alix A, Gedye K, Giordano M, Giunta C, Gleeson P, Goarant C, Gong H, Gora D, Gough M, Goyal R, Graham K, Grande-Pérez A, Graves P, Greidanus H, Grice D, Grunau C, Gumulya Y, Guo Y, Gurevich V, Gusev O, Hacker E, Hage S, Hagen G, Hahn S, Haller D, Hammerschmidt S, Han J, Han R, Handfield M, Hapuarachchi H, Harder T, Hardingham J, Heck M, Heers M, Hew K, Higuchi Y, St Hilaire C, Hilton R, Hodzic E, Hone A, Hongoh Y, Hu G, Huber H, Hueso L, Huirne J, Hurt L, Idborg H, Ikeo K, Ingley E, Jakeman P, Jensen A, Jia H, Jia H, Jia S, Jiang J, Jiang X, Jin Y, Jo D, Johnson A, Johnston M, Jonscher K, Jorens P, Jorgensen J, Joubert J, Jung S, M A, Kahan T, Kamboj S, Kang Y, Karamanos Y, Karp N, Kelly R, Kenna R, Kennedy J, Kersten B, Khalaf R, Khalid J, Khatlani T, Khider T, Kijanka G, King S, Kluz T, Knox P, Kobayashi T, Koch K, Kohonen-Corish M, Kong X, Konkle-Parker D, Korpela K, Kostrikis L, Kraiczy P, Kratz H, Krause G, Krebsbach P, Kristensen S, Kumari P, Kunimatsu A, Kurdak H, Kwon Y, Lachat C, Lagisz M, Laky B, Lammerding J, Lange M, Larrosa M, Laslett A, LeClair E, Lee K, Lee M, Lee M, Li G, Li J, Lieb K, Lim Y, Lindsey M, Line P, Liu D, Liu F, Liu H, Liu H, Lloyd V, Lo T, Locci E, Loidl J, Lorenzen J, Lorkowski S, Lovell N, Lu H, Lu W, Lu Z, Luengo G, Lundh L, Lysy P, Mabb A, Mack H, Mackey D, Mahdavi S, Maher P, Maher T, Maity S, Malgrange B, Mamoulakis C, Mangoni A, Manke T, Manstead A, Mantalaris A, Marsal J, Marschall H, Martin F, Martinez-Raga J, Martinez-Salas E, Mathieu D, Matsui Y, Maza E, McCutcheon J, McKay G, McMillan B, McMillan N, Meads C, Medina L, Merrick B, Metzger D, Meunier F, Michaelis M, Micheau O, Mihara H, Mintz E, Mizukami T, Moalic Y, Mohapatra D, Monteiro A, Montes M, Moran J, Morozov S, Mort M, Murai N, Murphy D, Murphy S, Murray S, Naganawa S, Nammi S, Nasios G, Natoli R, Nguyen F, Nicol C, van Nieuwerburgh F, Nilsen E, Nobile C, O’Mahony M, Ohlsson S, Olatunbosun O, Olofsson P, Ortiz A, Ostrikov K, Otto S, Outeiro T, Ouyang S, Paganoni S, Page A, Palm C, Paradies Y, Parsons M, Parsons N, Pascal P, Paul E, Peckham M, Pedemonte N, Pellizzon M, Petrelli M, Pichugin A, Pinto C, Plevris J, Pollesello P, Polz M, Ponti G, Porcelli P, Prince M, Quinn G, Quinn T, Ramula S, Rappsilber J, Rehfeldt F, Reiling J, Remacle C, Rezaei M, Riddick E, Ritter U, Roach N, Roberts D, Robles G, Rodrigues T, Rodriguez C, Roislien J, Roobol M, Rowe J, Ruepp A, van Ruitenbeek J, Rust P, Saad S, Sack G, Santos M, Saudemont A, Sava G, Schrading S, Schramm A, Schreiber M, Schuler S, Schymkowitz J, Sczyrba A, Seib K, Shi H, Shimada T, Shin J, Shortt C, Silveyra P, Skinner D, Small I, Smeets P, So P, Solano F, Sonenshine D, Song J, Southall T, Speakman J, Srinivasan M, Stabile L, Stasiak A, Steadman K, Stein N, Stephens A, Stewart D, Stine K, Storlazzi C, Stoynova N, Strzalka W, Suarez O, Sultana T, Sumant A, Summers M, Sun G, Tacon P, Tanaka K, Tang H, Tanino Y, Targett-Adams P, Tayebi M, Tayyem R, Tebbe C, Telfer E, Tempel W, Teodorczyk-Injeyan J, Thijs G, Thorne S, Thrift A, Tiffon C, Tinnefeld P, Tjahjono D, Tolle F, Toth E, del Tredici A, Tsapas A, Tsirigotis K, Turak A, Tzotzos G, Udo E, Utsumi T, Vaidyanathan S, Vaillant M, Valsesia A, Vandenbroucke R, Veiga F, Vendrell M, Vesk P, Vickers P, Victor V, Villemur R, Vohl M, Voolstra C, Vuillemin A, Wakelin S, Waldron L, Walsh L, Wang A, Wang F, Wang Y, Watanabe Y, Weigert A, Wen J, Wham C, White E, Wiener J, Wilharm G, Wilkinson S, Willmann R, Wilson C, Wirth B, Wojan T, Wolff M, Wong B, Wu T, Wuerbel H, Xiao X, Xu D, Xu J, Xu J, Xue B, Yalcin S, Yan H, Yang E, Yang S, Yang W, Ye Y, Ye Z, Yli-Kauhaluoma J, Yoneyama H, Yu Y, Yuan G, Yuh C, Zaccolo M, Zeng C, Zevnik B, Zhang C, Zhang L, Zhang L, Zhang Y, Zhang Y, Zhang Z, Zhang Z, Zhao Y, Zhou M, Zuberbier T, Aanei C, Ahmad R, Al-Lawama M, Alanio A, Allardyce J, Alonso-Caneiro D, Atack J, Baier D, Bansal A, Benezeth Y, Berbesque C, Berrevoet F, Biedermann P, Bijleveld E, Bittner F, Blombach F, van den Bos W, Boudreau S, Bramoweth A, Braubach O, Cai Y, Campbell M, Cao Z, Catry T, Chen X, Cheng S, Chung H, Chávez-Fumagalli M, Conway A, Costa B, Cyr N, Dean L, Denzel M, Dlamini S, Dudley K, Dufies M, Ecke T, Eckweiler D, Eixarch E, El-Adawy H, Emmrich J, Eustace A, Falter-Wagner C, Fuss J, Gao J, Gill M, Gloyn L, Goggs R, Govinden U, Greene G, Greiff V, Grundle D, Grüneberg P, Gumede N, Haore G, Harrison P, Hoenner X, Hojsgaard D, Hori H, Ikonomopoulou M, Jeurissen P, Johnson D, Kabra D, Kamagata K, Karmakar C, Kasian O, Kaye L, Khan M, Kim Y, Kish J, Kobold S, Kohanbash G, Kohls G, Kugler J, Kumar G, Lacy-Colson J, Latif A, Lauschke V, Li B, Lim C, Liu F, Liu X, Lu J, Lu Q, Mahavadi P, Marzocchi U, McGarrigle C, van Meerten T, Min R, Moal I, Molari M, Molleman L, Mondal S, van de Mortel T, Moss W, Moultos O, Mukherjee M, Nakayama K, Narayan E, Navaratnarajah, Neumann P, Nie J, Nie Y, Niemeyer F, Nolan F, Nwaiwu O, Oldenmenger W, Olumayede E, Ou J, Pallebage-Gamarallage M, Pearce S, Pelkonen T, Pelleri M, Pereira J, Pheko M, Pinto K, Piovesan A, Pluess M, Podolsky I, Prescott J, Qi D, Qi X, Raikou V, Ranft A, Rhodes J, Rotge J, Rowe A, Saggar M, Schuon R, Shahid S, Shalchyan V, Shirvalkar P, Shiryayev O, Singh J, Smout M, Soares A, Song C, Srivastava K, Srivastava R, Sun J, Szabo A, Szymanski W, Tai C, Takeuchi H, Tanadini-Lang S, Tang F, Tao W, Theron G, Tian C, Tian Y, Tuttle L, Valenti A, Verlot P, Walker M, Wang J, Welter D, Winslade M, Wu D, Wu Y, Xiao H, Xu B, Xu J, Xu Z, Yang D, Yang M, Yankilevich P, You Y, Yu C, Zhan J, Zhang G, Zhang K, Zhang T, Zhang Y, Zhao G, Zhao J, Zhou X, Zhu Z, Ajani P, Anazodo U, Bagloee S, Bail K, Bar I, Bathelt J, Benkeser D, Bernier M, Blanchard A, Boakye D, Bonatsos V, Boon M, Bouboulis G, Bromfield E, Brown J, Bul K, Burton K, Butkowski E, Carroll G, Chao F, Charrier E, Chen X, Chen Y, Chenguang, Choi J, Christoffersen T, Comel J, Cosse C, Cui Y, van Dessel P, Dhaval, Diodato D, Duffey M, Dutt A, Egea L, El-Said M, Faye M, Fernandez-Fernandez B, Foley K, Founou L, Fu F, Gadelkareem R, Galimov E, Garip G, Gemmill A, Gouil Q, Grey J, Gridneva Z, Grothe M, Grébert T, Guerrero F, Guignard L, Haenssgen M, Hasler D, Holgate J, Huang A, Hulse-Kemp A, Jean-Quartier C, Jeon S, Jia Y, Jutzeler C, Kalatzis P, Karim M, Karsay K, Keitel A, Kempe A, Keown J, Khoo C, Khwaja N, Kievit R, Kosanic A, Koutoukidis D, Kramer P, Kumar D, Kırağ N, Lanza G, Le T, Leem J, Leightley D, Leite A, Lercher L, Li Y, Lim R, Lima L, Lin L, Ling T, Liu Y, Liu Z, Lu Y, Lum F, Luo H, Machhi J, Macleod A, Macwan I, Madala H, Madani N, de Maio N, Makowiecki K, Mallinson D, Margelyte R, Maria C, Markonis Y, Marsili L, Mavoa S, McWilliams L, Megersa M, Mendes C, Menichetti J, Mercieca-Bebber R, Miller J, Minde D, Minges A, Mishra E, Mishra V, Moores C, Morrice N, Moskalensky A, Navarin N, Negera E, Nolet P, Nordberg A, Nordén R, Nowicki J, Olova N, Olszewski P, Onzima R, Pan C, Park C, Park D, Park S, Patil C, Pedro S, Perry S, Peter J, Peterson B, Pezzuolo A, Pozdnyakov I, Qian S, Qin L, Rafe A, Raote I, Raza A, Rebl H, Refai O, Regan T, Richa T, Richardson M, Robinson K, Rossoni L, Rouet R, Safaei S, Schneeberger P, Schwotzer D, Sebastian A, Selinski J, Seltmann S, Sha F, Shalev N, Shang J, Singer J, Singh M, Smith T, Solomon-Moore E, Song L, Soraggi S, Stanley R, Steckhan N, Strobl F, Subissi L, Supriyanto I, Surve C, Suzuki T, Syme C, Sörelius K, Tang Y, Tantawy M, Tennakoon S, Teseo S, Toelzer C, Tomov N, Tovar M, Tran L, Tripathi S, Tuladhar A, Ukubuiwe A, Ung C, Valgepea K, Vatanparast H, Vidal A, Wang F, Wang Q, Watari R, Webster R, Webster R, Wei J, Wibowo D, Wingenbach T, Xavier R, Xiao S, Xiong P, Xu S, Xu S, Yao R, Yao W, Yin Q, Yu Y, Zaitsu M, Zeineb Z, Zhan X, Zhang J, Zhang R, Zhang W, Zhang X, Zheng S, Zhou B, Zhou X, Ahmad H, Akinwumi S, Albery G, Alhowimel A, Ali J, Alshehri M, Alsuhaibani M, Anikin A, Azubuike S, Bach-Mortensen A, Baltiansky L, Bartas M, Belachew K, Bhardwaj V, Binder K, Bland N, Boah M, Bullen B, Calabrò G, Callahan T, Cao B, Chalmers K, Chang W, Che Z, Chen A, Chen H, Chen H, Chen Y, Chen Z, Choi Y, Chowdhury M, Christensen M, Cooke R, Cottini M, Covington N, Cunningham C, Delarocque J, Devos L, Dhar A, Ding K, Dong K, Dong Z, Dreyer N, Ekstrand C, Fardet T, Feleke B, Feurer T, Freitas A, Gao T, Asefa N, Giganti F, Grabowski P, Guerra-Mora J, Guo C, Guo X, Gupta H, He S, Heijne M, Heinemann S, Hogrebe A, Huang Z, Iskander-Rizk S, Iyer L, Jahan Y, James A, Joel E, Joffroy B, Jégousse C, Kambondo G, Karnati P, Kaya C, Ke A, Kelly D, Kickert R, Kidibule P, Kieselmann J, Kim H, Kitazawa T, Lamberts A, Li Y, Liang H, Linn S, Litfin T, Liusuo W, Lygirou V, Mahato A, Mai Z, Major R, Mali S, Mallis P, Mao W, Mao W, Marvin-Dowle K, Mason L, Merideth B, Merino-Plaza M, Merlaen B, Messina R, Mishra A, Muhammad J, Musinguzi C, Nanou A, Naqash A, Nguyen J, Nguyen T, Ni D, Nida, Notcovich S, Ohst B, Ollivier Q, Osses D, Peng X, Plantinga A, Pulia M, Rafiq M, Raman A, Raucher-Chéné D, Rawski R, Ray A, Razak L, Rudolf K, Rusch P, Sadoine M, Schmidt A, Schurr R, Searles S, Sharma S, Sheehan B, Shi C, Shohayeb B, Sommerlad A, Strehlow J, Sun X, Sundar R, Taherzadeh G, Tahir N, Tang J, Testa J, Tian Z, Tingting Q, Verheijen G, Vickstrom C, Wang T, Wang X, Wang Z, Wei P, Wilson A, Wyart, Yassine A, Yousefzadeh A, Zare A, Zeng Z, Zhang C, Zhang H, Zhang L, Zhang T, Zhang W, Zhang Z, Zhou J, Zhu D, Adamo V, Adeyemo A, Aggelidou M, Al-Owaifeer A, Al-Riyami A, Alzghari S, Andersen V, Angus K, Asaduzzaman M, Asady H, Ato D, Bai X, Baines R, Ballantyne M, Ban B, Beck J, Ben-Nafa W, Black E, Blancher A, Blankstein R, Bodagh N, Borges P, Brooks A, Brox-Ponce J, Brunetti A, Canham C, Carninci P, Carvajal R, Chang S, Chao J, Chatterjee P, Chen H, Chen Y, Chhatriwalla A, Chikowe I, Chuang T, Collevatti R, Valera-Cornejo D, Cuenda A, Dao M, Dauga D, Deng Z, Devkota K, Doan L, Elewa Y, Fan D, Faruk M, Feifei S, Ferguson T, Fleres F, Foster E, Foster C, Furer T, Gao Y, Garcia-Rivera E, Gazdar A, George R, Ghosh S, Gianchecchi E, Gleason J, Hackshaw A, Hall A, Hall R, Harper P, Hogg W, Huang G, Hunter K, IJzerman A, Jesus C, Jian G, Lewis J, Kanj S, Kaur H, Kelly S, Kheir F, Kichatova V, Kiyani M, Klein R, Kovesi T, Kraschnewski J, Kumar A, Labutin D, Lazo-Langner A, Leclercq G, Li M, Li Q, Li T, Li Y, Liao W, Liao Z, Lin J, Lizer J, Lobreglio G, Lowies C, Lu C, Majeed H, Martin A, Martinez-Sobrido L, Meresh E, Middelveen M, Mohebbi A, Mota J, Mozaheb Z, Muyaya L, Nandhakumar A, Ng S, Obeidat M, Oh D, Owais M, Pace-Asciak P, Panwar A, Park C, Patterson C, Penagos-Tabaree F, Pianosi P, Pinzi V, Pridans C, Psaroulaki A, Pujala R, Pulido-Arjona L, Qi P, Rahman P, K N, Rassaf T, Refardt J, Ricciardi W, Riess O, Rovas A, Sacks F, Saleh S, Sampson C, Schmutz A, Sepanski R, Sharma N, Singh M, Spearman P, Subramaniapillai M, Swali R, Tan C, Tellechea J, Thomas L, Tong X, Vavvas D, Veys R, Vitriol V, Wang H, Wang J, Wang J, Waugh J, Webb S, Williams B, Workman A, Xiang T, Xie L, Xu J, Xu T, Yang C, Yoon J, Yuan C, Zaritsky A, Zhang Y, Zhao H, Zuckerman H, Lyu R, Pullan W, Zhou Y. Large expert-curated database for benchmarking document similarity detection in biomedical literature search. Database 2019, 2019: baz085. PMID: 33326193, PMCID: PMC7291946, DOI: 10.1093/database/baz085.
- Yong W, Rha S, Tan I, Choo S, Syn N, Koh V, Tan S, Asuncion B, Sundar R, So J, Shabbir A, Tan C, Kim H, Jung M, Chung H, Ng M, Tai D, Lee M, Wu J, Yeoh K, Tan P, Consortium O. Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept “3G” Trial. Clinical Cancer Research 2018, 24: 5272-5281. PMID: 30045931, DOI: 10.1158/1078-0432.ccr-18-0193.
- Garces A, Ang J, Ameratunga M, Chénard-Poirier M, Dolling D, Diamantis N, Seeramreddi S, Sundar R, de Bono J, Lopez J, Banerji U. A study of 1088 consecutive cases of electrolyte abnormalities in oncology phase I trials. European Journal Of Cancer 2018, 104: 32-38. PMID: 30316017, PMCID: PMC6259582, DOI: 10.1016/j.ejca.2018.08.019.
- Huang Y, Wong A, Soo R, Soh T, Pang A, Tan C, Ling W, Voon P, Lim J, Sundar R, Kumarakulasinghe N, Lim H, Goh B, Chin T. P1.01-38 A Phase II With a Lead-In Phase I Study to Examine Safety and Efficacy of Hydroxychloroquine and Gefitinib in Advanced NSCLC. Journal Of Thoracic Oncology 2018, 13: s474-s475. DOI: 10.1016/j.jtho.2018.08.594.
- Sundar R, McVeigh T, Dolling D, Petruckevitch A, Diamantis N, Ang J, Chenard-Poiriér M, Collins D, Lim J, Ameratunga M, Khan K, Kaye S, Banerji U, Lopez J, George A, de Bono J, van der Graaf W. Clinical outcomes of adolescents and young adults with advanced solid tumours participating in phase I trials. European Journal Of Cancer 2018, 101: 55-61. PMID: 30025230, DOI: 10.1016/j.ejca.2018.06.003.
- Basu B, Krebs M, Sundar R, Wilson R, Spicer J, Jones R, Brada M, Talbot D, Steele N, Garces A, Brugger W, Harrington E, Evans J, Hall E, Tovey H, de Oliveira F, Carreira S, Swales K, Ruddle R, Raynaud F, Purchase B, Dawes J, Parmar M, Turner A, Tunariu N, Banerjee S, de Bono J, Banerji U. Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer. Annals Of Oncology 2018, 29: 1918-1925. PMID: 30016392, PMCID: PMC6158767, DOI: 10.1093/annonc/mdy245.
- Sundar R, Qamra A, Tan A, Zhang S, Ng C, Teh B, Lee J, Kim K, Tan P. Transcriptional analysis of immune genes in Epstein–Barr virus-associated gastric cancer and association with clinical outcomes. Gastric Cancer 2018, 21: 1064-1070. PMID: 29915957, DOI: 10.1007/s10120-018-0851-9.
- Sundar R, Miranda S, Rodrigues D, Chénard-Poirier M, Dolling D, Clarke M, Figueiredo I, Bertan C, Yuan W, Ferreira A, Chistova R, Boysen G, Perez D, Tunariu N, Mateo J, Wotherspoon A, Chau I, Cunningham D, Valeri N, Carreira S, de Bono J. Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer. Clinical Colorectal Cancer 2018, 17: 280-284. PMID: 30042009, DOI: 10.1016/j.clcc.2018.05.011.
- Sundar R, Qamra A, Tan A, Zhang S, Ng C, Teh B, Lee J, Kim K, Tan P. Transcriptional analysis of immune genes in Epstein-Barr virus-associated gastric cancer and association with clinical outcomes. Journal Of Clinical Oncology 2018, 36: e16024-e16024. DOI: 10.1200/jco.2018.36.15_suppl.e16024.
- Dose finding study of varlitinib ± trastuzumab with carboplatin/paclitaxel in advanced solid tumors.Lee M, Wong A, Ow S, Sundar R, Wang L, Tan D, Soo R, Chee C, Heong V, Chen Y, Lim J, Yong W, Lim S, Goh B, Lee S. Dose finding study of varlitinib ± trastuzumab with carboplatin/paclitaxel in advanced solid tumors. Journal Of Clinical Oncology 2018, 36: 2588-2588. DOI: 10.1200/jco.2018.36.15_suppl.2588.
- Sundar R, Bandla A, Tan S, Kumarakulasinghe N, Huang Y, Ang S, Hairom Z, Lim J, Wong A, Chan G, Ngoi N, Ang E, Chan A, Lee S, Thakor N, Wilder-Smith E. Cryocompression for enhanced limb hypothermia in preventing paclitaxel-induced peripheral neuropathy. Journal Of Clinical Oncology 2018, 36: 10095-10095. DOI: 10.1200/jco.2018.36.15_suppl.10095.
- Hoppe M, Sundar R, Tan D, Jeyasekharan A. Biomarkers for Homologous Recombination Deficiency in Cancer. Journal Of The National Cancer Institute 2018, 110: 704-713. PMID: 29788099, DOI: 10.1093/jnci/djy085.
- McVeigh T, Sundar R, Diamantis N, Kaye S, Banerji U, Lopez J, de Bono J, van der Graaf W, George A. The role of genomic profiling in adolescents and young adults (AYAs) with advanced cancer participating in phase I clinical trials. European Journal Of Cancer 2018, 95: 20-29. PMID: 29614442, PMCID: PMC6296443, DOI: 10.1016/j.ejca.2018.02.028.
- Sundar R, Rha S, Yamaue H, Katsuda M, Kono K, Kim H, Kim C, Mimura K, Kua L, Yong W. A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer. BMC Cancer 2018, 18: 332. PMID: 29587677, PMCID: PMC5870101, DOI: 10.1186/s12885-018-4234-8.
- Lam W, Wang L, Roudi R, Yong W, Syn N, Sundar R. Resisting resistance to cancer immunotherapy. Thoracic Cancer 2018, 9: 507-508. PMID: 29512891, PMCID: PMC5928381, DOI: 10.1111/1759-7714.12614.
- Chan D, Syn N, Neogh C, Phua N, . E, Ho J, Sundar R, Tan C, Ngoi N, Chee C, Shabbir A, So J, Yong W. Extended outcomes of intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastases. Journal Of Clinical Oncology 2018, 36: 125-125. DOI: 10.1200/jco.2018.36.4_suppl.125.
- Sundar R, Tan P. Genomic Analyses and Precision Oncology in Gastroesophageal Cancer: Forwards or Backwards? Cancer Discovery 2018, 8: 14-16. PMID: 29311223, DOI: 10.1158/2159-8290.cd-17-1295.
- Sundar R, Custodio A, Petruckevich A, Chénard-Poirier M, Ameratunga M, Collins D, Lim J, Kaye S, Tunariu N, Banerji U, de Bono J, Lopez J. Clinical Outcome of Patients with Advanced Biliary Tract Cancer in a Dedicated Phase I Unit. Clinical Oncology 2017, 30: 185-191. PMID: 29224898, DOI: 10.1016/j.clon.2017.11.011.
- Brown J, Sundar R, Lopez J. Combining DNA damaging therapeutics with immunotherapy: more haste, less speed. British Journal Of Cancer 2017, 118: 312-324. PMID: 29123260, PMCID: PMC5808021, DOI: 10.1038/bjc.2017.376.
- Garces A, Ang J, Ameratunga M, Chenard-Poirier M, Dolling D, Sundar R, Kaye S, de Bono J, Banerji U, Lopez J. 1194P Impact of prior immune checkpoint inhibitors on haematological toxicity in phase I patients receiving chemotherapy. Annals Of Oncology 2017, 28: v422. DOI: 10.1093/annonc/mdx376.057.
- Garces A, Ang J, Ameratunga M, Chenard-Poirier M, Dolling D, Diamantis N, Seeramreddi S, Sundar R, de Bono J, Lopez J, Banerji U. 398P Drug-induced electrolyte abnormalities in oncology phase I trials: Analysis of 1088 cases treated at The Royal Marsden Hospital. Annals Of Oncology 2017, 28: v132-v133. DOI: 10.1093/annonc/mdx367.031.
- Sundar R, Miranda S, Carreira S, Chénard-Poirier M, Rodrigues D, Figueiredo I, Bertan C, Yuan W, Perez D, Ferreira A, Tunariu N, Mateo J, Bono J. Abstract 3807: ATM protein loss and clinical outcomes with platinum chemotherapy in patients with advanced solid tumors. Cancer Research 2017, 77: 3807-3807. DOI: 10.1158/1538-7445.am2017-3807.
- Lim J, Harris S, Ameratunga M, Sundar R, Ang J, Collins D, Chénard-Poirier M, Garces A, Kaye S, Lopez J, Banerji U, Bono J, Yap T. Abstract 3081: Precision medicine for patients with advanced small cell lung cancer treated with novel therapeutic agents in a phase I clinical trials unit. Cancer Research 2017, 77: 3081-3081. DOI: 10.1158/1538-7445.am2017-3081.
- Sundar R, Hong D, Kopetz S, Yap T. Targeting BRAF-Mutant Colorectal Cancer: Progress in Combination Strategies. Cancer Discovery 2017, 7: 558-560. PMID: 28576843, PMCID: PMC5458523, DOI: 10.1158/2159-8290.cd-17-0087.
- Yanagitani N, Horiike A, Kitazono S, Ohyanagi F, Kondo S, Shimomura A, Fujiwara Y, Doi T, Kuboki Y, Kawazoe A, Shitara K, Ohno I, Banerji U, Sundar R, Ohkubo S, Huang J, Nishio M, Yamamoto N. First-in-human phase I study of an oral HSP90 inhibitor, TAS-116, in advanced solid tumors. Journal Of Clinical Oncology 2017, 35: 2546-2546. DOI: 10.1200/jco.2017.35.15_suppl.2546.
- Pierce A, Berges A, Cheung S, Standifer N, Ross G, Smith S, Hollingsworth S, Krebs M, Postel-Vinay S, Bang Y, El-Khoueiry A, Abida W, Sundar R, Carter L, Castanon-Alvarez E, Im S, Lopez J, Yap T, Harrington K, Soria J. Dose-exposure-response relationship between AZD6738 and peripheral monocytes. Journal Of Clinical Oncology 2017, 35: e14063-e14063. DOI: 10.1200/jco.2017.35.15_suppl.e14063.
- Wong A, Tan K, Sundar R, Ow S, Pang A, Yap H, Chan C, Hartman M, Iau P, Buhari S, Mogro M, Tan I, Wang L, Yang H, Goh B, Lee S. Genomic predictors of neoadjuvant chemotherapy (NACT) response in breast cancer (BC). Journal Of Clinical Oncology 2017, 35: e12122-e12122. DOI: 10.1200/jco.2017.35.15_suppl.e12122.
- Sundar R, Basu B, Wilson R, Spicer J, Jones R, Krebs M, Brada M, Talbot D, Steele N, Hall E, Tovey H, Carreira S, de Oliveira F, Swales K, Balarajah G, Dawes J, Parmar M, De Bono J, Banerji U. TAX-TORC: A phase I trial of vistusertib (AZD2014) in combination with weekly paclitaxel with integrated pharmacodynamic (PD) and molecular characterization (MC) studies. Journal Of Clinical Oncology 2017, 35: 2571-2571. DOI: 10.1200/jco.2017.35.15_suppl.2571.
- Heong V, Wee B, Goh S, Tay D, Lee X, Soo R, Lim J, Sundar R, Chee C, Lee S, Ow S, Goh B, Yong W, Wong A, Gopinathan A, Lim D, Pang B, Feroz M, Soong R, Tan D. Whole exome sequencing (WES) of multiple spatially distinct biopsies from single metastatic lesions to evaluate tumour heterogeneity and identify actionable truncal mutations (ATMs) in patients (pts) with advanced solid malignancies using a radiologically-guided single-pass percutaneous technique. Journal Of Clinical Oncology 2017, 35: 2550-2550. DOI: 10.1200/jco.2017.35.15_suppl.2550.
- Chenard-Poirier M, Ang J, Harris S, Ingles Garces A, Seeramreddi S, Sundar R, Collins D, Ameratunga M, Lopez J, De Bono J, Banerji U. Adherence to novel oral anticancer therapies in the phase I setting: The Royal Marsden experience. Journal Of Clinical Oncology 2017, 35: 2542-2542. DOI: 10.1200/jco.2017.35.15_suppl.2542.
- Sundar R, McVeigh T, Petruckevitch A, Diamantis N, Ang J, Chenard-Poirier M, Collins D, Lim J, Ameratunga M, Khan K, Kaye S, Banerji U, Lopez J, De Bono J, Van Der Graaf W. Clinical outcomes of adolescents and young adults (AYA) with advanced solid tumors participating in phase I trials. Journal Of Clinical Oncology 2017, 35: 10536-10536. DOI: 10.1200/jco.2017.35.15_suppl.10536.
- Collins D, Constantinidou A, Sundar R, Chenard-Poirier M, Yap T, Banerji U, De Bono J, Lopez J, Tunariu N. Patterns of metastases in malignant pleural mesothelioma in the modern era: Redefining the spread of an old disease. Journal Of Clinical Oncology 2017, 35: 8556-8556. DOI: 10.1200/jco.2017.35.15_suppl.8556.
- Walsh R, Lee S, Seng K, Wang L, Ho G, Ow S, Kumarakulasinghe N, Sundar R, Lee X, Yap H, Jeyasekharan A, Pang A, Ho J, Tan C, Lim Y, Malik R, Wan Ishak W, Goh B, Tai B, Wong A. Prospective study of UDP-glucuronosyltransferase (UGT) 2B17 genotype and exemestane (Exe) pharmacokinetics (PK) and pharmacodynamics (PD) in Asian, hormone receptor (HR) positive, metastatic breast cancer (MBC) patients. Journal Of Clinical Oncology 2017, 35: 1056-1056. DOI: 10.1200/jco.2017.35.15_suppl.1056.
- Sundar R, Brown J, Russo A, Yap T. Targeting ATR in cancer medicine. Current Problems In Cancer 2017, 41: 302-315. PMID: 28662958, DOI: 10.1016/j.currproblcancer.2017.05.002.
- Sundar R, Chénard-Poirier M, Collins D, Yap T. Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer. Frontiers In Medicine 2017, 4: 39. PMID: 28443282, PMCID: PMC5385461, DOI: 10.3389/fmed.2017.00039.
- Dolly S, Collins D, Sundar R, Popat S, Yap T. Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer. Drugs 2017, 77: 813-827. PMID: 28378229, DOI: 10.1007/s40265-017-0732-2.
- Sundar R, Valeri N, Harrington K, Yap T. Combining Molecularly Targeted Agents: Is More Always Better? Clinical Cancer Research 2017, 23: 1123-1125. PMID: 27836864, DOI: 10.1158/1078-0432.ccr-16-2399.
- Sundar R, Bandla A, Tan S, Liao L, Kumarakulasinghe N, Jeyasekharan A, Ow S, Ho J, Tan D, Lim J, Vijayan J, Therimadasamy A, Hairom Z, Ang E, Ang S, Thakor N, Lee S, Wilder-Smith E. Limb Hypothermia for Preventing Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients: A Pilot Study. Frontiers In Oncology 2017, 6: 274. PMID: 28119855, PMCID: PMC5222823, DOI: 10.3389/fonc.2016.00274.
- Lim J, Sundar R, Chnard-Poirier M, Lopez J, Yap T. Emerging biomarkers for PD-1 pathway cancer therapy. Biomarkers In Medicine 2016, 11: 53-67. PMID: 27936870, DOI: 10.2217/bmm-2016-0228.
- Yap T, Krebs M, Postel-Vinay S, Bang Y, El-Khoueiry A, Abida W, Harrington K, Sundar R, Carter L, Castanon-Alvarez E, Im S, Berges A, Khan M, Stephens C, Ross G, Soria J. 1LBA Phase I modular study of AZD6738, a novel oral, potent and selective ataxia telangiectasia Rad3-related (ATR) inhibitor in combination (combo) with carboplatin, olaparib or durvalumab in patients (pts) with advanced cancers. European Journal Of Cancer 2016, 69: s2. DOI: 10.1016/s0959-8049(16)32607-7.
- Collins D, Sundar R, Lim J, Yap T. Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics. Trends In Pharmacological Sciences 2016, 38: 25-40. PMID: 27871777, DOI: 10.1016/j.tips.2016.10.012.
- Sundar R, Jeyasekharan A, Pang B, Soong R, Kumarakulasinghe N, Ow S, Ho J, Lim J, Tan D, Wilder-Smith E, Bandla A, Tan S, Asuncion B, Fazreen Z, Hoppe M, Putti T, Poh L, Goh B, Lee S. Low Levels of NDRG1 in Nerve Tissue Are Predictive of Severe Paclitaxel-Induced Neuropathy. PLOS ONE 2016, 11: e0164319. PMID: 27716814, PMCID: PMC5055363, DOI: 10.1371/journal.pone.0164319.
- Sundar R, Tan D, S. Lei L, Chia W. Overcoming Chemotherapy Resistance in High Grade Serous Ovarian Cancer. Current Cancer Therapy Reviews 2016, 12: 23-36. DOI: 10.2174/1573394712666160609121238.
- Heong V, Koe P, Yong W, Soo R, Chee C, Wong A, Thian Y, Sundar R, Ho J, Gopinathan A, Lee S, Goh B, Tan D. 383P RAS/AKT pathway mutations as predictive biomarkers in patients with colorectal cancer treated with the exportin 1 (XPO1) inhibitor selinexor (SEL) – inhibition of nuclear-cytoplasmic translocation of p27 as a mechanism of anti-tumour activity. Annals Of Oncology 2016, 27: vi122. DOI: 10.1093/annonc/mdw368.26.
- Banerji U, Basu B, Spicer J, Wilson R, Hall E, Sundar R, Kumar S, Wu Y, Coyle V, Carreira S, Parmar M, Dawes J, Banerjee S, de Bono J. 362PD TAX-TORC: An investigator initiated phase I study combining the dual mTORC1/2 inhibitor AZD2014 in combination with weekly paclitaxel in high-grade serous ovarian cancer. Annals Of Oncology 2016, 27: vi115. DOI: 10.1093/annonc/mdw368.05.
- Sundar R, Custodio A, Lim J, Chenard-Poirier M, Collins D, Kaye S, Yap T, Banerji U, Lopez J, de Bono J. 404P Clinical outcome of patients with advanced biliary tract cancer in a dedicated phase 1 unit. Annals Of Oncology 2016, 27: vi130. DOI: 10.1093/annonc/mdw368.47.
- Wong A, Sundar R, Wang T, Ng T, Zhang B, Tan S, Soh T, Pang A, Tan C, Ow S, Wang L, Mogro J, Ho J, Jeyasekharan A, Huang Y, Thng C, Chan C, Hartman M, Iau P, Buhari S, Goh B, Lee S. Phase Ib/II randomized, open-label study of doxorubicin and cyclophosphamide with or without low-dose, short-course sunitinib in the pre-operative treatment of breast cancer. Oncotarget 2016, 7: 64089-64099. PMID: 27577069, PMCID: PMC5325427, DOI: 10.18632/oncotarget.11596.
- Tan C, Wang T, Lim C, Loh T, Chin S, Sundar R, Chong W, Ow S, Soo R, Lee S, Goh B. Randomised study of 2 low doses of sunitinib to modulate tumor microvasculature prior to chemotherapy in nasopharyngeal carcinoma (NPC). Journal Of Clinical Oncology 2016, 34: 6034-6034. DOI: 10.1200/jco.2016.34.15_suppl.6034.
- Ang Y, Soo R, Ho G, Sundar R, Tan S, Lim J, Yong W, Chong W, Ho J, Kumarakulasinghe N, Aung M, Koh E, Ramlee M, Phyu P, Kyin L, Goh B, Lee S. A phase II randomized study of docetaxel +/- low-dose, short course sunitinib in advanced solid tumours. Journal Of Clinical Oncology 2016, 34: e14124-e14124. DOI: 10.1200/jco.2016.34.15_suppl.e14124.
- Sundar R, Bandla A, Tan S, Kumarakulasinghe N, Jeyasekharan A, Ow S, Ho J, Tan D, Lim J, Vijayan J, Hairom Z, Ang S, Liao L, Lee S, Thakor N, Wilder-Smith E. The role of limb hypothermia in preventing paclitaxel-induced peripheral neuropathy. Journal Of Clinical Oncology 2016, 34: e21696-e21696. DOI: 10.1200/jco.2016.34.15_suppl.e21696.
- Heong V, Koe P, Yong W, Soo R, Chee C, Thian Y, Gopinathan A, Wong A, Sundar R, Ho J, Friedlander S, McCauley D, Choe-Juliak C, Lee S, Goh B, Tan D. 127O Phase 1 study of safety and tolerability of selinexor in Asian patients with advanced solid cancers: updated results. Annals Of Oncology 2015, 26: ix37. DOI: 10.1093/annonc/mdv521.03.
- Bandla A, Sundar R, Liao L, Tan S, Lee S, Thakor N, Wilder-Smith E. Hypothermia for preventing chemotherapy-induced neuropathy – a pilot study on safety and tolerability in healthy controls. Acta Oncologica 2015, 55: 430-436. PMID: 26360921, DOI: 10.3109/0284186x.2015.1075664.
- Tan D, Pang M, Yong W, Soo R, Chee C, Thian Y, Gopinathan A, Wong A, Koe P, Sundar R, Ho J, Friedlander S, Landesman Y, Rashal T, McCauley D, Shacham S, Lee S, Goh B. Phase I study of the safety and tolerability of the Exportin 1 (XPO1) inhibitor Selinexor (SXR) in Asian patients (pts) with advanced solid cancers. Journal Of Clinical Oncology 2015, 33: 2542-2542. DOI: 10.1200/jco.2015.33.15_suppl.2542.
- Sundar R, Sundar G. Zinner syndrome: an uncommon cause of painful ejaculation. BMJ Case Reports 2015, 2015: bcr2014207618. PMID: 25750220, PMCID: PMC4368968, DOI: 10.1136/bcr-2014-207618.
- Soh I, Mogro M, Soo R, Pang A, Tan C, Chuah B, Zee Y, Wong A, Ow S, Sundar R, Lim J, Huang Y, Ling W, Yong W. The optimization of 5-fluorouracil (5FU) dose by pharmacokinetic (PK) monitoring in Asian patients with advanced-stage gastrointestinal (GI) cancer. Journal Of Clinical Oncology 2015, 33: 770-770. DOI: 10.1200/jco.2015.33.3_suppl.770.
- Sundar R, Cho B, Brahmer J, Soo R. Nivolumab in NSCLC: latest evidence and clinical potential. Therapeutic Advances In Medical Oncology 2015, 7: 85-96. PMID: 25755681, PMCID: PMC4346216, DOI: 10.1177/1758834014567470.
- Wong A, Tan S, Soh I, Tan C, Lim Y, Pang A, Ho J, Ow S, Sundar R, Pang M, Chan C, Buhari S, Hartman M, Iau P, Tang A, Wong N, Yap Y, Khoo B, Thiery J, Lee S. Phase II study of neoadjuvant weekly paclitaxel and carboplatin with lapatinib in HER2+ breast cancer. Journal Of Clinical Oncology 2014, 32: 619-619. DOI: 10.1200/jco.2014.32.15_suppl.619.
- Wong A, Sundar R, Ow S, Wang T, Ng T, Chan C, Hartman M, Iau P, Tan S, Zhang B, Thng C, Mogro M, Voon P, Buhari S, Soh I, Goh B, Lee S. Effect of low-dose, short-course sunitinib (Su) on tumor vasculature and tumor blood flow for enhancement of chemotherapy efficacy in breast cancer. Journal Of Clinical Oncology 2014, 32: 1060-1060. DOI: 10.1200/jco.2014.32.15_suppl.1060.
- Sundar R, Jeyasekharan A, Tan K, Putti T, Poh L, Yap H, Sapari N, Soong R, Lee S. Paclitaxel-induced severe sensory peripheral neuropathy is associated with NDRG-1 genetic variant and negative NDRG-1 expression in nerve tissue. Journal Of Clinical Oncology 2014, 32: 1054-1054. DOI: 10.1200/jco.2014.32.15_suppl.1054.
- Sundar R, Soong R, Cho B, Brahmer J, Soo R. Immunotherapy in the treatment of non-small cell lung cancer. Lung Cancer 2014, 85: 101-109. PMID: 24880938, PMCID: PMC4332778, DOI: 10.1016/j.lungcan.2014.05.005.
Departments and Programs
- Center for Gastrointestinal Cancers
- Internal Medicine
- Medical Oncology and Hematology
- Yale Cancer Center
Locations
- Smilow Cancer Hospital at Yale New Haven35 Park StreetNew Haven, CT 06511
Biography
Raghav Sundar, MD, PhD, is a medical oncologist specializing in gastrointestinal cancers, with particular expertise in gastroesophageal cancers and tumors that spread to the peritoneum (the lining of the abdominal cavity). At Yale Cancer Center and Smilow Cancer Hospital, he leads the Gastroesophageal Cancer Program, specifically focused on complex, multidisciplinary care and innovative treatment approaches and clinical trials.
"Building meaningful relationships with my patients and their families is the heart of what I do," Dr. Sundar says. "Cancer brings uncertainty, and I believe in taking this journey together, one step at a time. My team and I are here to support you with both advanced medical care and the emotional guidance needed during treatment."
Dr. Sundar takes a collaborative approach to patient care, working closely with surgeons, radiation oncologists, and other specialists to provide comprehensive treatment plans tailored to each patient. "Every patient's cancer is unique," he explains. "By bringing together experts from different fields, we can offer the most advanced and personalized care possible."
As an associate professor at Yale School of Medicine, Dr. Sundar is internationally recognized for his research in gastroesophageal cancers. He pioneers innovative clinical trials and treatment approaches, particularly for patients with challenging conditions like peritoneal metastases. His work has led to significant discoveries that help predict how cancers might respond to treatment, potentially opening new paths for more effective therapies.
Dr. Sundar completed his medical training and doctoral degree at the National University of Singapore and received specialized fellowship training at the prestigious Royal Marsden Hospital in the United Kingdom in experimental therapeutics and early phase clinical trials. Before joining Yale, he served as a senior consultant medical oncologist and research director in Singapore, where he led numerous clinical trials and research initiatives. His work has been published in top medical journals, advancing the field of cancer treatment globally.
"I will be with you every step of the way," Dr. Sundar assures his patients. "We'll work together to understand your diagnosis, explore all treatment options, and ensure you feel informed and empowered throughout your care journey."
Titles
- Associate Professor of Internal Medicine (Medical Oncology & Hematology)
- Leader, Gastroesophageal Cancer Program, Medical Oncology
Education & Training
- PhDNational University of Singapore
- FellowshipNational University Hospital, Singapore
- ResidencyNational University Hospital, Singapore
- MDNational University of Singapore
Additional Information
Publications
- Sundar R, Chia D, Zhao J, Lee A, Kim G, Tan H, Pang A, Shabbir A, Willaert W, Ma H, Huang K, Hagihara T, Tan A, Ong C, Wong J, Seo C, Walsh R, Chan G, Cheo S, Soh C, Callebout E, Geboes K, Ng M, Lum J, Leow W, Selvarajan S, Hoorens A, Ang W, Pang H, Tan P, Yong W, Chia C, Ceelen W, So J. Phase I PIANO trial—PIPAC-oxaliplatin and systemic nivolumab combination for gastric cancer peritoneal metastases: clinical and translational outcomes. ESMO Open 2024, 9: 103681. PMID: 39288528, PMCID: PMC11421236, DOI: 10.1016/j.esmoop.2024.103681.
- Zhao J, Ong C, Srivastava S, Chia D, Ma H, Huang K, Sheng T, Ramnarayanan K, Ong X, Tay S, Hagihara T, Tan A, Teo M, Tan Q, Ng G, Tan J, Ng M, Gwee Y, Walsh R, Law J, Shabbir A, Kim G, Tay Y, Her Z, Leoncini G, Teh B, Hong J, Tay R, Teo C, Dings M, Bijlsma M, Lum J, Mathur S, Pietrantonio F, Blum S, van Laarhoven H, Klempner S, Yong W, So J, Chen Q, Tan P, Sundar R. Spatially Resolved Niche and Tumor Microenvironmental Alterations in Gastric Cancer Peritoneal Metastases. Gastroenterology 2024, 167: 1384-1398.e4. PMID: 39147169, DOI: 10.1053/j.gastro.2024.08.007.
- Yap D, Leone A, Wong N, Zhao J, Tey J, Sundar R, Pietrantonio F. Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma. JAMA Oncology 2023, 9: 215-224. PMID: 36480211, PMCID: PMC9857522, DOI: 10.1001/jamaoncol.2022.5816.
- Yeong J, Lum H, Teo C, Tan B, Chan Y, Tay R, Choo J, Jeyasekharan A, Miow Q, Loo L, Yong W, Sundar R. Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy. Gastric Cancer 2022, 25: 741-750. PMID: 35661944, PMCID: PMC9226082, DOI: 10.1007/s10120-022-01301-0.
- Gwee Y, Chia D, So J, Ceelen W, Yong W, Tan P, Ong C, Sundar R. Integration of Genomic Biology Into Therapeutic Strategies of Gastric Cancer Peritoneal Metastasis. Journal Of Clinical Oncology 2022, 40: 2830. PMID: 35649219, PMCID: PMC9390822, DOI: 10.1200/jco.21.02745.
- Lee A, Wong S, Chai L, Lee S, Lee M, Muthiah M, Tay S, Teo C, Tan B, Chan Y, Sundar R, Soon Y. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. The BMJ 2022, 376: e068632. PMID: 35236664, PMCID: PMC8889026, DOI: 10.1136/bmj-2021-068632.
- Kumar V, Ramnarayanan K, Sundar R, Padmanabhan N, Srivastava S, Koiwa M, Yasuda T, Koh V, Huang K, Tay S, Ho S, Tan A, Ishimoto T, Kim G, Shabbir A, Chen Q, Zhang B, Xu S, Lam K, Lum H, Teh M, Yong W, So J, Tan P. Single-Cell Atlas of Lineage States, Tumor Microenvironment, and Subtype-Specific Expression Programs in Gastric CancerSingle-Cell Atlas of Gastric Cancer Subtypes. Cancer Discovery 2022, 12: 670-691. PMID: 34642171, PMCID: PMC9394383, DOI: 10.1158/2159-8290.cd-21-0683.
- Zhao J, Yap D, Chan Y, Tan B, Teo C, Syn N, Smyth E, Soon Y, Sundar R. Low Programmed Death-Ligand 1–Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma. Journal Of Clinical Oncology 2021, 40: 392-402. PMID: 34860570, DOI: 10.1200/jco.21.01862.
- Sundar R, Huang K, Kumar V, Ramnarayanan K, Demircioglu D, Her Z, Ong X, Bin Adam Isa Z, Xing M, Tan A, Tai D, Choo S, Zhai W, Lim J, Thakur M, Molinero L, Cha E, Fasso M, Niger M, Pietrantonio F, Lee J, Jeyasekharan A, Qamra A, Patnala R, Fabritius A, De Simone M, Yeong J, Ng C, Rha S, Narita Y, Muro K, Guo Y, Skanderup A, So J, Yong W, Chen Q, Göke J, Tan P. Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition. Gut 2021, 71: 1277-1288. PMID: 34433583, PMCID: PMC9185816, DOI: 10.1136/gutjnl-2021-324420.
- Sundar R, Kumarakulasinghe N, Chan Y, Yoshida K, Yoshikawa T, Miyagi Y, Rino Y, Masuda M, Guan J, Sakamoto J, Tanaka S, Tan A, Hoppe M, Jeyasekharan A, Ng C, De Simone M, Grabsch H, Lee J, Oshima T, Tsuburaya A, Tan P. Machine-learning model derived gene signature predictive of paclitaxel survival benefit in gastric cancer: results from the randomised phase III SAMIT trial. Gut 2021, 71: 676-685. PMID: 33980610, PMCID: PMC8921574, DOI: 10.1136/gutjnl-2021-324060.
- Sundar R, Liu D, Hutchins G, Slaney H, Silva A, Oosting J, Hayden J, Hewitt L, Ng C, Mangalvedhekar A, Ng S, Tan I, Tan P, Grabsch H. Spatial profiling of gastric cancer patient-matched primary and locoregional metastases reveals principles of tumour dissemination. Gut 2020, 70: 1823-1832. PMID: 33229445, PMCID: PMC8458060, DOI: 10.1136/gutjnl-2020-320805.
- Molassiotis A, Cheng H, Lopez V, Au J, Chan A, Bandla A, Leung K, Li Y, Wong K, Suen L, Chan C, Yorke J, Farrell C, Sundar R. Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy. BMC Cancer 2019, 19: 132. PMID: 30736741, PMCID: PMC6368751, DOI: 10.1186/s12885-019-5302-4.
- Sachdeva M, Zhao J, Zhu K, Yap D, Wong N, Kumarakulasinghe N, Tey J, Sundar R. PD-L1 expression as a negative predictive biomarker in advanced esophageal squamous-cell cancer treated with chemotherapy alone. ESMO Gastrointestinal Oncology 2025, 7: 100109. DOI: 10.1016/j.esmogo.2024.100109.
- Bandla A, Wong R, Santhanakrishnan P, Magarajah G, Yee Y, Ng W, Ow S, Chan G, Choo J, Lim S, Wong A, Vijayan J, Paxman R, Lee Y, Hui F, Hairom Z, Ang E, Loprinzi C, Thakor N, Lee S, Kumarakulasinghe N, Lim J, Sundar R. Safety and feasibility of concomitant scalp cooling and limb cryocompression to prevent paclitaxel-induced alopecia and neuropathy. Supportive Care In Cancer 2025, 33: 180. PMID: 39937296, PMCID: PMC11821790, DOI: 10.1007/s00520-024-08982-6.
- Zhao J, Ong J, Liu Y, Srivastava S, Teo M, Lee J, Walsh R, Loo L, Tan Q, Ng G, Tan J, Ma H, Ong X, Tay S, Sheng T, Lum J, Yong W, Pietrantonio F, Tan P, Sundar R. Diverse stromal phenotypes at spatial resolution in colorectal cancer peritoneal metastasis. Journal Of Clinical Oncology 2025, 43: 218-218. DOI: 10.1200/jco.2025.43.4_suppl.218.
- Zhao J, Ong J, Chia D, Ng M, Walsh R, Tan Q, Tan J, Ma H, Ong X, Tay S, Yong W, So J, Tan P, Sundar R. 160P Peritoneal niche evolution and micro-environmental remodeling in gastric cancer peritoneal metastasis. Annals Of Oncology 2024, 35: s1467-s1468. DOI: 10.1016/j.annonc.2024.10.184.
- Lee V, Loh J, Hui F, Sundar R, Tan B, Lee M, Lin H, Ong L, Visvanadan N, Ow S, Wong A, Chan G, Lim S, Lim Y, Tan D, Ang Y, Choo J, Lee M, Ngoi N, Lee S, Paxman R, Parker A, Lee Y, Lim J. Scalp cooling therapy for chemotherapy-induced hair loss in patients with breast or gynecological cancers—an Asian tertiary institution experience. Supportive Care In Cancer 2024, 32: 762. PMID: 39482416, DOI: 10.1007/s00520-024-08940-2.
- Leone A, Mai A, Fong K, Yap D, Kato K, Smyth E, Moehler M, Seong J, Sundar R, Zhao J, Pietrantonio F. Immune checkpoint inhibitors in advanced gastroesophageal adenocarcinoma: a series of patient-level meta-analyses in different programmed death-ligand 1 subgroups. ESMO Open 2024, 9: 103962. PMID: 39426081, PMCID: PMC11533044, DOI: 10.1016/j.esmoop.2024.103962.
- Srikumar T, Sundar R. Multimodality Treatment for Locally Advanced Gastric Adenocarcinoma. Surgical Clinics Of North America 2024, 105: 75-94. PMID: 39523078, DOI: 10.1016/j.suc.2024.06.007.
- Sachdeva M, Tay R, KIM Y, Kim H, Cheong J, Grabsch H, Sundar R. 1418P Tumor microenvironment B-cell abundance and survival in resectable gastric cancer: A translational analysis from the CLASSIC trial. Annals Of Oncology 2024, 35: s885. DOI: 10.1016/j.annonc.2024.08.1484.
- Walsh R, Jayagopal A, Tan T, Pitt J, Sundar R, Lee S, Goh B, Rajan V, Tan D, Jeyasekharan A. 229TiP A phase II trial of a neural network-based treatment decision support tool in patients (pts) with refractory solid organ malignancies. Annals Of Oncology 2024, 35: s307-s308. DOI: 10.1016/j.annonc.2024.08.2233.
- Petrillo A, Oudijk L, Sundar R, Daumer C, Casas J, D’Haese D, Mauer M, van Grieken N, Smyth E, Moehler M. EORTC stomach cancer PD-L1 biomarker European initiative: the ASPIRE study protocol. ESMO Gastrointestinal Oncology 2024, 5: 100071. DOI: 10.1016/j.esmogo.2024.100071.
- Blasiak A, Tan L, Chong L, Tadeo X, Truong A, Senthil Kumar K, Sapanel Y, Poon M, Sundar R, de Mel S, Ho D. Personalized dose selection for the first Waldenström macroglobulinemia patient on the PRECISE CURATE.AI trial. Npj Digital Medicine 2024, 7: 223. PMID: 39191913, PMCID: PMC11350179, DOI: 10.1038/s41746-024-01195-5.
- Lee C, Yoo C, Hong J, Park J, Kim J, Tai D, Kim H, Korphaisarn K, Tanasanvimon S, Chen S, Kim J, Kim I, Kim M, Choo J, Oh S, Chen C, Bae W, Kim H, Huh S, Yen C, Park S, Lee D, Chan L, Kang B, Kang M, Sundar R, Choi H, Chan S, Chon H, Lee M. Real-World Study of Systemic Treatment after First-Line Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma in Asia-Pacific Countries. Liver Cancer 2024, 1-15. DOI: 10.1159/000540969.
- Hirano H, Naito Y, Sundar R, Komatsu Y, Kurokawa Y, Li J, Ozaka M, Iwatsuki M, Chen J, Yen C, Zalcberg J, Roy A, Chen L, Nishida T, Doi T. CHAPTER-GIST-101: A phase I study of pimitespib combined with imatinib in patients with imatinib-refractory gastrointestinal stromal tumor. Journal Of Clinical Oncology 2024, 42: tps97-tps97. DOI: 10.1200/jco.2024.42.23_suppl.tps97.
- Lim J, Aau M, Yeong J, Goh B, Yong W, Soo R, Wong A, Tan D, Chee C, Sundar R, Jeyasekharan A, Wong C, Chen P, Liu H, Yu Q, Tam W, Lee S. A phase Ib/II study of pacritinib, an interleukin 1 receptor associated kinase 1 (IRAK1) inhibitor, in patients (pts) with solid tumors harboring the 1q21.3 copy number amplification (CNA). Journal Of Clinical Oncology 2024, 42: 43-43. DOI: 10.1200/jco.2024.42.23_suppl.43.
- Thanh T, Tu N, Nguyet L, Thuy C, Thuan N, Ny N, Nhu L, Thanh L, Hong N, Anh N, Truong N, Van Vinh Chau N, Yen L, Van E P, Thuong N, Van Truc N, Trung P, Yap W, Pandey R, Yee S, Weng R, Mongkolsapaya J, Dejnirattisai W, Hamers R, Chantratita N, Screaton G, Dunachie S, Jones E, Stuart D, Dung N, Thwaites G, Wang L, Tan C, Van Tan L, Wang L, Cruz K, Yee S, Lu H, Ruifen W, Pandey R, Young B, Sundar R, Soebandrio A, Sawitri A, Sutarsa I, Chan Y, Jantarabenjakul W, Chan N, Tan C, Van Tan L, Anh N, Hong N, Truc T, Ny N, Han D, Thanh L, Nguyet L, Thuy C, Nhu L, Thanh T, Yen L, Hang V, Kieu P, Hoang V, Thao N, Chambers M, Thanh V, Hoang T, van Doorn H, Tung T, Thwaites C, Thwaites G, Wang L, Lim B, Hamers R, Shankar A, Suwarti S, Tayipto Y, Simarmata E, Dien R, Mongkolsapaya J, Dejnirattisai W, Chantima W, Chantratita N, Poolchanuan P, Tiacharoen V, Dulsuk A, Iamsirithaworn S, Day N, Cheah P, Poomchaichote T, Boonthaworn K, Screaton G, Dijokaite-Guraliuc A, Das R, Liu C, Supasa P, Selvaraj M, Dunachie S, Klenerman P, Jones E, Stuart D, Kronsteiner-Dobramysl B, Zewdie M, Abraham P, Hill J, Ngoc N, Grifoni A, Sette A, Yap W, Tan C, Van Tan L. Immunogenicity of Abdala COVID-19 vaccine in Vietnamese people after primary and booster vaccinations: a prospective observational study in Vietnam. International Journal Of Infectious Diseases 2024, 147: 107173. PMID: 39094762, DOI: 10.1016/j.ijid.2024.107173.
- Cecchini M, Sundar R. Proofreading the way: immune checkpoint inhibitors in polymerase ε/polymerase δ (POLE/POLD1)-altered colorectal cancer. Annals Of Oncology 2024, 35: 582-584. PMID: 38910015, DOI: 10.1016/j.annonc.2024.04.006.
- Balmaceda N, Petrillo A, Krishnan M, Zhao J, Kim S, Klute K, Sundar R. State-of-the-Art Advancements in Gastroesophageal Cancer Treatment: Harnessing Biomarkers for Precision Care. American Society Of Clinical Oncology Educational Book 2024, 44: e431060. PMID: 38771996, DOI: 10.1200/edbk_431060.
- Lee M, Ow S, Wong A, Lim S, Lim J, Soo R, Cheng Ean C, Tan D, Yong W, Chan G, Ho J, Sooi K, Low Q, Ang C, Cheo S, Sundar R, Goh B, Lee S. A phase Ib/II study of an anti-CD137 agonist antibody ADG106 in combination with weekly paclitaxel and dose-dense doxorubicin/cyclophosphamide. Journal Of Clinical Oncology 2024, 42: e14507-e14507. DOI: 10.1200/jco.2024.42.16_suppl.e14507.
- Walsh R, Ong R, Cheo S, Low P, Jayagopal A, Lee M, Ngoi N, Ow S, Wong A, Lim S, Lim Y, Heong V, Sundar R, Soo R, Chee C, Yong W, Goh B, Lee S, Tan D, Lim J. Molecular profiling of metastatic breast cancer and target-based therapeutic matching in an Asian tertiary phase I oncology unit. Frontiers In Oncology 2024, 14: 1342346. PMID: 38812774, PMCID: PMC11133600, DOI: 10.3389/fonc.2024.1342346.
- Lee Y, Chen L, Chew V, Chow E, Deng L, Hunziker W, Lee A, Leong G, Ngeow J, Pervaiz S, Sabapathy K, Skanderup A, Sundar R, Tay Y, Virshup D, Wong S, Tergaonkar V, Tam W. Pushing the Frontiers of Cancer Research: Highlights from the Frontiers in Cancer Science Conference 2023. Cancer Research 2024, 84: 1195-1198. PMID: 38616656, DOI: 10.1158/0008-5472.can-24-0721.
- Hagihara T, Huang K, Sundar R, Uchihara T, Ng C, Tay S, Tan A, So J, Tan P. Abstract P37: Establishment of Gastric Organoids Biobank and Its Usage. Cancer Research 2024, 84: p37-p37. DOI: 10.1158/1538-7445.fcs2023-p37.
- Xu C, Huang K, Law J, Chua J, Sheng T, Flores N, Pizzi M, Okabe A, Tan A, Zhu F, Kumar V, Lu X, Benitez A, Lian B, Ma H, Ho S, Ramnarayanan K, Anene-Nzelu C, Razavi-Mohseni M, Ghani S, Tay S, Ong X, Lee M, Guo Y, Ashktorab H, Smoot D, Li S, Skanderup A, Beer M, Foo R, Wong J, Sanghvi K, Yong W, Sundar R, Kaneda A, Prabhakar S, Mazur P, Ajani J, Yeoh K, So J, Tan P. Abstract P28: Comprehensive Molecular Phenotyping of ARID1A -deficient Gastric Cancer Reveals Pervasive Epigenomic Reprogramming and Therapeutic Opportunities. Cancer Research 2024, 84: p28-p28. DOI: 10.1158/1538-7445.fcs2023-p28.
- Choo J, Tan W, Luk L, Zeng J, Soh T, Soon S, Lieow J, Wong C, Pang M, Bari S, Poon M, Koh L, Chng W, Jeyasekharan A, Tan L, Chan E, Sundar R. Abstract CT160: A phase I trial to evaluate allogeneic NKG2DL-targeting chimeric antigen receptor-grafted γδ T cells in subjects with advanced solid tumors or hematological malignancies (the ANGELICA Trial). Cancer Research 2024, 84: ct160-ct160. DOI: 10.1158/1538-7445.am2024-ct160.
- Zhao J, Ong J, Chia D, Teo M, Tan Q, Ng G, Tan J, Ma H, Ong X, Tay S, Tan P, Sundar R. Abstract 2759: Transcriptional intra-tumoral heterogeneity of putative therapeutic targets in colorectal cancer peritoneal metastases. Cancer Research 2024, 84: 2759-2759. DOI: 10.1158/1538-7445.am2024-2759.
- Zhao J, Chia D, Her Z, Ma H, Ong X, Tay S, So J, Chen Q, Tan P, Sundar R. Abstract 1497: Humanized mouse model unveils niche conditioning in gastric cancer peritoneal metastasis. Cancer Research 2024, 84: 1497-1497. DOI: 10.1158/1538-7445.am2024-1497.
- Fu J, Pukhari M, Dela Cruz K, Soebandrio A, Tan L, Jantarabenjakul W, Sawitri A, Chantasrisawad N, Yee S, Weng R, Sundar R, Tan C, Wang L, Sam I, Young B, Sutarsa I, Chan Y, Putcharoen O, Wacharapluesadee S, Syed Omar S, Rajasuriar R, Kukreja A, Basri S, Kamarulzaman A, Tan C, Said A, Su’ut L, Tu N, Thuy C, Nguyet L, Thanh L, Ny N, Hong N, Nhu L, Thanh T, Truong N, Ho Y, Pandey R, Diong S, Libau E, Ongko J, Lim J, Abdullah R, Yeo H, Chin Y, Jin J, Lim B, Zhu F, Chee Y, Lumandas M, Dizon T, Demetria C, Biocarles M, Inobaya M, Sornillo J, Morin J, Digman A, Roxas C, Jiz M, Pinatih K, Yuliyatni P, Manuaba I, Wisnawa I, Kusmawati A, Rissa Cempaka P. Charting the path forward in Southeast Asia: Learning from the COVID-19 vaccination challenges in six ASEAN countries. Journal Of Global Health 2024, 14: 03016. PMCID: PMC10940960, DOI: 10.7189/jogh.14.03016.
- Sundar R, Smyth E. Inconsistencies in the predictive value of PD-L1 in metastatic gastroesophageal cancer. The Lancet Gastroenterology & Hepatology 2024, 9: 495-497. PMID: 38492581, DOI: 10.1016/s2468-1253(24)00043-8.
- Ling R, Ueno R, Alamgeer M, Sundararajan K, Sundar R, Bailey M, Pilcher D, Subramaniam A. FRailty in Australian patients admitted to Intensive care unit after eLective CANCER-related SURGery: a retrospective multicentre cohort study (FRAIL-CANCER-SURG study). British Journal Of Anaesthesia 2024, 132: 695-706. PMID: 38378383, DOI: 10.1016/j.bja.2024.01.020.
- Shitara K, Falcone A, Fakih M, George B, Sundar R, Ranjan S, Van Cutsem E. Efficacy and Safety of Trifluridine/Tipiracil-Containing Combinations in Colorectal Cancer and Other Advanced Solid Tumors: A Systematic Review. The Oncologist 2024, 29: e601-e615. PMID: 38366864, PMCID: PMC11067808, DOI: 10.1093/oncolo/oyae007.
- Zhao J, Huang K, Chia D, Law J, Tan A, So J, Tan P, Sundar R. Oncogenic aberrations in primary gastric cancer tumors to predict metachronous peritoneal metastasis. Journal Of Clinical Oncology 2024, 42: 392-392. DOI: 10.1200/jco.2024.42.3_suppl.392.
- Wang M, Gwee Y, Lin Z, Yong W, Sundar R, Tan H, Choo J, Tan K, Lieske B, Cheong W, Tan T, Tey J, Chee C, Chan G. Total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC): Real-world experience from a tertiary Asian cancer center. Journal Of Clinical Oncology 2024, 42: 39-39. DOI: 10.1200/jco.2024.42.3_suppl.39.
- Provenzano L, Gwee Y, Conca V, Lonardi S, Bozzarelli S, Tamburini E, Passardi A, Zaniboni A, Tosi F, Aprile G, Nasca V, Boccaccino A, Ambrosini M, Vetere G, Carullo M, Guaglio M, Battaglia L, Zhao J, Chia D, Yong W, Tan P, So J, Kim G, Shabbir A, Ong C, Casella F, Cremolini C, Bencivenga M, Sundar R, Pietrantonio F. Unveiling the prognostic significance of malignant ascites in advanced gastrointestinal cancers: a marker of peritoneal carcinomatosis burden. Therapeutic Advances In Medical Oncology 2024, 16: 17588359241289517. PMID: 39502404, PMCID: PMC11536604, DOI: 10.1177/17588359241289517.
- A proteomic-based approach for tumour neoantigen discovery on pre-clinical model of pancreas cancer.Chew C, Lee Y, Yang H, Sundar R, Chee C, Bonney G. A proteomic-based approach for tumour neoantigen discovery on pre-clinical model of pancreas cancer. Hepato Pancreato Biliary 2024, 26: s809. DOI: 10.1016/j.hpb.2024.07.276.
- Alamgeer M, Ling R, Ueno R, Sundararajan K, Sundar R, Pilcher D, Subramaniam A. Frailty and long-term survival among patients in Australian intensive care units with metastatic cancer (FRAIL-CANCER study): a retrospective registry-based cohort study. The Lancet Healthy Longevity 2023, 4: e675-e684. PMID: 38042160, DOI: 10.1016/s2666-7568(23)00209-x.
- Choo J, Jeraj S, Chan G, Sundar R, Yong W, Lee M, Ngoi N, Wong A, Soo R, Chee C, Lim J, Goh B, Lee S, Tan D. 82P NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies. Annals Of Oncology 2023, 34: s1498. DOI: 10.1016/j.annonc.2023.10.217.
- Low Q, Zhao J, Wong R, Ho C, Lin Z, Tan L, Choo J, Chan G, Ho J, Asokumaran Y, Sundar R, Chee C, Yong W. MO34-4 Advanced hepatocellular carcinoma viral status and immunotherapy efficacy: A propensity-score matched analysis. Annals Of Oncology 2023, 34: s1417-s1418. DOI: 10.1016/j.annonc.2023.09.240.
- Huang K, Ma H, Chong R, Uchihara T, Lian B, Zhu F, Sheng T, Srivastava S, Tay S, Sundar R, Tan A, Ong X, Lee M, Ho S, Lesluyes T, Ashktorab H, Smoot D, Van Loo P, Chua J, Ramnarayanan K, Lau L, Gotoda T, Kim H, Ang T, Khor C, Lee J, Tsao S, Yang W, Teh M, Chung H, So J, Yeoh K, Tan P, Consortium S. Spatiotemporal genomic profiling of intestinal metaplasia reveals clonal dynamics of gastric cancer progression. Cancer Cell 2023, 41: 2019-2037.e8. PMID: 37890493, PMCID: PMC10729843, DOI: 10.1016/j.ccell.2023.10.004.
- Wong N, Yap D, Ong R, Zhao J, Chan Y, Tey J, Sundar R, Lim J, Dawood S. Efficacy of Oral SERDs in the treatment of ER+, HER2 - metastatic breast cancer, a stratified analysis of the ESR1 wild type and mutant subgroups. Annals Of Oncology 2023 PMID: 37871699, DOI: 10.1016/j.annonc.2023.10.122.
- Smyth E, Sundar R. Combining chemotherapy, trastuzumab, and immune-checkpoint inhibitors in HER2-positive gastro-oesophageal cancer. The Lancet 2023, 402: 2168-2170. PMID: 37871605, DOI: 10.1016/s0140-6736(23)02296-1.
- Low Q, Looi W, Sukumar S, Ang Y, Wong A, Soo R, Sundar R, Lum J, Chee C, Bonney G, Tan H, Yong W. 2282P Tissue glycan profiling in predicting immunotherapy response in renal cell carcinoma and hepatocelllular carcinoma. Annals Of Oncology 2023, 34: s1170. DOI: 10.1016/j.annonc.2023.09.1310.
- Moschetta M, Doi T, Kuboki Y, Sundar R, Möbitz H, Jaco I, Cros M, Ferretti S, Jankovic D, Thérier M, Clementi G, Li Y, De Kanter R, Quadt C. 719TiP A phase I/Ib study of the Werner (WRN) helicase inhibitor HRO761 as single agent and in combination with irinotecan or tislelizumab in patients with microsatellite instability-high (MSIhi) or mismatch repair deficient (dMMR) advanced solid tumors. Annals Of Oncology 2023, 34: s496. DOI: 10.1016/j.annonc.2023.09.1905.
- Sachdeva M, Zhao J, Zhu K, Yap D, Wong N, Barr N, Sundar R. 1559P PD-L1 expression as a negative predictive biomarker in advanced esophageal squamous cell cancer treated with chemotherapy alone: A KMSubtraction derived analysis. Annals Of Oncology 2023, 34: s873. DOI: 10.1016/j.annonc.2023.09.1471.
- Sundar R, Chia D, Ceelen W, Chia C, Kim G, Shabbir A, Willaert W, Ong J, Wong J, Seo C, Tan H, Callebout E, Geboes K, Ng M, Lum J, Leow W, Selvarajan S, Hoorens A, Yong W, So J. 1550P Evaluating the novel combination of pressurized intraperitoneal aerosol chemotherapy-oxaliplatin (PIPAC-OX) as an immunomodulator in combination with systemic nivolumab for gastric cancer peritoneal metastases. Annals Of Oncology 2023, 34: s869. DOI: 10.1016/j.annonc.2023.09.1462.
- Loh J, Choo J, Sooi K, Low P, Ang C, Sundar R, Walsh R, Wijaya S, Low J, Hsing S, Jain S, Chee C. 593P Role of circulating tumor DNA (ctDNA) in assessing primary anti–epidermal growth factor receptor (EGFR) resistance in untreated RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC) patients (pts). Annals Of Oncology 2023, 34: s429. DOI: 10.1016/j.annonc.2023.09.1784.
- Keogh G, Ann D, Cunningham D, Langley R, Allum W, Nankivell M, Tan P, Sundar R, Grabsch H. 1565P ERCC1 gene polymorphism influences overall survival in early oesophageal cancer: Results from the phase III MRC OEO2 randomised controlled trial. Annals Of Oncology 2023, 34: s875. DOI: 10.1016/j.annonc.2023.09.1477.
- Zhao J, Fong K, Chan Y, Tey J, Dawood S, Lee S, Finn R, Sundar R, Lim J. Indirect Treatment Comparison of First-Line CDK4/6-Inhibitors in Post-Menopausal Patients with HR+/HER2− Metastatic Breast Cancer. Cancers 2023, 15: 4558. PMID: 37760527, PMCID: PMC10527344, DOI: 10.3390/cancers15184558.
- Tan W, Tan J, Lim J, Tan R, Bin Lee A, Leong F, Lee S, Chai L, Tan T, Bin Abdul Malek M, Ong B, Lye D, Chiew C, Chng W, Lim S, Bharwani L, Tan I, Sundar R, Tan K. COVID-19 Severity and Waning Immunity After up to 4 mRNA Vaccine Doses in 73 608 Patients With Cancer and 621 475 Matched Controls in Singapore. JAMA Oncology 2023, 9: 1221-1229. PMID: 37440245, PMCID: PMC10346511, DOI: 10.1001/jamaoncol.2023.2271.
- Lim J, Ow S, Wong A, Lee M, Chan G, Low J, Sundar R, Choo J, Chong W, Ang Y, Tai B, Lee S. Phase II study of trifluridine/tipiracil in metastatic breast cancers with or without prior exposure to fluoropyrimidines. European Journal Of Cancer 2023, 193: 113311. PMID: 37717281, DOI: 10.1016/j.ejca.2023.113311.
- Zhao J, Pietrantonio F, Sundar R. Evidence on Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma—Reply. JAMA Oncology 2023, 9: 1005-1006. PMID: 37166787, DOI: 10.1001/jamaoncol.2023.0975.
- Wong Zhun Hong N, Zhao J, Zhu K, Yap D, Kumarakulasinghe N, Huang Y, Sundar R. PD-L1 expression as a unique negative predictive biomarker in advanced squamous NSCLC when treated with first-line chemotherapy. Journal Of Clinical Oncology 2023, 41: e21140-e21140. DOI: 10.1200/jco.2023.41.16_suppl.e21140.
- Chan G, Ho C, Lin Z, Wu J, Chieng J, Lieske B, Yong W, Sundar R, Tan H, Ho J, Choo J, Walsh R, Cheong W, Tan K, Chee C, Liu X, Lim F, Goh S, Chee C. Value-driven colorectal cancer survivorship through partnership with primary care. Journal Of Clinical Oncology 2023, 41: 6649-6649. DOI: 10.1200/jco.2023.41.16_suppl.6649.
- Zhao J, Fong K, Chan Y, Tey J, Dawood S, Lee S, Finn R, Sundar R, Lim J. Indirect treatment comparison of first-line CDK4/6-inhibitors in post-menopausal patients with HR+/HER2- metastatic breast cancer. Journal Of Clinical Oncology 2023, 41: 1071-1071. DOI: 10.1200/jco.2023.41.16_suppl.1071.
- Lim J, Ow S, Wong A, Lee M, Chan G, Low J, Sundar R, Choo J, Tai B, Lee S. Phase II study of trifluridine/tipiracil (FTD/TPI) in HER2-negative metastatic breast cancers with or without prior exposure to fluoropyrimidines. Journal Of Clinical Oncology 2023, 41: 1099-1099. DOI: 10.1200/jco.2023.41.16_suppl.1099.
- Zhao J, Wong Zhun Hong N, Yap D, Ong R, Sundar R, Lim J, Dawood S. Efficacy of oral selective estrogen receptor degraders (SERD)s in the treatment of estrogen receptor positive (ER+), HER2-negative metastatic breast cancer (MBC): A stratified analysis of the ESR1 wild type (wt) and mutant (mt) subgroups. Journal Of Clinical Oncology 2023, 41: 1096-1096. DOI: 10.1200/jco.2023.41.16_suppl.1096.
- Shitara K, George B, Taieb J, Sundar R, Fakih M, Makris L, Benhadji K, Ghidini M. Effects of prior therapies on outcomes with trifluridine/tipiracil in patients with metastatic gastric/gastroesophageal junction cancer in a randomized phase III trial (TAGS). Journal Of Cancer Research And Clinical Oncology 2023, 149: 9361-9374. PMID: 37213030, PMCID: PMC10374776, DOI: 10.1007/s00432-023-04813-z.
- Senthil Kumar K, Miskovic V, Blasiak A, Sundar R, Pedrocchi A, Pearson A, Prelaj A, Ho D. Artificial Intelligence in Clinical Oncology: From Data to Digital Pathology and Treatment. American Society Of Clinical Oncology Educational Book 2023, 43: e390084. PMID: 37235822, DOI: 10.1200/edbk_390084.
- Chee C, Ooi M, Lee S, Sundar R, Heong V, Yong W, Ng C, Wong A, Lim J, Tan D, Soo R, Tan J, Yang S, Thura M, Al-Aidaroos A, Chng W, Zeng Q, Goh B. A Phase I, First-in-Human Study of PRL3-zumab in Advanced, Refractory Solid Tumors and Hematological Malignancies. Targeted Oncology 2023, 18: 391-402. PMID: 37060431, PMCID: PMC10192144, DOI: 10.1007/s11523-023-00962-w.
- Petrillo A, Maron S, Sundar R. Controversies in upper GI oncology: first-line checkpoint inhibitor use in metastatic GEA: guided by PD-L1 CPS or not? ESMO Open 2023, 8: 101211. PMID: 37054477, PMCID: PMC10123152, DOI: 10.1016/j.esmoop.2023.101211.
- Xu C, Huang K, Law J, Chua J, Sheng T, Flores N, Pizzi M, Okabe A, Tan A, Zhu F, Kumar V, Lu X, Benitez A, Lian B, Ma H, Ho S, Ramnarayanan K, Anene-Nzelu C, Razavi-Mohseni M, Ghani S, Tay S, Ong X, Lee M, Guo Y, Ashktorab H, Smoot D, Li S, Skanderup A, Beer M, Foo R, Wong J, Sanghvi K, Yong W, Sundar R, Kaneda A, Prabhakar S, Mazur P, Ajani J, Yeoh K, So J, Tan P. Comprehensive molecular phenotyping of ARID1A-deficient gastric cancer reveals pervasive epigenomic reprogramming and therapeutic opportunities. Gut 2023, 72: 1651-1663. PMID: 36918265, DOI: 10.1136/gutjnl-2022-328332.
- Li J, Lee M, Peng S, Bin Lee A, Tay R, Chee C, Ho C, Walsh J, Chan Y, Tan K, Lee S, Chai L, Sundar R. Clinical efficacy and Long-term Immunogenicity of early triple dose COVID-19 mRNA vaccine in cancer patients. European Journal Of Surgical Oncology 2023, 49: e60-e61. PMCID: PMC9941290, DOI: 10.1016/j.ejso.2022.11.202.
- Loh J, Wu J, Chieng J, Chan A, Yong W, Sundar R, Lee S, Wong A, Lim J, Tan D, Soo R, Goh B, Tai B, Chee C. Clinical outcome and prognostic factors for Asian patients in Phase I clinical trials. British Journal Of Cancer 2023, 128: 1514-1520. PMID: 36797357, PMCID: PMC10070409, DOI: 10.1038/s41416-023-02193-2.
- Choo J, Kua L, Soe M, Asuncion B, Tan B, Teo C, Tay R, So J, Shabbir A, Guowei K, Tan H, Chan G, Ma H, Ramachandran G, Lum J, Chee C, Sridharan S, Tan P, Sundar R, Yong W. Clinical relevance of PD-1 positive CD8 T-cells in gastric cancer. Gastric Cancer 2023, 26: 393-404. PMID: 36781556, PMCID: PMC10115710, DOI: 10.1007/s10120-023-01364-7.
- Walsh R, Sundar R, Lim J. Immune checkpoint inhibitor combinations—current and emerging strategies. British Journal Of Cancer 2023, 128: 1415-1417. PMID: 36747017, PMCID: PMC10070427, DOI: 10.1038/s41416-023-02181-6.
- Lee M, Peng S, Lee A, Wong S, Tay R, Li J, Tariq A, Goh C, Tan Y, Tan B, Teo C, Chan E, Ooi M, Chng W, Chee C, Ho C, Walsh R, Wong M, Su Y, Alexander L, Sethi S, Tan S, Chan Y, Tan K, Lee S, Chai L, Sundar R. Clinical efficacy and long-term immunogenicity of an early triple dose regimen of SARS-CoV-2 mRNA vaccination in cancer patients. Annals, Academy Of Medicine, Singapore 2023, 52: 8-16. PMID: 36730801, DOI: 10.47102/annals-acadmedsg.2022302.
- Lee M, Peng S, Bin Lee A, Tay R, Li J, Wong S, Tariq A, Goh C, Tan Y, Tan B, Teo C, Chan E, Ooi M, Chng W, Chee C, Ho C, Walsh R, Sethi S, Tan S, Chan Y, Tan K, Lee S, Chai L, Sundar R. Neutralising antibody titers and COVID outcomes in cancer patients. Pathology 2023, 55: s33. PMCID: PMC9906789, DOI: 10.1016/j.pathol.2022.12.108.
- Gwee Y, Chia D, Provenzano L, Lonardi S, Conca V, Cremolini C, Yong W, Tan P, So J, Kim G, Shabbir A, Ong J, Pietrantonio F, Sundar R. Malignant ascites as a marker of peritoneal carcinomatosis burden in patients with colorectal and gastroesophageal cancer. Journal Of Clinical Oncology 2023, 41: 455-455. DOI: 10.1200/jco.2023.41.4_suppl.455.
- Chia D, Sundar R, Kim G, Ang J, Shabbir A, So J, Yong W. Outcomes of a Phase II Study of Intraperitoneal Paclitaxel Plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases. Annals Of Surgical Oncology 2022, 30: 1889-1890. PMID: 36564654, DOI: 10.1245/s10434-022-12877-3.
- Teo Y, Tan B, Tan N, Yap D, Chai Y, Teo Y, Sia C, Sundar R, Tan E, See A, Toh S. Obstructive sleep apnea and the incidence and mortality of gastrointestinal cancers: a systematic review and meta-analysis of 5,120,837 participants. Journal Of Gastrointestinal Oncology 2022, 0: 0-0. PMID: 36636076, PMCID: PMC9830329, DOI: 10.21037/jgo-22-153.
- Chia D, Sundar R, Kim G, Ang J, Lum J, Nga M, Goh G, Seet J, Chee C, Tan H, Ho J, Ngoi N, Lee M, Muthu V, Chan G, Pang A, Ang Y, Choo J, Lim J, Teh J, Lwin A, Soon Y, Shabbir A, So J, Yong W. ASO Visual Abstract: Outcomes of a Phase II Study of Intraperitoneal Paclitaxel Plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases. Annals Of Surgical Oncology 2022, 29: 8608-8609. DOI: 10.1245/s10434-022-12043-9.
- Chia D, Ang J, Sundar R, Kim G, Shabbir A, So J, Yong W. ASO Author Reflections: Combination Intra-Peritoneal and Systemic Chemotherapy for Gastric Cancer with Peritoneal Metastases. Annals Of Surgical Oncology 2022, 29: 8606-8607. PMID: 36192514, DOI: 10.1245/s10434-022-12102-1.
- Yeong J, Teo C, Tay R, Tan B, Chan Y, Smyth E, Sundar R. Reply to: Letter to editor on the article “Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy”. Gastric Cancer 2022, 25: 1133-1135. PMID: 36152122, DOI: 10.1007/s10120-022-01343-4.
- Chia D, Sundar R, Kim G, Ang J, Lum J, Nga M, Goh G, Seet J, Chee C, Tan H, Ho J, Ngoi N, Lee M, Muthu V, Chan G, Pang A, Ang Y, Choo J, Lim J, Teh J, Lwin A, Soon Y, Shabbir A, So J, Yong W. Outcomes of a Phase II Study of Intraperitoneal Paclitaxel plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases. Annals Of Surgical Oncology 2022, 29: 8597-8605. PMID: 36070113, DOI: 10.1245/s10434-022-11998-z.
- Wang M, Bandla A, Sundar R, Molassiotis A. The phenotype and value of nerve conduction studies in measuring chemotherapy-induced peripheral neuropathy: A secondary analysis of pooled data. European Journal Of Oncology Nursing 2022, 60: 102196. PMID: 36067640, DOI: 10.1016/j.ejon.2022.102196.
- Fong K, Zhao J, Sultana R, Lee J, Lee S, Chan S, Yau T, Tai D, Sundar R, Too C. First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Systematic Review and Patient-Level Network Meta-Analysis. Liver Cancer 2022, 12: 7-18. PMID: 36872922, PMCID: PMC9982345, DOI: 10.1159/000526639.
- Ho S, Sheng T, Xing M, Ooi W, Xu C, Sundar R, Huang K, Li Z, Kumar V, Ramnarayanan K, Zhu F, Srivastava S, Bin Adam Isa Z, Anene-Nzelu C, Razavi-Mohseni M, Shigaki D, Ma H, Tan A, Ong X, Lee M, Tay S, Guo Y, Huang W, Li S, Beer M, Foo R, Teh M, Skanderup A, Teh B, Tan P. Regulatory enhancer profiling of mesenchymal-type gastric cancer reveals subtype-specific epigenomic landscapes and targetable vulnerabilities. Gut 2022, 72: 226-241. PMID: 35817555, DOI: 10.1136/gutjnl-2021-326483.
- Loh J, Ang Y, Jain A, Yeong J, Sundar R. Targeting Anaplastic Lymphoma Kinase in GI Primary Malignancies. JCO Precision Oncology 2022, 6: e2200208. PMID: 35939772, PMCID: PMC9384951, DOI: 10.1200/po.22.00208.
- Chia D, Gwee Y, Sundar R. Resistance to systemic immune checkpoint inhibition in the peritoneal niche. Journal For ImmunoTherapy Of Cancer 2022, 10: e004749. PMID: 35728873, PMCID: PMC9214396, DOI: 10.1136/jitc-2022-004749.
- Chan S, Chotipanich C, Choo S, Kwang S, Mo F, Worakitsitisatorn A, Tai D, Sundar R, Ng D, Loke K, Li L, Ng K, Peng Y, Yu S. Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres Followed by Gemcitabine plus Cisplatin for Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Single-Arm Multicenter Clinical Trial. Liver Cancer 2022, 11: 451-459. PMID: 36158588, PMCID: PMC9485918, DOI: 10.1159/000525489.
- Mai A, Lee A, Tay R, Shapiro L, Thakkar A, Halmos B, Grinshpun A, Herishanu Y, Benjamini O, Tadmor T, Shroff R, LaFleur B, Bhattacharya D, Peng S, Tey J, Lee S, Chai L, Soon Y, Sundar R, Lee M. Booster doses of COVID-19 vaccines for patients with haematological and solid cancer: a systematic review and individual patient data meta-analysis. European Journal Of Cancer 2022, 172: 65-75. PMID: 35753213, PMCID: PMC9163022, DOI: 10.1016/j.ejca.2022.05.029.
- Tay R, Yeong J, Lum J, Teo C, Tan B, Chan Y, Choo J, Jeyasekhran A, Miow Q, Loo L, Yong W, Sundar R. Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy. Journal Of Clinical Oncology 2022, 40: 4026-4026. DOI: 10.1200/jco.2022.40.16_suppl.4026.
- Ang C, Low Q, Ho C, Walsh R, Asokumaran Y, Choo J, Chan G, Ho J, Ang Y, Tan L, Yong W, Sundar R, Chee C. Real-world experience on the efficacy and tolerability of biweekly trifluridine/tipiracil with or without bevacizumab in metastatic colorectal cancer. Journal Of Clinical Oncology 2022, 40: 3584-3584. DOI: 10.1200/jco.2022.40.16_suppl.3584.
- Blasiak A, Truong A, Jeit L, Kumar K, Tan S, Teo C, Tan B, Tadeo X, Tan L, Chee C, Yong W, Ho D, Sundar R. PRECISE CURATE.AI: A prospective feasibility trial to dynamically modulate personalized chemotherapy dose with artificial intelligence. Journal Of Clinical Oncology 2022, 40: 1574-1574. DOI: 10.1200/jco.2022.40.16_suppl.1574.
- Sooi K, Low J, Miow Q, Kumarakulasinghe N, Sundar R, Huang Y. Pan-immune-inflammation value as a predictive biomarker for survival in advanced non-small cell lung cancer patients treated with immunotherapy. Journal Of Clinical Oncology 2022, 40: e21095-e21095. DOI: 10.1200/jco.2022.40.16_suppl.e21095.
- Chan J, Zhang B, Chew X, Salhi A, Kwok Z, Lim C, Desi N, Subramaniam N, Siemens A, Kinanti T, Ong S, Sanchez-Mejias A, Ly P, An O, Sundar R, Fan X, Wang S, Siew B, Lee K, Chong C, Lieske B, Cheong W, Goh Y, Fam W, Ooi M, Koh B, Iyer S, Ling W, Chen J, Yoong B, Chanwat R, Bonney G, Goh B, Zhai W, Fullwood M, Wang W, Tan K, Chng W, Dan Y, Pitt J, Roca X, Guccione E, Vardy L, Chen L, Gao X, Chow P, Yang H, Tay Y. Pan-cancer pervasive upregulation of 3′ UTR splicing drives tumourigenesis. Nature Cell Biology 2022, 24: 928-939. PMID: 35618746, PMCID: PMC9203280, DOI: 10.1038/s41556-022-00913-z.
- Nargund A, Xu C, Mandoli A, Okabe A, Chen G, Huang K, Sheng T, Yao X, Teo J, Sundar R, Kok Y, See Y, Xing M, Li Z, Yong C, Anand A, Bin Adam Isa Z, Poon L, Ng M, Koh J, Ooi W, Tay S, Ong X, Tan A, Smoot D, Ashktorab H, Grabsch H, Fullwood M, Teh B, Bi X, Kaneda A, Li S, Tan P. Chromatin Rewiring by Mismatch Repair Protein MSH2 Alters Cell Adhesion Pathways and Sensitivity to BET Inhibition in Gastric Cancer. Cancer Research 2022, 82: 2538-2551. PMID: 35583999, DOI: 10.1158/0008-5472.can-21-2072.
- Tan B, Teo Y, Tan N, Yap D, Sundar R, Lee C, See A, Toh S. Association of obstructive sleep apnea and nocturnal hypoxemia with all-cancer incidence and mortality: a systematic review and meta-analysis. Journal Of Clinical Sleep Medicine 2022, 18: 1427-1440. PMID: 34755597, PMCID: PMC9059590, DOI: 10.5664/jcsm.9772.
- Zhao J, Syn N, Tan B, Yap D, Teo C, Chan Y, Sundar R. KMSubtraction: reconstruction of unreported subgroup survival data utilizing published Kaplan-Meier survival curves. BMC Medical Research Methodology 2022, 22: 93. PMID: 35369867, PMCID: PMC8978435, DOI: 10.1186/s12874-022-01567-z.
- Lim J, Wong A, Ow S, Ngoi N, Chan G, Ang Y, Chong W, Lim S, Lim Y, Lee M, Choo J, Tan H, Yong W, Soo R, Tan D, Chee C, Sundar R, Yadav K, Jain S, Wang L, Tai B, Goh B, Lee S. Phase Ib/II Dose Expansion Study of Lenvatinib Combined with Letrozole in Postmenopausal Women with Hormone Receptor-Positive Breast Cancer. Clinical Cancer Research 2022, 28: 2248-2256. PMID: 35363275, DOI: 10.1158/1078-0432.ccr-21-4179.
- Lee M, Wong A, Ow S, Sundar R, Tan D, Soo R, Chee C, Lim J, Yong W, Lim S, Goh B, Wang L, Lee S. Phase Ib Dose-Finding Study of Varlitinib Combined with Weekly Paclitaxel With or Without Carboplatin ± Trastuzumab in Advanced Solid Tumors. Targeted Oncology 2022, 17: 141-151. PMID: 35195837, PMCID: PMC8995271, DOI: 10.1007/s11523-022-00867-0.
- Tan D, Lim W, Yong J, Ng C, Muthiah M, Tan E, Xiao J, Lim S, Pin Tang A, Pan X, Kabir T, Bonney G, Sundar R, Syn N, Kim B, Dan Y, Noureddin M, Loomba R, Huang D. UNOS Down-Staging Criteria for Liver Transplantation of Hepatocellular Carcinoma: Systematic Review and Meta-Analysis of 25 Studies. Clinical Gastroenterology And Hepatology 2022, 21: 1475-1484. PMID: 35181565, DOI: 10.1016/j.cgh.2022.02.018.
- Peng S, Ying A, Chan N, Sundar R, Soon Y, Bandla A. Prevention of Oxaliplatin-Induced Peripheral Neuropathy: A Systematic Review and Meta-Analysis. Frontiers In Oncology 2022, 12: 731223. PMID: 35186722, PMCID: PMC8853097, DOI: 10.3389/fonc.2022.731223.
- Cheo S, Lee J, Walsh R, Sundar R, Choo J, Chan G, Yong W, Meah W, Khor C, Chee C. Ciprofloxacin plus gemcitabine-based chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma: A pilot study of microbiome manipulation. Journal Of Clinical Oncology 2022, 40: 570-570. DOI: 10.1200/jco.2022.40.4_suppl.570.
- Tayeb Z, Dragomir A, Lee J, Abbasi N, Dean E, Bandla A, Bose R, Sundar R, Bezerianos A, Thakor N, Cheng G. Distinct spatio-temporal and spectral brain patterns for different thermal stimuli perception. Scientific Reports 2022, 12: 919. PMID: 35042875, PMCID: PMC8766611, DOI: 10.1038/s41598-022-04831-w.
- Leen A, Yap D, Teo C, Tan B, Molassiotis A, Ishiguro H, Fan S, Sundar R, Soon Y, Bandla A. A Systematic Review and Meta-Analysis of the Effectiveness of Neuroprotectants for Paclitaxel-Induced Peripheral Neuropathy. Frontiers In Oncology 2022, 11: 763229. PMID: 35070969, PMCID: PMC8766304, DOI: 10.3389/fonc.2021.763229.
- Ho J, Heong V, Yong W, Soo R, Chee C, Wong A, Sundar R, Thian Y, Gopinathan A, Pang M, Koe P, Jeraj S, Soe P, Soe M, Tang T, Ng M, Tai D, Tan T, Xu H, Chang H, Landesman Y, Shah J, Shacham S, Lee S, Tan D, Goh B, Tan D. A phase 1 study of the safety, pharmacokinetics and pharmacodynamics of escalating doses followed by dose expansion of the selective inhibitor of nuclear export (SINE) selinexor in Asian patients with advanced or metastatic malignancies. Therapeutic Advances In Medical Oncology 2022, 14: 17588359221087555. PMID: 35432603, PMCID: PMC9008867, DOI: 10.1177/17588359221087555.
- Jia J, Guo Y, Sundar R, Bandla A, Hao Z. Cryotherapy for Prevention of Taxane-Induced Peripheral Neuropathy: A Meta-Analysis. Frontiers In Oncology 2021, 11: 781812. PMID: 34912720, PMCID: PMC8667340, DOI: 10.3389/fonc.2021.781812.
- Chin Y, Jain S, Lee M, Ng C, Lin S, Mai A, Muthiah M, Foo F, Sundar R, Ong D, Leow W, Leong R, Chan W. Small bowel adenocarcinoma in Crohn’s disease: a systematic review and meta-analysis of the prevalence, manifestation, histopathology, and outcomes. International Journal Of Colorectal Disease 2021, 37: 239-250. PMID: 34704127, DOI: 10.1007/s00384-021-04050-1.
- Sheng T, Ho S, Ooi W, Xu C, Xing M, Padmanabhan N, Huang K, Ma L, Ray M, Guo Y, Sim N, Anene-Nzelu C, Chang M, Razavi-Mohseni M, Beer M, Foo R, Sundar R, Chan Y, Tan A, Ong X, Skanderup A, White K, Jha S, Tan P. Integrative epigenomic and high-throughput functional enhancer profiling reveals determinants of enhancer heterogeneity in gastric cancer. Genome Medicine 2021, 13: 158. PMID: 34635154, PMCID: PMC8504099, DOI: 10.1186/s13073-021-00970-3.
- Loh J, Wu J, Chieng J, Chan A, Yong W, Sundar R, Lee S, Wong A, Lim J, Tan D, Soo R, Chng W, Goh B, Tai B, Chee C. 1835P Clinical outcome and prognostic factors for Asian patients in phase I clinical trials. Annals Of Oncology 2021, 32: s1241. DOI: 10.1016/j.annonc.2021.08.723.
- Lim J, Sundar R, Wong A, Yong W, Soo R, Chee C, Lee S, Goh B, Dent R, Jeraj S, Kwok L, Schiavon G, Kaliaperumal N, Foxley A, Connolly J, Tan D. 515MO A phase I trial of durvalumab (Durv) in combination with olaparib (Ola) and capivasertib (Cap) in patients (pts) with advanced or metastatic cancers (Ca) (MEDIPAC). Annals Of Oncology 2021, 32: s585-s586. DOI: 10.1016/j.annonc.2021.08.1037.
- Teo C, Tan B, Tadeo X, Peng S, Soh H, Du S, Luo V, Bandla A, Sundar R, Ho D, Kee T, Blasiak A. Abstract CT211: Personalized, rational, efficacy-driven chemotherapy dosing via an artificial intelligence system (PRECISE): A protocol for the PRECISE CURATE.AI pilot clinical trial. Cancer Research 2021, 81: ct211-ct211. DOI: 10.1158/1538-7445.am2021-ct211.
- Chan S, Chotipanich C, Choo S, Kwang S, Worakitsitisatorn A, Tai D, Yong W, Sundar R, Li L, Yu S, Sungkasubun P. P-19 A multicentred phase II clinical trial on yttrium 90-resin microspheres followed by gemcitabine-cisplatin for treatment of locally advanced intra-hepatic cholangiocarcinoma. Annals Of Oncology 2021, 32: s102. DOI: 10.1016/j.annonc.2021.05.074.
- Ong S, Sundar R, Bandla A, Kim N. Wearable Physiological Stress Monitoring System—A Proof-of-Concept Study. 2021, 623-633. DOI: 10.1007/978-981-15-9472-4_54.
- Tan B, Teo C, Tadeo X, Peng S, Soh H, Du S, Luo V, Bandla A, Sundar R, Ho D, Kee T, Blasiak A. Personalised, Rational, Efficacy-Driven Cancer Drug Dosing via an Artificial Intelligence SystEm (PRECISE): A Protocol for the PRECISE CURATE.AI Pilot Clinical Trial. Frontiers In Digital Health 2021, 3: 635524. PMID: 34713106, PMCID: PMC8521832, DOI: 10.3389/fdgth.2021.635524.
- Collins D, Sundar R, Constantinidou A, Dolling D, Yap T, Popat S, O’Brien M, Banerji U, de Bono J, Lopez J, Tunariu N, Minchom A. Correction to: Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease. BMC Cancer 2021, 21: 245. PMID: 33685408, PMCID: PMC7938531, DOI: 10.1186/s12885-021-07999-y.
- Low J, Huang Y, Sooi K, Ang Y, Chan Z, Spencer K, Jeyasekharan A, Sundar R, Goh B, Soo R, Yong W. Low‐dose pembrolizumab in the treatment of advanced non‐small cell lung cancer. International Journal Of Cancer 2021, 149: 169-176. PMID: 33634869, PMCID: PMC9545741, DOI: 10.1002/ijc.33534.
- Ho J, Heong V, Yong W, Soo R, Chee C, Wong A, Thian Y, Sundar R, Gopinathan A, Lee S, Goh B, Xu H, Tan D. 40P Phase I study of the safety, pharmacokinetics and pharmacodynamics of escalating doses followed by dose expansion of selinexor in Asian patients with advanced solid tumour malignancies. Annals Of Oncology 2021, 32: s17. DOI: 10.1016/j.annonc.2021.01.055.
- An O, Song Y, Ke X, So J, Sundar R, Yang H, Rha S, Lee M, Tay S, Ong X, Tan A, Ng M, Tantoso E, Chen L, Tan P, Yong W, Consortium S. “3G” Trial: An RNA Editing Signature to Guide Gastric Cancer ChemotherapyRNA Editing Signature in Gastric Cancer. Cancer Research 2021, 81: 2788-2798. PMID: 33558338, DOI: 10.1158/0008-5472.can-20-2872.
- Shitara K, George B, Taieb J, Sundar R, Fakih M, Makris L, Benhadji K, Ghidini M. The impact of prior therapies on outcomes with trifluridine/tipiracil (FTD/TPI) in the phase III TAGS trial. Journal Of Clinical Oncology 2021, 39: 247-247. DOI: 10.1200/jco.2021.39.3_suppl.247.
- Chia D, Sundar R, Kim G, Ang J, Lum J, Nga M, Cheng Ean C, Tan H, Ho J, Ngoi N, Lee M, Muthu V, Chan G, Pang A, Ang Y, Choo J, Lim J, Shabbir A, Yong W, So J. Outcomes of a phase II study of intraperitoneal paclitaxel plus systemic capecitabine and oxaliplatin (XELOX) for gastric cancer with peritoneal metastases. Journal Of Clinical Oncology 2021, 39: 165-165. DOI: 10.1200/jco.2021.39.3_suppl.165.
- Binder J, Unver E, Clayton J, Burke P, Paxman R, Sundar R, Bandla A. A Limb Hypothermia Wearable for Chemotherapy-Induced Peripheral Neuropathy: A Mixed-Methods Approach in Medical Product Development. Frontiers In Digital Health 2020, 2: 573234. PMID: 34713046, PMCID: PMC8521967, DOI: 10.3389/fdgth.2020.573234.
- Collins D, Sundar R, Constantinidou A, Dolling D, Yap T, Popat S, O’Brien M, Banerji U, de Bono J, Lopez J, Tunariu N, Minchom A. Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease. BMC Cancer 2020, 20: 1210. PMID: 33298007, PMCID: PMC7724793, DOI: 10.1186/s12885-020-07662-y.
- Ang Y, Ho G, Soo R, Sundar R, Tan S, Yong W, Ow S, Lim J, Chong W, Soe P, Tai B, Wang L, Goh B, Lee S. A randomized phase II trial evaluating the addition of low dose, short course sunitinib to docetaxel in advanced solid tumours. BMC Cancer 2020, 20: 1118. PMID: 33203399, PMCID: PMC7672922, DOI: 10.1186/s12885-020-07616-4.
- Kim G, Tan L, Sundar R, Lieske B, Chee C, Ho J, Shabbir A, Babak M, Ang W, Goh B, Yong W, Wang L, So J. PIPAC-OX: A Phase I Study of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy in Patients with Peritoneal Metastases. Clinical Cancer Research 2020, 27: 1875-1881. PMID: 33148667, DOI: 10.1158/1078-0432.ccr-20-2152.
- Chong W, Lim C, Sinha A, Tan C, Chan G, Huang Y, Kumarakulasinghe N, Sundar R, Jeyasekharan A, Loh W, Tay J, Yadav K, Wang L, Wong A, Kong L, Soo R, Lau J, Soon Y, Goh R, Ho F, Chong S, Lee S, Loh K, Tai B, Lim Y, Goh B. Integration of Antiangiogenic Therapy with Cisplatin and Gemcitabine Chemotherapy in Patients with Nasopharyngeal Carcinoma. Clinical Cancer Research 2020, 26: 5320-5328. PMID: 32816944, DOI: 10.1158/1078-0432.ccr-20-1727.
- Cheong C, Nistala K, Ng C, Syn N, Chang H, Sundar R, Yang S, Chong C. Neoadjuvant therapy in locally advanced colon cancer: a meta-analysis and systematic review. Journal Of Gastrointestinal Oncology 2020, 11: 847-857. PMID: 33209481, PMCID: PMC7657836, DOI: 10.21037/jgo-20-220.
- Lee S, Shimasaki N, Lim J, Wong A, Yadav K, Yong W, Tan L, Koh L, Poon M, Tan S, Ow S, Bharwani L, Yap Y, Foo M, Coustan-Smith E, Sundar R, Tan L, Chong W, Kumarakulasinghe N, Lieow J, Koe P, Goh B, Campana D. Phase I Trial of Expanded, Activated Autologous NK-cell Infusions with Trastuzumab in Patients with HER2-positive Cancers. Clinical Cancer Research 2020, 26: 4494-4502. PMID: 32522887, DOI: 10.1158/1078-0432.ccr-20-0768.
- Toh J, Hoppe M, Thakur T, Yang H, Tan K, Pang B, Ho S, Roy R, Ho K, Yeoh K, Tan P, Sundar R, Jeyasekharan A. Profiling of gastric cancer cell-surface markers to achieve tumour–normal discrimination. BMJ Open Gastroenterology 2020, 7: e000452. PMID: 32816956, PMCID: PMC7437876, DOI: 10.1136/bmjgast-2020-000452.
- Cheng H, Lopez V, Lam S, Leung A, Li Y, Wong K, Au J, Sundar R, Chan A, De Ng T, Suen L, Chan C, Yorke J, Molassiotis A. Psychometric testing of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group—Neurotoxicity (FACT/GOG-Ntx) subscale in a longitudinal study of cancer patients treated with chemotherapy. Health And Quality Of Life Outcomes 2020, 18: 246. PMID: 32703223, PMCID: PMC7376939, DOI: 10.1186/s12955-020-01493-y.
- Tan H, Kim G, Charles C, Li R, Jang C, Shabbir A, Chue K, Tai C, Sundar R, Goh B, Bonney G, Looi W, Cheow E, So J, Wang L, Yong W. Safety, pharmacokinetics and tissue penetration of PIPAC paclitaxel in a swine model. European Journal Of Surgical Oncology 2020, 47: 1124-1131. PMID: 32800400, DOI: 10.1016/j.ejso.2020.06.031.
- Bandla A, Santhanakrishnan P, Magarajah G, Vaidya G, Subramanian A, Wei H, Wilder-Smith E, Chin L, Thakor N, Sundar R. Limb Hypothermia for the Prevention of Chemotherapy-Induced Peripheral Neuropathy – Modality for Optimal Cooling. Annual International Conference Of The IEEE Engineering In Medicine And Biology Society (EMBC) 2020, 00: 5061-5064. PMID: 33019124, DOI: 10.1109/embc44109.2020.9175432.
- Kim G, Tan H, Sundar R, Wang L, Shabbir A, Yong W, So J. P-159 First-in-human phase 1 dose-escalating study protocol of pressurized intraperitoneal aerosol chemotherapy with paclitaxel in peritoneal carcinomatosis (PIPAC2 study). Annals Of Oncology 2020, 31: s141. DOI: 10.1016/j.annonc.2020.04.241.
- Ng C, Jiang A, Toh E, Ng C, Ong Z, Peng S, Tham H, Sundar R, Chong C, Khoo C. Metformin and colorectal cancer: a systematic review, meta-analysis and meta-regression. International Journal Of Colorectal Disease 2020, 35: 1501-1512. PMID: 32592092, DOI: 10.1007/s00384-020-03676-x.
- Walsh R, Ngoi N, Ong R, Ow S, Wong A, Eng L, Lim Y, Heong V, Sundar R, Soo R, Yong W, Chee C, Goh B, Lee S, Tan D, Lim J. Molecular profiling of metastatic breast cancer (MBC) and target-based therapeutic matching in an Asian tertiary phase I oncology unit. Journal Of Clinical Oncology 2020, 38: 3561-3561. DOI: 10.1200/jco.2020.38.15_suppl.3561.
- Wong R, Wu J, Leen A, Tey G, Asokumaran Y, Chan G, Siddappan C, Jeyasekharan A, Chee C, Yong W, Ngiam K, Sundar R. The role of targeted therapy (TKI) in the treatment of advanced hepatocellular carcinoma (aHCC) in the era of immunotherapy: Real-world data using AI analytics from an academic medical center. Journal Of Clinical Oncology 2020, 38: e16623-e16623. DOI: 10.1200/jco.2020.38.15_suppl.e16623.
- Lim J, Wong A, Ow S, Ngoi N, Ang Y, Chan G, Eng L, Chong W, Choo J, Lee M, Tan H, Jan Y, Tan K, Sundar R, Tan D, Soo R, Chee C, Yong W, Goh B, Lee S. Clinical efficacy and molecular effects of lenvatinib (Len) and letrozole (Let) in hormone receptor-positive (HR+) metastatic breast cancer (MBC). Journal Of Clinical Oncology 2020, 38: 1019-1019. DOI: 10.1200/jco.2020.38.15_suppl.1019.
- Sundar R, Magarajah G, Ow S, Chan G, Choo J, Eng L, Wong A, Vijayan J, Hairom Z, Ang E, Paxman R, Wilder-Smith E, Thakor N, Lee S, Bandla A. Concomitant limb cryocompression and scalp cooling to reduce paclitaxel-induced neuropathy and alopecia. Journal Of Clinical Oncology 2020, 38: e24157-e24157. DOI: 10.1200/jco.2020.38.15_suppl.e24157.
- Lee M, Chong W, Tan H, Chan G, Ho J, Sundar R, Chee C, Nasrallah F, Koo E, Yong W. The chemo-brain effect in colorectal cancer patients. Journal Of Clinical Oncology 2020, 38: e24095-e24095. DOI: 10.1200/jco.2020.38.15_suppl.e24095.
- Low J, Sooi K, Huang Y, Chan G, Ang Y, Chong W, Tan H, Ngoi N, Choo J, Lee M, Muthu V, Asokumaran Y, Walsh R, Wong R, Chan Z, Soo R, Sundar R, Yong W. Cost and efficacy of low-dose pembrolizumab in the treatment of non-small cell lung cancer patients in Asia. Journal Of Clinical Oncology 2020, 38: e19385-e19385. DOI: 10.1200/jco.2020.38.15_suppl.e19385.
- Sundar R, Smyth E, Peng S, Yeong J, Tan P. Predictive Biomarkers of Immune Checkpoint Inhibition in Gastroesophageal Cancers. Frontiers In Oncology 2020, 10: 763. PMID: 32500029, PMCID: PMC7243739, DOI: 10.3389/fonc.2020.00763.
- Sundar R, Kim G, Tan H, Wang L, Chue K, Tai C, Teo S, Jang C, Chee C, Lieske B, Chee C, Shabbir A, So J, Yong W. Safety and tolerability of oxaliplatin based pressurized intraperitoneal aerosol chemotherapy (PIPAC) for patients with peritoneal carcinomatosis: A phase I dose-finding study in Asian patients. Journal Of Clinical Oncology 2020, 38: 360-360. DOI: 10.1200/jco.2020.38.4_suppl.360.
- Wang W, Xiang P, Chew W, Torta F, Bandla A, Lopez V, Seow W, Lam B, Chang J, Wong P, Chayaburakul K, Ong W, Wenk M, Sundar R, Herr D. Activation of sphingosine 1-phosphate receptor 2 attenuates chemotherapy-induced neuropathy. Journal Of Biological Chemistry 2020, 295: 1143-1152. DOI: 10.1016/s0021-9258(17)49922-4.
- Wang W, Xiang P, Chew W, Torta F, Bandla A, Lopez V, Seow W, Lam B, Chang J, Wong P, Chayaburakul K, Ong W, Wenk M, Sundar R, Herr D. Activation of sphingosine 1-phosphate receptor 2 attenuates chemotherapy-induced neuropathy. Journal Of Biological Chemistry 2019, 295: 1143-1152. PMID: 31882542, PMCID: PMC6983853, DOI: 10.1074/jbc.ra119.011699.
- Bandla A, Tan S, Kumarakulasinghe N, Huang Y, Ang S, Magarajah G, Hairom Z, Lim J, Wong A, Chan G, Ngoi N, Ang E, Lee Y, Chan A, Lee S, Thakor N, Wilder-Smith E, Sundar R. Safety and tolerability of cryocompression as a method of enhanced limb hypothermia to reduce taxane-induced peripheral neuropathy. Supportive Care In Cancer 2019, 28: 3691-3699. PMID: 31811482, PMCID: PMC7316694, DOI: 10.1007/s00520-019-05177-2.
- Wang M, Cheng H, Lopez V, Sundar R, Yorke J, Molassiotis A. Redefining chemotherapy-induced peripheral neuropathy through symptom cluster analysis and patient-reported outcome data over time. BMC Cancer 2019, 19: 1151. PMID: 31775665, PMCID: PMC6882224, DOI: 10.1186/s12885-019-6352-3.
- Sundar R, Ng A, Zouridis H, Padmanabhan N, Sheng T, Zhang S, Lee M, Ooi W, Qamra A, Inam I, Hewitt L, So J, Koh V, Nankivell M, Langley R, Allum W, Cunningham D, Rozen S, Yong W, Grabsch H, Tan P. DNA epigenetic signature predictive of benefit from neoadjuvant chemotherapy in oesophageal adenocarcinoma: results from the MRC OE02 trial. European Journal Of Cancer 2019, 123: 48-57. PMID: 31655359, DOI: 10.1016/j.ejca.2019.09.016.
- Eu J, Yadav K, Lim Y, Hirpara J, Kong L, Ng Z, Lee V, Lee S, Tan D, Soo R, Chee C, Yong W, Sundar R, Lim J, Wang L, Ohi N, Tsunoda T, Pervaiz S, Goh B, Wong A. 463P Evaluation of pharmacodynamic (PD) biomarkers in advanced cancer patients treated with oxidative phosphorylation (OXPHOS) inhibitor, OPC-317 (OPC). Annals Of Oncology 2019, 30: v174. DOI: 10.1093/annonc/mdz244.025.
- Sundar R, Tan I, Chee C. Negative Predictive Biomarkers in Colorectal Cancer: PRESSING Ahead. Journal Of Clinical Oncology 2019, 37: 3066-3068. PMID: 31550189, DOI: 10.1200/jco.19.01977.
- Scaranti M, Sundar R, Daly R, Collins D, Dolling D, Gennatas S, Rao Baikady B, Kaye S, Banerji U, Lopez J, De Bono J, Minchom A. Evaluation of Electronic Activity Monitors (EAMs) during phase I clinical trials. Journal Of Clinical Oncology 2019, 37: e18175-e18175. DOI: 10.1200/jco.2019.37.15_suppl.e18175.
- Sundar R, Qamra A, Tan A, Zhang S, Ng C, Teh B, Lee J, Kim K, Tan P. Epigenetic alternate promoter utilization and association with PD-L1 expression in Epstein–Barr virus positive gastric cancer. Journal Of Clinical Oncology 2019, 37: e15509-e15509. DOI: 10.1200/jco.2019.37.15_suppl.e15509.
- Lim J, Wong A, Ow S, Eng L, Sundar R, Chan G, Yadav K, Heong V, Tan D, Soo R, Chee C, Yong W, Goh B, Lee S. A phase Ib/II trial of lenvatinib (len) and letrozole (let) incorporating pharmacodynamics studies in postmenopausal women with hormone receptor positive (HR+) locally advanced/metastatic breast cancer (LABC/MBC). Journal Of Clinical Oncology 2019, 37: 1045-1045. DOI: 10.1200/jco.2019.37.15_suppl.1045.
- Molassiotis A, Cheng H, Leung K, Li Y, Wong K, Au J, Sundar R, Chan A, De Ng T, Suen L, Chan C, Yorke J, Lopez V. Risk factors for chemotherapy‐induced peripheral neuropathy in patients receiving taxane‐ and platinum‐based chemotherapy. Brain And Behavior 2019, 9: e01312. PMID: 31063261, PMCID: PMC6576180, DOI: 10.1002/brb3.1312.
- Yeo F, Ng C, Loh K, Molassiotis A, Cheng H, Au J, Leung K, Li Y, Wong K, Suen L, Chan C, Yorke J, Farrell C, Bandla A, Ang E, Lopez V, Sundar R, Chan A. Minimal clinically important difference of the EORTC QLQ-CIPN20 for worsening peripheral neuropathy in patients receiving neurotoxic chemotherapy. Supportive Care In Cancer 2019, 27: 4753-4762. PMID: 30972646, DOI: 10.1007/s00520-019-04771-8.
- Shimomura A, Yamamoto N, Kondo S, Fujiwara Y, Suzuki S, Yanagitani N, Horiike A, Kitazono S, Ohyanagi F, Doi T, Kuboki Y, Kawazoe A, Shitara K, Ohno I, Banerji U, Sundar R, Ohkubo S, Calleja E, Nishio M. First-in-human phase I study of an oral HSP90 inhibitor, TAS-116, in patients with advanced solid tumors. Molecular Cancer Therapeutics 2019, 18: molcanther.0831.2018. PMID: 30679388, DOI: 10.1158/1535-7163.mct-18-0831.
- Sundar R, Ng A, Zouridis H, Sheng T, Zhang S, Lee M, Padmanabhan N, Ooi W, Qamra A, Nankivell M, Langley R, Allum W, Cunningham D, Grabsch H, Tan P. DNA methylation signature predictive of benefit from neoadjuvant chemotherapy in esophageal adenocarcinoma: Results from the MRC OEO2 phase III trial. Journal Of Clinical Oncology 2019, 37: 43-43. DOI: 10.1200/jco.2019.37.4_suppl.43.
- Sundar R, Huang K, Qamra A, Kim K, Kim S, Kang W, Tan A, Lee J, Tan P. Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer. Annals Of Oncology 2019, 30: 424-430. PMID: 30624548, PMCID: PMC6442650, DOI: 10.1093/annonc/mdy550.
- Brown P, Tan A, El-Esawi M, Liehr T, Blanck O, Gladue D, Almeida G, Cernava T, Sorzano C, Yeung A, Engel M, Chandrasekaran A, Muth T, Staege M, Daulatabad S, Widera D, Zhang J, Meule A, Honjo K, Pourret O, Yin C, Zhang Z, Cascella M, Flegel W, Goodyear C, van Raaij M, Bukowy-Bieryllo Z, Campana L, Kurniawan N, Lalaouna D, Hüttner F, Ammerman B, Ehret F, Cobine P, Tan E, Han H, Xia W, McCrum C, Dings R, Marinello F, Nilsson H, Nixon B, Voskarides K, Yang L, Costa V, Bengtsson-Palme J, Bradshaw W, Grimm D, Kumar N, Martis E, Prieto D, Sabnis S, Amer S, Liew A, Perco P, Rahimi F, Riva G, Zhang C, Devkota H, Ogami K, Basharat Z, Fierz W, Siebers R, Tan K, Boehme K, Brenneisen P, Brown J, Dalrymple B, Harvey D, Ng G, Werten S, Bleackley M, Dai Z, Dhariwal R, Gelfer Y, Hartmann M, Miotla P, Tamaian R, Govender P, Gurney-Champion O, Kauppila J, Zhang X, Echeverría N, Subhash S, Sallmon H, Tofani M, Bae T, Bosch O, Cuív P, Danchin A, Diouf B, Eerola T, Evangelou E, Filipp F, Klump H, Kurgan L, Smith S, Terrier O, Tuttle N, Ascher D, Janga S, Schulte L, Becker D, Browngardt C, Bush S, Gaullier G, Ide K, Meseko C, Werner G, Zaucha J, Al-Farha A, Greenwald N, Popoola S, Rahman S, Xu J, Yang S, Hiroi N, Alper O, Baker C, Bitzer M, Chacko G, Debrabant B, Dixon R, Forano E, Gilliham M, Kelly S, Klempnauer K, Lidbury B, Lin M, Lynch I, Ma W, Maibach E, Mather D, Nandakumar K, Ohgami R, Parchi P, Tressoldi P, Xue Y, Armitage C, Barraud P, Chatzitheochari S, Coelho L, Diao J, Doxey A, Gobet A, Hu P, Kaiser S, Mitchell K, Salama M, Shabalin I, Song H, Stevanovic D, Yadollahpour A, Zeng E, Zinke K, Alimba C, Beyene T, Cao Z, Chan S, Gatchell M, Kleppe A, Piotrowski M, Torga G, Woldesemayat A, Cosacak M, Haston S, Ross S, Williams R, Wong A, Abramowitz M, Effiong A, Lee S, Abid M, Agarabi C, Alaux C, Albrecht D, Atkins G, Beck C, Bonvin A, Bourke E, Brand T, Braun R, Bull J, Cardoso P, Carter D, Delahay R, Ducommun B, Duijf P, Epp T, Eskelinen E, Fallah M, Farber D, Fernandez-Triana J, Feyerabend F, Florio T, Friebe M, Furuta S, Gabrielsen M, Gruber J, Grybos M, Han Q, Heinrich M, Helanterä H, Huber M, Jeltsch A, Jiang F, Josse C, Jurman G, Kamiya H, de Keersmaecker K, Kristiansson E, de Leeuw F, Li J, Liang S, Lopez-Escamez J, Lopez-Ruiz F, Marchbank K, Marschalek R, Martín C, Miele A, Montagutelli X, Morcillo E, Nicoletti R, Niehof M, O’Toole R, Ohtomo T, Oster H, Palma J, Paterson R, Peifer M, Portilla M, Portillo M, Pritchard A, Pusch S, Raghava G, Roberts N, Ross K, Schuele B, Sergeant K, Shen J, Stella A, Sukocheva O, Uversky V, Vanneste S, Villet M, Viveiros M, Vorholt J, Weinstock C, Yamato M, Zabetakis I, Zhao X, Ziegler A, Aizat W, Atlas L, Bridges K, Chakraborty S, Deschodt M, Domingues H, Esfahlani S, Falk S, Guisado J, Kane N, Kueberuwa G, Lau C, Liang D, Liu E, Luu A, Ma C, Ma L, Moyer R, Norris A, Panthee S, Parsons J, Peng Y, Pinto I, Reschke C, Sillanpää E, Stewart C, Uhle F, Yang H, Zhou K, Zhu S, Ashry M, Bergsland N, Berthold M, Chen C, Colella V, Cuypers M, Eskew E, Fan X, Gajda M, Gonzálezlez-Prendes R, Goodin A, Graham E, Groen E, Gutiérrez-Sacristán A, Habes M, Heffler E, Higginbottom D, Janzen T, Jayaraman J, Jibb L, Jongen S, Kinyanjui T, Koleva-Kolarova R, Li Z, Liu Y, Lund B, Lussier A, Ma L, Mier P, Moore M, Nagler K, Orme M, Pearson J, Prajapati A, Saito Y, Tröder S, Uchendu F, Verloh N, Voutchkova D, Abu-Zaid A, Bakkach J, Baumert P, Dono M, Hanson J, Herbelet S, Hobbs E, Kulkarni A, Kumar N, Liu S, Loft N, Reddan T, Senghore T, Vindin H, Xu H, Bannon R, Chen B, Cheung J, Cooper J, Esnakula A, Feghali K, Ghelardi E, Gnasso A, Horbar J, Lai H, Li J, Ma L, Ma R, Pan Z, Peres M, Pranata R, Seow E, Sydes M, Testoni I, Westermair A, Yang Y, Afnan M, Albiol J, Albuquerque L, Amiya E, Amorim R, An Q, Andersen S, Aplin J, Argyropoulos C, Asmann Y, Assaeed A, Atanasov A, Atchison D, Avery S, Avillach P, Baade P, Backman L, Badie C, Baldi A, Ball E, Bardot O, Barnett A, Basner M, Batra J, Bazanova O, Beale A, Beddoe T, Bell M, Berezikov E, Berners-Price S, Bernhardt P, Berry E, Bessa T, Billington C, Birch J, Blakely R, Blaskovich M, Blum R, Boelaert M, Bogdanos D, Bosch C, Bourgoin T, Bouvard D, Boykin L, Bradley G, Braun D, Brownlie J, Brühl A, Burt A, Butler L, Byrareddy S, Byrne H, Cabantous S, Calatayud S, Candal E, Carlson K, Casillas S, Castelvetro V, Caswell P, Cavalli G, Cerovsky V, Chagoyen M, Chen C, Chen D, Chen H, Chen H, Chen J, Chen Y, Cheng C, Cheng J, Chinapaw M, Chinopoulos C, Cho W, Chong L, Chowdhury D, Chwalibog A, Ciresi A, Cockcroft S, Conesa A, Cook P, Cooper D, Coqueret O, Corea E, Costa E, Coupland C, Crawford S, Cruz A, Cui H, Cui Q, Culver D, D’Angiulli A, Dahms T, Daigle F, Dalgleish R, Danielsen H, Darras S, Davidson S, Day D, Degirmenci V, Demaison L, Devriendt K, Ding J, Dogan Y, Dong X, Donner C, Dressick W, Drevon C, Duan H, Ducho C, Dumaz N, Dwarakanath B, Ebell M, Eisenhardt S, Elkum N, Engel N, Erickson T, Fairhead M, Faville M, Fejzo M, Festa F, Feteira A, Flood-Page P, Forsayeth J, Fox S, Franks S, Frentiu F, Frilander M, Fu X, Fujita S, Galea I, Galluzzi L, Gani F, Ganpule A, García-Alix A, Gedye K, Giordano M, Giunta C, Gleeson P, Goarant C, Gong H, Gora D, Gough M, Goyal R, Graham K, Grande-Pérez A, Graves P, Greidanus H, Grice D, Grunau C, Gumulya Y, Guo Y, Gurevich V, Gusev O, Hacker E, Hage S, Hagen G, Hahn S, Haller D, Hammerschmidt S, Han J, Han R, Handfield M, Hapuarachchi H, Harder T, Hardingham J, Heck M, Heers M, Hew K, Higuchi Y, St Hilaire C, Hilton R, Hodzic E, Hone A, Hongoh Y, Hu G, Huber H, Hueso L, Huirne J, Hurt L, Idborg H, Ikeo K, Ingley E, Jakeman P, Jensen A, Jia H, Jia H, Jia S, Jiang J, Jiang X, Jin Y, Jo D, Johnson A, Johnston M, Jonscher K, Jorens P, Jorgensen J, Joubert J, Jung S, M A, Kahan T, Kamboj S, Kang Y, Karamanos Y, Karp N, Kelly R, Kenna R, Kennedy J, Kersten B, Khalaf R, Khalid J, Khatlani T, Khider T, Kijanka G, King S, Kluz T, Knox P, Kobayashi T, Koch K, Kohonen-Corish M, Kong X, Konkle-Parker D, Korpela K, Kostrikis L, Kraiczy P, Kratz H, Krause G, Krebsbach P, Kristensen S, Kumari P, Kunimatsu A, Kurdak H, Kwon Y, Lachat C, Lagisz M, Laky B, Lammerding J, Lange M, Larrosa M, Laslett A, LeClair E, Lee K, Lee M, Lee M, Li G, Li J, Lieb K, Lim Y, Lindsey M, Line P, Liu D, Liu F, Liu H, Liu H, Lloyd V, Lo T, Locci E, Loidl J, Lorenzen J, Lorkowski S, Lovell N, Lu H, Lu W, Lu Z, Luengo G, Lundh L, Lysy P, Mabb A, Mack H, Mackey D, Mahdavi S, Maher P, Maher T, Maity S, Malgrange B, Mamoulakis C, Mangoni A, Manke T, Manstead A, Mantalaris A, Marsal J, Marschall H, Martin F, Martinez-Raga J, Martinez-Salas E, Mathieu D, Matsui Y, Maza E, McCutcheon J, McKay G, McMillan B, McMillan N, Meads C, Medina L, Merrick B, Metzger D, Meunier F, Michaelis M, Micheau O, Mihara H, Mintz E, Mizukami T, Moalic Y, Mohapatra D, Monteiro A, Montes M, Moran J, Morozov S, Mort M, Murai N, Murphy D, Murphy S, Murray S, Naganawa S, Nammi S, Nasios G, Natoli R, Nguyen F, Nicol C, van Nieuwerburgh F, Nilsen E, Nobile C, O’Mahony M, Ohlsson S, Olatunbosun O, Olofsson P, Ortiz A, Ostrikov K, Otto S, Outeiro T, Ouyang S, Paganoni S, Page A, Palm C, Paradies Y, Parsons M, Parsons N, Pascal P, Paul E, Peckham M, Pedemonte N, Pellizzon M, Petrelli M, Pichugin A, Pinto C, Plevris J, Pollesello P, Polz M, Ponti G, Porcelli P, Prince M, Quinn G, Quinn T, Ramula S, Rappsilber J, Rehfeldt F, Reiling J, Remacle C, Rezaei M, Riddick E, Ritter U, Roach N, Roberts D, Robles G, Rodrigues T, Rodriguez C, Roislien J, Roobol M, Rowe J, Ruepp A, van Ruitenbeek J, Rust P, Saad S, Sack G, Santos M, Saudemont A, Sava G, Schrading S, Schramm A, Schreiber M, Schuler S, Schymkowitz J, Sczyrba A, Seib K, Shi H, Shimada T, Shin J, Shortt C, Silveyra P, Skinner D, Small I, Smeets P, So P, Solano F, Sonenshine D, Song J, Southall T, Speakman J, Srinivasan M, Stabile L, Stasiak A, Steadman K, Stein N, Stephens A, Stewart D, Stine K, Storlazzi C, Stoynova N, Strzalka W, Suarez O, Sultana T, Sumant A, Summers M, Sun G, Tacon P, Tanaka K, Tang H, Tanino Y, Targett-Adams P, Tayebi M, Tayyem R, Tebbe C, Telfer E, Tempel W, Teodorczyk-Injeyan J, Thijs G, Thorne S, Thrift A, Tiffon C, Tinnefeld P, Tjahjono D, Tolle F, Toth E, del Tredici A, Tsapas A, Tsirigotis K, Turak A, Tzotzos G, Udo E, Utsumi T, Vaidyanathan S, Vaillant M, Valsesia A, Vandenbroucke R, Veiga F, Vendrell M, Vesk P, Vickers P, Victor V, Villemur R, Vohl M, Voolstra C, Vuillemin A, Wakelin S, Waldron L, Walsh L, Wang A, Wang F, Wang Y, Watanabe Y, Weigert A, Wen J, Wham C, White E, Wiener J, Wilharm G, Wilkinson S, Willmann R, Wilson C, Wirth B, Wojan T, Wolff M, Wong B, Wu T, Wuerbel H, Xiao X, Xu D, Xu J, Xu J, Xue B, Yalcin S, Yan H, Yang E, Yang S, Yang W, Ye Y, Ye Z, Yli-Kauhaluoma J, Yoneyama H, Yu Y, Yuan G, Yuh C, Zaccolo M, Zeng C, Zevnik B, Zhang C, Zhang L, Zhang L, Zhang Y, Zhang Y, Zhang Z, Zhang Z, Zhao Y, Zhou M, Zuberbier T, Aanei C, Ahmad R, Al-Lawama M, Alanio A, Allardyce J, Alonso-Caneiro D, Atack J, Baier D, Bansal A, Benezeth Y, Berbesque C, Berrevoet F, Biedermann P, Bijleveld E, Bittner F, Blombach F, van den Bos W, Boudreau S, Bramoweth A, Braubach O, Cai Y, Campbell M, Cao Z, Catry T, Chen X, Cheng S, Chung H, Chávez-Fumagalli M, Conway A, Costa B, Cyr N, Dean L, Denzel M, Dlamini S, Dudley K, Dufies M, Ecke T, Eckweiler D, Eixarch E, El-Adawy H, Emmrich J, Eustace A, Falter-Wagner C, Fuss J, Gao J, Gill M, Gloyn L, Goggs R, Govinden U, Greene G, Greiff V, Grundle D, Grüneberg P, Gumede N, Haore G, Harrison P, Hoenner X, Hojsgaard D, Hori H, Ikonomopoulou M, Jeurissen P, Johnson D, Kabra D, Kamagata K, Karmakar C, Kasian O, Kaye L, Khan M, Kim Y, Kish J, Kobold S, Kohanbash G, Kohls G, Kugler J, Kumar G, Lacy-Colson J, Latif A, Lauschke V, Li B, Lim C, Liu F, Liu X, Lu J, Lu Q, Mahavadi P, Marzocchi U, McGarrigle C, van Meerten T, Min R, Moal I, Molari M, Molleman L, Mondal S, van de Mortel T, Moss W, Moultos O, Mukherjee M, Nakayama K, Narayan E, Navaratnarajah, Neumann P, Nie J, Nie Y, Niemeyer F, Nolan F, Nwaiwu O, Oldenmenger W, Olumayede E, Ou J, Pallebage-Gamarallage M, Pearce S, Pelkonen T, Pelleri M, Pereira J, Pheko M, Pinto K, Piovesan A, Pluess M, Podolsky I, Prescott J, Qi D, Qi X, Raikou V, Ranft A, Rhodes J, Rotge J, Rowe A, Saggar M, Schuon R, Shahid S, Shalchyan V, Shirvalkar P, Shiryayev O, Singh J, Smout M, Soares A, Song C, Srivastava K, Srivastava R, Sun J, Szabo A, Szymanski W, Tai C, Takeuchi H, Tanadini-Lang S, Tang F, Tao W, Theron G, Tian C, Tian Y, Tuttle L, Valenti A, Verlot P, Walker M, Wang J, Welter D, Winslade M, Wu D, Wu Y, Xiao H, Xu B, Xu J, Xu Z, Yang D, Yang M, Yankilevich P, You Y, Yu C, Zhan J, Zhang G, Zhang K, Zhang T, Zhang Y, Zhao G, Zhao J, Zhou X, Zhu Z, Ajani P, Anazodo U, Bagloee S, Bail K, Bar I, Bathelt J, Benkeser D, Bernier M, Blanchard A, Boakye D, Bonatsos V, Boon M, Bouboulis G, Bromfield E, Brown J, Bul K, Burton K, Butkowski E, Carroll G, Chao F, Charrier E, Chen X, Chen Y, Chenguang, Choi J, Christoffersen T, Comel J, Cosse C, Cui Y, van Dessel P, Dhaval, Diodato D, Duffey M, Dutt A, Egea L, El-Said M, Faye M, Fernandez-Fernandez B, Foley K, Founou L, Fu F, Gadelkareem R, Galimov E, Garip G, Gemmill A, Gouil Q, Grey J, Gridneva Z, Grothe M, Grébert T, Guerrero F, Guignard L, Haenssgen M, Hasler D, Holgate J, Huang A, Hulse-Kemp A, Jean-Quartier C, Jeon S, Jia Y, Jutzeler C, Kalatzis P, Karim M, Karsay K, Keitel A, Kempe A, Keown J, Khoo C, Khwaja N, Kievit R, Kosanic A, Koutoukidis D, Kramer P, Kumar D, Kırağ N, Lanza G, Le T, Leem J, Leightley D, Leite A, Lercher L, Li Y, Lim R, Lima L, Lin L, Ling T, Liu Y, Liu Z, Lu Y, Lum F, Luo H, Machhi J, Macleod A, Macwan I, Madala H, Madani N, de Maio N, Makowiecki K, Mallinson D, Margelyte R, Maria C, Markonis Y, Marsili L, Mavoa S, McWilliams L, Megersa M, Mendes C, Menichetti J, Mercieca-Bebber R, Miller J, Minde D, Minges A, Mishra E, Mishra V, Moores C, Morrice N, Moskalensky A, Navarin N, Negera E, Nolet P, Nordberg A, Nordén R, Nowicki J, Olova N, Olszewski P, Onzima R, Pan C, Park C, Park D, Park S, Patil C, Pedro S, Perry S, Peter J, Peterson B, Pezzuolo A, Pozdnyakov I, Qian S, Qin L, Rafe A, Raote I, Raza A, Rebl H, Refai O, Regan T, Richa T, Richardson M, Robinson K, Rossoni L, Rouet R, Safaei S, Schneeberger P, Schwotzer D, Sebastian A, Selinski J, Seltmann S, Sha F, Shalev N, Shang J, Singer J, Singh M, Smith T, Solomon-Moore E, Song L, Soraggi S, Stanley R, Steckhan N, Strobl F, Subissi L, Supriyanto I, Surve C, Suzuki T, Syme C, Sörelius K, Tang Y, Tantawy M, Tennakoon S, Teseo S, Toelzer C, Tomov N, Tovar M, Tran L, Tripathi S, Tuladhar A, Ukubuiwe A, Ung C, Valgepea K, Vatanparast H, Vidal A, Wang F, Wang Q, Watari R, Webster R, Webster R, Wei J, Wibowo D, Wingenbach T, Xavier R, Xiao S, Xiong P, Xu S, Xu S, Yao R, Yao W, Yin Q, Yu Y, Zaitsu M, Zeineb Z, Zhan X, Zhang J, Zhang R, Zhang W, Zhang X, Zheng S, Zhou B, Zhou X, Ahmad H, Akinwumi S, Albery G, Alhowimel A, Ali J, Alshehri M, Alsuhaibani M, Anikin A, Azubuike S, Bach-Mortensen A, Baltiansky L, Bartas M, Belachew K, Bhardwaj V, Binder K, Bland N, Boah M, Bullen B, Calabrò G, Callahan T, Cao B, Chalmers K, Chang W, Che Z, Chen A, Chen H, Chen H, Chen Y, Chen Z, Choi Y, Chowdhury M, Christensen M, Cooke R, Cottini M, Covington N, Cunningham C, Delarocque J, Devos L, Dhar A, Ding K, Dong K, Dong Z, Dreyer N, Ekstrand C, Fardet T, Feleke B, Feurer T, Freitas A, Gao T, Asefa N, Giganti F, Grabowski P, Guerra-Mora J, Guo C, Guo X, Gupta H, He S, Heijne M, Heinemann S, Hogrebe A, Huang Z, Iskander-Rizk S, Iyer L, Jahan Y, James A, Joel E, Joffroy B, Jégousse C, Kambondo G, Karnati P, Kaya C, Ke A, Kelly D, Kickert R, Kidibule P, Kieselmann J, Kim H, Kitazawa T, Lamberts A, Li Y, Liang H, Linn S, Litfin T, Liusuo W, Lygirou V, Mahato A, Mai Z, Major R, Mali S, Mallis P, Mao W, Mao W, Marvin-Dowle K, Mason L, Merideth B, Merino-Plaza M, Merlaen B, Messina R, Mishra A, Muhammad J, Musinguzi C, Nanou A, Naqash A, Nguyen J, Nguyen T, Ni D, Nida, Notcovich S, Ohst B, Ollivier Q, Osses D, Peng X, Plantinga A, Pulia M, Rafiq M, Raman A, Raucher-Chéné D, Rawski R, Ray A, Razak L, Rudolf K, Rusch P, Sadoine M, Schmidt A, Schurr R, Searles S, Sharma S, Sheehan B, Shi C, Shohayeb B, Sommerlad A, Strehlow J, Sun X, Sundar R, Taherzadeh G, Tahir N, Tang J, Testa J, Tian Z, Tingting Q, Verheijen G, Vickstrom C, Wang T, Wang X, Wang Z, Wei P, Wilson A, Wyart, Yassine A, Yousefzadeh A, Zare A, Zeng Z, Zhang C, Zhang H, Zhang L, Zhang T, Zhang W, Zhang Z, Zhou J, Zhu D, Adamo V, Adeyemo A, Aggelidou M, Al-Owaifeer A, Al-Riyami A, Alzghari S, Andersen V, Angus K, Asaduzzaman M, Asady H, Ato D, Bai X, Baines R, Ballantyne M, Ban B, Beck J, Ben-Nafa W, Black E, Blancher A, Blankstein R, Bodagh N, Borges P, Brooks A, Brox-Ponce J, Brunetti A, Canham C, Carninci P, Carvajal R, Chang S, Chao J, Chatterjee P, Chen H, Chen Y, Chhatriwalla A, Chikowe I, Chuang T, Collevatti R, Valera-Cornejo D, Cuenda A, Dao M, Dauga D, Deng Z, Devkota K, Doan L, Elewa Y, Fan D, Faruk M, Feifei S, Ferguson T, Fleres F, Foster E, Foster C, Furer T, Gao Y, Garcia-Rivera E, Gazdar A, George R, Ghosh S, Gianchecchi E, Gleason J, Hackshaw A, Hall A, Hall R, Harper P, Hogg W, Huang G, Hunter K, IJzerman A, Jesus C, Jian G, Lewis J, Kanj S, Kaur H, Kelly S, Kheir F, Kichatova V, Kiyani M, Klein R, Kovesi T, Kraschnewski J, Kumar A, Labutin D, Lazo-Langner A, Leclercq G, Li M, Li Q, Li T, Li Y, Liao W, Liao Z, Lin J, Lizer J, Lobreglio G, Lowies C, Lu C, Majeed H, Martin A, Martinez-Sobrido L, Meresh E, Middelveen M, Mohebbi A, Mota J, Mozaheb Z, Muyaya L, Nandhakumar A, Ng S, Obeidat M, Oh D, Owais M, Pace-Asciak P, Panwar A, Park C, Patterson C, Penagos-Tabaree F, Pianosi P, Pinzi V, Pridans C, Psaroulaki A, Pujala R, Pulido-Arjona L, Qi P, Rahman P, K N, Rassaf T, Refardt J, Ricciardi W, Riess O, Rovas A, Sacks F, Saleh S, Sampson C, Schmutz A, Sepanski R, Sharma N, Singh M, Spearman P, Subramaniapillai M, Swali R, Tan C, Tellechea J, Thomas L, Tong X, Vavvas D, Veys R, Vitriol V, Wang H, Wang J, Wang J, Waugh J, Webb S, Williams B, Workman A, Xiang T, Xie L, Xu J, Xu T, Yang C, Yoon J, Yuan C, Zaritsky A, Zhang Y, Zhao H, Zuckerman H, Lyu R, Pullan W, Zhou Y. Large expert-curated database for benchmarking document similarity detection in biomedical literature search. Database 2019, 2019: baz085. PMID: 33326193, PMCID: PMC7291946, DOI: 10.1093/database/baz085.
- Yong W, Rha S, Tan I, Choo S, Syn N, Koh V, Tan S, Asuncion B, Sundar R, So J, Shabbir A, Tan C, Kim H, Jung M, Chung H, Ng M, Tai D, Lee M, Wu J, Yeoh K, Tan P, Consortium O. Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept “3G” Trial. Clinical Cancer Research 2018, 24: 5272-5281. PMID: 30045931, DOI: 10.1158/1078-0432.ccr-18-0193.
- Garces A, Ang J, Ameratunga M, Chénard-Poirier M, Dolling D, Diamantis N, Seeramreddi S, Sundar R, de Bono J, Lopez J, Banerji U. A study of 1088 consecutive cases of electrolyte abnormalities in oncology phase I trials. European Journal Of Cancer 2018, 104: 32-38. PMID: 30316017, PMCID: PMC6259582, DOI: 10.1016/j.ejca.2018.08.019.
- Huang Y, Wong A, Soo R, Soh T, Pang A, Tan C, Ling W, Voon P, Lim J, Sundar R, Kumarakulasinghe N, Lim H, Goh B, Chin T. P1.01-38 A Phase II With a Lead-In Phase I Study to Examine Safety and Efficacy of Hydroxychloroquine and Gefitinib in Advanced NSCLC. Journal Of Thoracic Oncology 2018, 13: s474-s475. DOI: 10.1016/j.jtho.2018.08.594.
- Sundar R, McVeigh T, Dolling D, Petruckevitch A, Diamantis N, Ang J, Chenard-Poiriér M, Collins D, Lim J, Ameratunga M, Khan K, Kaye S, Banerji U, Lopez J, George A, de Bono J, van der Graaf W. Clinical outcomes of adolescents and young adults with advanced solid tumours participating in phase I trials. European Journal Of Cancer 2018, 101: 55-61. PMID: 30025230, DOI: 10.1016/j.ejca.2018.06.003.
- Basu B, Krebs M, Sundar R, Wilson R, Spicer J, Jones R, Brada M, Talbot D, Steele N, Garces A, Brugger W, Harrington E, Evans J, Hall E, Tovey H, de Oliveira F, Carreira S, Swales K, Ruddle R, Raynaud F, Purchase B, Dawes J, Parmar M, Turner A, Tunariu N, Banerjee S, de Bono J, Banerji U. Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer. Annals Of Oncology 2018, 29: 1918-1925. PMID: 30016392, PMCID: PMC6158767, DOI: 10.1093/annonc/mdy245.
- Sundar R, Qamra A, Tan A, Zhang S, Ng C, Teh B, Lee J, Kim K, Tan P. Transcriptional analysis of immune genes in Epstein–Barr virus-associated gastric cancer and association with clinical outcomes. Gastric Cancer 2018, 21: 1064-1070. PMID: 29915957, DOI: 10.1007/s10120-018-0851-9.
- Sundar R, Miranda S, Rodrigues D, Chénard-Poirier M, Dolling D, Clarke M, Figueiredo I, Bertan C, Yuan W, Ferreira A, Chistova R, Boysen G, Perez D, Tunariu N, Mateo J, Wotherspoon A, Chau I, Cunningham D, Valeri N, Carreira S, de Bono J. Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer. Clinical Colorectal Cancer 2018, 17: 280-284. PMID: 30042009, DOI: 10.1016/j.clcc.2018.05.011.
- Sundar R, Qamra A, Tan A, Zhang S, Ng C, Teh B, Lee J, Kim K, Tan P. Transcriptional analysis of immune genes in Epstein-Barr virus-associated gastric cancer and association with clinical outcomes. Journal Of Clinical Oncology 2018, 36: e16024-e16024. DOI: 10.1200/jco.2018.36.15_suppl.e16024.
- Dose finding study of varlitinib ± trastuzumab with carboplatin/paclitaxel in advanced solid tumors.Lee M, Wong A, Ow S, Sundar R, Wang L, Tan D, Soo R, Chee C, Heong V, Chen Y, Lim J, Yong W, Lim S, Goh B, Lee S. Dose finding study of varlitinib ± trastuzumab with carboplatin/paclitaxel in advanced solid tumors. Journal Of Clinical Oncology 2018, 36: 2588-2588. DOI: 10.1200/jco.2018.36.15_suppl.2588.
- Sundar R, Bandla A, Tan S, Kumarakulasinghe N, Huang Y, Ang S, Hairom Z, Lim J, Wong A, Chan G, Ngoi N, Ang E, Chan A, Lee S, Thakor N, Wilder-Smith E. Cryocompression for enhanced limb hypothermia in preventing paclitaxel-induced peripheral neuropathy. Journal Of Clinical Oncology 2018, 36: 10095-10095. DOI: 10.1200/jco.2018.36.15_suppl.10095.
- Hoppe M, Sundar R, Tan D, Jeyasekharan A. Biomarkers for Homologous Recombination Deficiency in Cancer. Journal Of The National Cancer Institute 2018, 110: 704-713. PMID: 29788099, DOI: 10.1093/jnci/djy085.
- McVeigh T, Sundar R, Diamantis N, Kaye S, Banerji U, Lopez J, de Bono J, van der Graaf W, George A. The role of genomic profiling in adolescents and young adults (AYAs) with advanced cancer participating in phase I clinical trials. European Journal Of Cancer 2018, 95: 20-29. PMID: 29614442, PMCID: PMC6296443, DOI: 10.1016/j.ejca.2018.02.028.
- Sundar R, Rha S, Yamaue H, Katsuda M, Kono K, Kim H, Kim C, Mimura K, Kua L, Yong W. A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer. BMC Cancer 2018, 18: 332. PMID: 29587677, PMCID: PMC5870101, DOI: 10.1186/s12885-018-4234-8.
- Lam W, Wang L, Roudi R, Yong W, Syn N, Sundar R. Resisting resistance to cancer immunotherapy. Thoracic Cancer 2018, 9: 507-508. PMID: 29512891, PMCID: PMC5928381, DOI: 10.1111/1759-7714.12614.
- Chan D, Syn N, Neogh C, Phua N, . E, Ho J, Sundar R, Tan C, Ngoi N, Chee C, Shabbir A, So J, Yong W. Extended outcomes of intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastases. Journal Of Clinical Oncology 2018, 36: 125-125. DOI: 10.1200/jco.2018.36.4_suppl.125.
- Sundar R, Tan P. Genomic Analyses and Precision Oncology in Gastroesophageal Cancer: Forwards or Backwards? Cancer Discovery 2018, 8: 14-16. PMID: 29311223, DOI: 10.1158/2159-8290.cd-17-1295.
- Sundar R, Custodio A, Petruckevich A, Chénard-Poirier M, Ameratunga M, Collins D, Lim J, Kaye S, Tunariu N, Banerji U, de Bono J, Lopez J. Clinical Outcome of Patients with Advanced Biliary Tract Cancer in a Dedicated Phase I Unit. Clinical Oncology 2017, 30: 185-191. PMID: 29224898, DOI: 10.1016/j.clon.2017.11.011.
- Brown J, Sundar R, Lopez J. Combining DNA damaging therapeutics with immunotherapy: more haste, less speed. British Journal Of Cancer 2017, 118: 312-324. PMID: 29123260, PMCID: PMC5808021, DOI: 10.1038/bjc.2017.376.
- Garces A, Ang J, Ameratunga M, Chenard-Poirier M, Dolling D, Sundar R, Kaye S, de Bono J, Banerji U, Lopez J. 1194P Impact of prior immune checkpoint inhibitors on haematological toxicity in phase I patients receiving chemotherapy. Annals Of Oncology 2017, 28: v422. DOI: 10.1093/annonc/mdx376.057.
- Garces A, Ang J, Ameratunga M, Chenard-Poirier M, Dolling D, Diamantis N, Seeramreddi S, Sundar R, de Bono J, Lopez J, Banerji U. 398P Drug-induced electrolyte abnormalities in oncology phase I trials: Analysis of 1088 cases treated at The Royal Marsden Hospital. Annals Of Oncology 2017, 28: v132-v133. DOI: 10.1093/annonc/mdx367.031.
- Sundar R, Miranda S, Carreira S, Chénard-Poirier M, Rodrigues D, Figueiredo I, Bertan C, Yuan W, Perez D, Ferreira A, Tunariu N, Mateo J, Bono J. Abstract 3807: ATM protein loss and clinical outcomes with platinum chemotherapy in patients with advanced solid tumors. Cancer Research 2017, 77: 3807-3807. DOI: 10.1158/1538-7445.am2017-3807.
- Lim J, Harris S, Ameratunga M, Sundar R, Ang J, Collins D, Chénard-Poirier M, Garces A, Kaye S, Lopez J, Banerji U, Bono J, Yap T. Abstract 3081: Precision medicine for patients with advanced small cell lung cancer treated with novel therapeutic agents in a phase I clinical trials unit. Cancer Research 2017, 77: 3081-3081. DOI: 10.1158/1538-7445.am2017-3081.
- Sundar R, Hong D, Kopetz S, Yap T. Targeting BRAF-Mutant Colorectal Cancer: Progress in Combination Strategies. Cancer Discovery 2017, 7: 558-560. PMID: 28576843, PMCID: PMC5458523, DOI: 10.1158/2159-8290.cd-17-0087.
- Yanagitani N, Horiike A, Kitazono S, Ohyanagi F, Kondo S, Shimomura A, Fujiwara Y, Doi T, Kuboki Y, Kawazoe A, Shitara K, Ohno I, Banerji U, Sundar R, Ohkubo S, Huang J, Nishio M, Yamamoto N. First-in-human phase I study of an oral HSP90 inhibitor, TAS-116, in advanced solid tumors. Journal Of Clinical Oncology 2017, 35: 2546-2546. DOI: 10.1200/jco.2017.35.15_suppl.2546.
- Pierce A, Berges A, Cheung S, Standifer N, Ross G, Smith S, Hollingsworth S, Krebs M, Postel-Vinay S, Bang Y, El-Khoueiry A, Abida W, Sundar R, Carter L, Castanon-Alvarez E, Im S, Lopez J, Yap T, Harrington K, Soria J. Dose-exposure-response relationship between AZD6738 and peripheral monocytes. Journal Of Clinical Oncology 2017, 35: e14063-e14063. DOI: 10.1200/jco.2017.35.15_suppl.e14063.
- Wong A, Tan K, Sundar R, Ow S, Pang A, Yap H, Chan C, Hartman M, Iau P, Buhari S, Mogro M, Tan I, Wang L, Yang H, Goh B, Lee S. Genomic predictors of neoadjuvant chemotherapy (NACT) response in breast cancer (BC). Journal Of Clinical Oncology 2017, 35: e12122-e12122. DOI: 10.1200/jco.2017.35.15_suppl.e12122.
- Sundar R, Basu B, Wilson R, Spicer J, Jones R, Krebs M, Brada M, Talbot D, Steele N, Hall E, Tovey H, Carreira S, de Oliveira F, Swales K, Balarajah G, Dawes J, Parmar M, De Bono J, Banerji U. TAX-TORC: A phase I trial of vistusertib (AZD2014) in combination with weekly paclitaxel with integrated pharmacodynamic (PD) and molecular characterization (MC) studies. Journal Of Clinical Oncology 2017, 35: 2571-2571. DOI: 10.1200/jco.2017.35.15_suppl.2571.
- Heong V, Wee B, Goh S, Tay D, Lee X, Soo R, Lim J, Sundar R, Chee C, Lee S, Ow S, Goh B, Yong W, Wong A, Gopinathan A, Lim D, Pang B, Feroz M, Soong R, Tan D. Whole exome sequencing (WES) of multiple spatially distinct biopsies from single metastatic lesions to evaluate tumour heterogeneity and identify actionable truncal mutations (ATMs) in patients (pts) with advanced solid malignancies using a radiologically-guided single-pass percutaneous technique. Journal Of Clinical Oncology 2017, 35: 2550-2550. DOI: 10.1200/jco.2017.35.15_suppl.2550.
- Chenard-Poirier M, Ang J, Harris S, Ingles Garces A, Seeramreddi S, Sundar R, Collins D, Ameratunga M, Lopez J, De Bono J, Banerji U. Adherence to novel oral anticancer therapies in the phase I setting: The Royal Marsden experience. Journal Of Clinical Oncology 2017, 35: 2542-2542. DOI: 10.1200/jco.2017.35.15_suppl.2542.
- Sundar R, McVeigh T, Petruckevitch A, Diamantis N, Ang J, Chenard-Poirier M, Collins D, Lim J, Ameratunga M, Khan K, Kaye S, Banerji U, Lopez J, De Bono J, Van Der Graaf W. Clinical outcomes of adolescents and young adults (AYA) with advanced solid tumors participating in phase I trials. Journal Of Clinical Oncology 2017, 35: 10536-10536. DOI: 10.1200/jco.2017.35.15_suppl.10536.
- Collins D, Constantinidou A, Sundar R, Chenard-Poirier M, Yap T, Banerji U, De Bono J, Lopez J, Tunariu N. Patterns of metastases in malignant pleural mesothelioma in the modern era: Redefining the spread of an old disease. Journal Of Clinical Oncology 2017, 35: 8556-8556. DOI: 10.1200/jco.2017.35.15_suppl.8556.
- Walsh R, Lee S, Seng K, Wang L, Ho G, Ow S, Kumarakulasinghe N, Sundar R, Lee X, Yap H, Jeyasekharan A, Pang A, Ho J, Tan C, Lim Y, Malik R, Wan Ishak W, Goh B, Tai B, Wong A. Prospective study of UDP-glucuronosyltransferase (UGT) 2B17 genotype and exemestane (Exe) pharmacokinetics (PK) and pharmacodynamics (PD) in Asian, hormone receptor (HR) positive, metastatic breast cancer (MBC) patients. Journal Of Clinical Oncology 2017, 35: 1056-1056. DOI: 10.1200/jco.2017.35.15_suppl.1056.
- Sundar R, Brown J, Russo A, Yap T. Targeting ATR in cancer medicine. Current Problems In Cancer 2017, 41: 302-315. PMID: 28662958, DOI: 10.1016/j.currproblcancer.2017.05.002.
- Sundar R, Chénard-Poirier M, Collins D, Yap T. Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer. Frontiers In Medicine 2017, 4: 39. PMID: 28443282, PMCID: PMC5385461, DOI: 10.3389/fmed.2017.00039.
- Dolly S, Collins D, Sundar R, Popat S, Yap T. Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer. Drugs 2017, 77: 813-827. PMID: 28378229, DOI: 10.1007/s40265-017-0732-2.
- Sundar R, Valeri N, Harrington K, Yap T. Combining Molecularly Targeted Agents: Is More Always Better? Clinical Cancer Research 2017, 23: 1123-1125. PMID: 27836864, DOI: 10.1158/1078-0432.ccr-16-2399.
- Sundar R, Bandla A, Tan S, Liao L, Kumarakulasinghe N, Jeyasekharan A, Ow S, Ho J, Tan D, Lim J, Vijayan J, Therimadasamy A, Hairom Z, Ang E, Ang S, Thakor N, Lee S, Wilder-Smith E. Limb Hypothermia for Preventing Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients: A Pilot Study. Frontiers In Oncology 2017, 6: 274. PMID: 28119855, PMCID: PMC5222823, DOI: 10.3389/fonc.2016.00274.
- Lim J, Sundar R, Chnard-Poirier M, Lopez J, Yap T. Emerging biomarkers for PD-1 pathway cancer therapy. Biomarkers In Medicine 2016, 11: 53-67. PMID: 27936870, DOI: 10.2217/bmm-2016-0228.
- Yap T, Krebs M, Postel-Vinay S, Bang Y, El-Khoueiry A, Abida W, Harrington K, Sundar R, Carter L, Castanon-Alvarez E, Im S, Berges A, Khan M, Stephens C, Ross G, Soria J. 1LBA Phase I modular study of AZD6738, a novel oral, potent and selective ataxia telangiectasia Rad3-related (ATR) inhibitor in combination (combo) with carboplatin, olaparib or durvalumab in patients (pts) with advanced cancers. European Journal Of Cancer 2016, 69: s2. DOI: 10.1016/s0959-8049(16)32607-7.
- Collins D, Sundar R, Lim J, Yap T. Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics. Trends In Pharmacological Sciences 2016, 38: 25-40. PMID: 27871777, DOI: 10.1016/j.tips.2016.10.012.
- Sundar R, Jeyasekharan A, Pang B, Soong R, Kumarakulasinghe N, Ow S, Ho J, Lim J, Tan D, Wilder-Smith E, Bandla A, Tan S, Asuncion B, Fazreen Z, Hoppe M, Putti T, Poh L, Goh B, Lee S. Low Levels of NDRG1 in Nerve Tissue Are Predictive of Severe Paclitaxel-Induced Neuropathy. PLOS ONE 2016, 11: e0164319. PMID: 27716814, PMCID: PMC5055363, DOI: 10.1371/journal.pone.0164319.
- Sundar R, Tan D, S. Lei L, Chia W. Overcoming Chemotherapy Resistance in High Grade Serous Ovarian Cancer. Current Cancer Therapy Reviews 2016, 12: 23-36. DOI: 10.2174/1573394712666160609121238.
- Heong V, Koe P, Yong W, Soo R, Chee C, Wong A, Thian Y, Sundar R, Ho J, Gopinathan A, Lee S, Goh B, Tan D. 383P RAS/AKT pathway mutations as predictive biomarkers in patients with colorectal cancer treated with the exportin 1 (XPO1) inhibitor selinexor (SEL) – inhibition of nuclear-cytoplasmic translocation of p27 as a mechanism of anti-tumour activity. Annals Of Oncology 2016, 27: vi122. DOI: 10.1093/annonc/mdw368.26.
- Banerji U, Basu B, Spicer J, Wilson R, Hall E, Sundar R, Kumar S, Wu Y, Coyle V, Carreira S, Parmar M, Dawes J, Banerjee S, de Bono J. 362PD TAX-TORC: An investigator initiated phase I study combining the dual mTORC1/2 inhibitor AZD2014 in combination with weekly paclitaxel in high-grade serous ovarian cancer. Annals Of Oncology 2016, 27: vi115. DOI: 10.1093/annonc/mdw368.05.
- Sundar R, Custodio A, Lim J, Chenard-Poirier M, Collins D, Kaye S, Yap T, Banerji U, Lopez J, de Bono J. 404P Clinical outcome of patients with advanced biliary tract cancer in a dedicated phase 1 unit. Annals Of Oncology 2016, 27: vi130. DOI: 10.1093/annonc/mdw368.47.
- Wong A, Sundar R, Wang T, Ng T, Zhang B, Tan S, Soh T, Pang A, Tan C, Ow S, Wang L, Mogro J, Ho J, Jeyasekharan A, Huang Y, Thng C, Chan C, Hartman M, Iau P, Buhari S, Goh B, Lee S. Phase Ib/II randomized, open-label study of doxorubicin and cyclophosphamide with or without low-dose, short-course sunitinib in the pre-operative treatment of breast cancer. Oncotarget 2016, 7: 64089-64099. PMID: 27577069, PMCID: PMC5325427, DOI: 10.18632/oncotarget.11596.
- Tan C, Wang T, Lim C, Loh T, Chin S, Sundar R, Chong W, Ow S, Soo R, Lee S, Goh B. Randomised study of 2 low doses of sunitinib to modulate tumor microvasculature prior to chemotherapy in nasopharyngeal carcinoma (NPC). Journal Of Clinical Oncology 2016, 34: 6034-6034. DOI: 10.1200/jco.2016.34.15_suppl.6034.
- Ang Y, Soo R, Ho G, Sundar R, Tan S, Lim J, Yong W, Chong W, Ho J, Kumarakulasinghe N, Aung M, Koh E, Ramlee M, Phyu P, Kyin L, Goh B, Lee S. A phase II randomized study of docetaxel +/- low-dose, short course sunitinib in advanced solid tumours. Journal Of Clinical Oncology 2016, 34: e14124-e14124. DOI: 10.1200/jco.2016.34.15_suppl.e14124.
- Sundar R, Bandla A, Tan S, Kumarakulasinghe N, Jeyasekharan A, Ow S, Ho J, Tan D, Lim J, Vijayan J, Hairom Z, Ang S, Liao L, Lee S, Thakor N, Wilder-Smith E. The role of limb hypothermia in preventing paclitaxel-induced peripheral neuropathy. Journal Of Clinical Oncology 2016, 34: e21696-e21696. DOI: 10.1200/jco.2016.34.15_suppl.e21696.
- Heong V, Koe P, Yong W, Soo R, Chee C, Thian Y, Gopinathan A, Wong A, Sundar R, Ho J, Friedlander S, McCauley D, Choe-Juliak C, Lee S, Goh B, Tan D. 127O Phase 1 study of safety and tolerability of selinexor in Asian patients with advanced solid cancers: updated results. Annals Of Oncology 2015, 26: ix37. DOI: 10.1093/annonc/mdv521.03.
- Bandla A, Sundar R, Liao L, Tan S, Lee S, Thakor N, Wilder-Smith E. Hypothermia for preventing chemotherapy-induced neuropathy – a pilot study on safety and tolerability in healthy controls. Acta Oncologica 2015, 55: 430-436. PMID: 26360921, DOI: 10.3109/0284186x.2015.1075664.
- Tan D, Pang M, Yong W, Soo R, Chee C, Thian Y, Gopinathan A, Wong A, Koe P, Sundar R, Ho J, Friedlander S, Landesman Y, Rashal T, McCauley D, Shacham S, Lee S, Goh B. Phase I study of the safety and tolerability of the Exportin 1 (XPO1) inhibitor Selinexor (SXR) in Asian patients (pts) with advanced solid cancers. Journal Of Clinical Oncology 2015, 33: 2542-2542. DOI: 10.1200/jco.2015.33.15_suppl.2542.
- Sundar R, Sundar G. Zinner syndrome: an uncommon cause of painful ejaculation. BMJ Case Reports 2015, 2015: bcr2014207618. PMID: 25750220, PMCID: PMC4368968, DOI: 10.1136/bcr-2014-207618.
- Soh I, Mogro M, Soo R, Pang A, Tan C, Chuah B, Zee Y, Wong A, Ow S, Sundar R, Lim J, Huang Y, Ling W, Yong W. The optimization of 5-fluorouracil (5FU) dose by pharmacokinetic (PK) monitoring in Asian patients with advanced-stage gastrointestinal (GI) cancer. Journal Of Clinical Oncology 2015, 33: 770-770. DOI: 10.1200/jco.2015.33.3_suppl.770.
- Sundar R, Cho B, Brahmer J, Soo R. Nivolumab in NSCLC: latest evidence and clinical potential. Therapeutic Advances In Medical Oncology 2015, 7: 85-96. PMID: 25755681, PMCID: PMC4346216, DOI: 10.1177/1758834014567470.
- Wong A, Tan S, Soh I, Tan C, Lim Y, Pang A, Ho J, Ow S, Sundar R, Pang M, Chan C, Buhari S, Hartman M, Iau P, Tang A, Wong N, Yap Y, Khoo B, Thiery J, Lee S. Phase II study of neoadjuvant weekly paclitaxel and carboplatin with lapatinib in HER2+ breast cancer. Journal Of Clinical Oncology 2014, 32: 619-619. DOI: 10.1200/jco.2014.32.15_suppl.619.
- Wong A, Sundar R, Ow S, Wang T, Ng T, Chan C, Hartman M, Iau P, Tan S, Zhang B, Thng C, Mogro M, Voon P, Buhari S, Soh I, Goh B, Lee S. Effect of low-dose, short-course sunitinib (Su) on tumor vasculature and tumor blood flow for enhancement of chemotherapy efficacy in breast cancer. Journal Of Clinical Oncology 2014, 32: 1060-1060. DOI: 10.1200/jco.2014.32.15_suppl.1060.
- Sundar R, Jeyasekharan A, Tan K, Putti T, Poh L, Yap H, Sapari N, Soong R, Lee S. Paclitaxel-induced severe sensory peripheral neuropathy is associated with NDRG-1 genetic variant and negative NDRG-1 expression in nerve tissue. Journal Of Clinical Oncology 2014, 32: 1054-1054. DOI: 10.1200/jco.2014.32.15_suppl.1054.
- Sundar R, Soong R, Cho B, Brahmer J, Soo R. Immunotherapy in the treatment of non-small cell lung cancer. Lung Cancer 2014, 85: 101-109. PMID: 24880938, PMCID: PMC4332778, DOI: 10.1016/j.lungcan.2014.05.005.
Departments and Programs
- Center for Gastrointestinal Cancers
- Internal Medicine
- Medical Oncology and Hematology
- Yale Cancer Center
Locations
- Smilow Cancer Hospital at Yale New Haven35 Park StreetNew Haven, CT 06511
- Smilow Cancer Hospital at Yale New Haven35 Park StreetNew Haven, CT 06511